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Chronic obstructive pulmonary disease (COPD) is a progressive and irreversible limitation of 
airflow which predominantly affectsa smokers. One of the mechanisms behind the 
development and progression of COPD is thought to be epithelial-mesenchymal transition 
(EMT). EMT is a process whereby epithelial cells, which normally act as the body’s primary 
means of defence against injury, external pathogens and other damaging factors, lose their 
ability to form a cohesive barrier and instead take on characteristics of a motile, fibrotic and 
mesenchymal phenotype.  
There is in vitro evidence that cigarette smoke extract (CSE) can directly induce EMT 
through production of transforming growth factor-β1 (TGF-β). However, isolated cells in 
these studies are typically sourced from people with established COPD or with lung cancer. It 
is not known whether this CSE-TGF-β-EMT pathway occurs at earlier stages of the disease, 
for example in smokers with normal lung function or in pre-COPD airflow obstruction. Also 
unclear is whether current therapies for COPD affect the CSE-TGF-β-EMT pathway and if 
they have beneficial effects early in the development of the disease.  
The aims of this study were to investigate the CSE-TGF-β-EMT pathway in isolated 
epithelial cells from healthy non-smokers, smokers with normal lung function and people 
with airflow limitation which does not reach the threshold for clinically diagnosed COPD. In 
doing so, this study attempted to determine whether EMT occurs at very early disease stages, 
perhaps even before manifestation of clinically significant airflow limitation, and to 
investigate the effects of CSE on healthy cells from non-smokers. At the same time, the 
effects of three current COPD therapies - a long acting β-agonist (salmeterol xinafoate), a 
long acting muscarinic agonist (tiotropium bromide) and a corticosteroid (fluticasone 
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proprionate) – on both early disease stages and the CSE-TGF-β-EMT pathway were 
investigated.  
Two cell culture models were examined: primary bronchial epithelial cells (pHBECs) and 
immortalised BEAS-2B airway epithelial cells. The models were tested for expression of 
EMT markers, as well as markers for the EMT-associated TGF-β and TWIST signalling 
pathways, using real-time qPCR, immunocytochemistry/histochemistry and ELISA.  
Cells from non-smokers, current smokers with normal lung function and both smokers and 
ex-smokers with airflow limitation were shown to survive both isolation and 
cryopreservation. The protein expression of EMT markers in the cultured cells agreed with 
the signals seen in biopsies from the same groups, indicating that phenotype was maintained 
in culture. However, cells from people with chronic airflow limitation did not show evidence 
of active EMT, either in culture or in the biopsies, when compared to cells from non-smokers 
or smokers with normal lung function. 
Despite BEAS-2B cells being widely used to study healthy bronchial epithelial cells when 
primary cells are unavailable, this study demonstrated that the immortalised cell line is not an 
ideal model for primary cells. Not only were the BEAS-2B cells more mesenchymal than 
primary cells taken from healthy non-smokers, but they also demonstrated differences in how 
they responded both to stimulation with TGF-β or CSE and to the drug treatments used in this 
study. In particular, the molecular mRNA level differences between the immortalised and the 
primary cells suggested that BEAS-2B cells may not be good models for healthy bronchial 
epithelium. 
In this study, TGF-β also exhibited lower levels of activity in BEAS-2B cells than expected 
from the literature, not managing to fully induce EMT in the immortalised cell line, nor in the 
primary cells taken from non-smokers. However, the cells trended towards an EMT-like 
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expression profile. Exposure to CSE failed to elicit a full EMT response in primary cells from 
non-smokers, although it did elicit a partial EMT-like phenotype without affecting the Smad 
signalling pathway. This further suggests that acute exposure to CSE is not sufficient to 
trigger the CSE-TGF-β-EMT pathway in healthy airway epithelial cells, although it may 
trigger other pathways to promote EMT-like changes.  
Of the three drugs studied, neither salmeterol, tiotropium or fluticasone had any significant 
suppressive effect on EMT in either primary or BEAS-2B cells. Tiotropium, in particular, 
appeared to actually promote EMT in primary cells taken from non-smokers and smokers 
with normal lung function.  
Overall, this study confirmed that primary bronchial epithelial cells can be successfully 
cultured and demonstrated that cryopreservation of these cells is possible, although smoking 
status had a negative impact on their viability. BEAS-2B cells did not appear to be a reliable 
model of healthy primary epithelial cells, particularly at the mRNA level of EMT-related 
expression. Cells from people with airflow limitation which did not reach the level of COPD 
did not appear to be undergoing active EMT, suggesting that EMT may only be active in 
fully developed COPD. Of the drugs used for treatment of COPD, only salmeterol indicating 
a trend towards suppression of EMT, while tiotropium and fluticasone appeared to have no 
suppressive effect on the process, with tiotropium promoting a partial EMT phenotype. 
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1.1.  Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a progressive and irreversible limitation of 
airflow, caused predominantly by cigarette smoking in developed countries. As of December 
2016, the Australian Institute of Health and Welfare (AIHW) reported that 5% of Australians 
over 45 have COPD, although this statistic is based on self-reporting. A cross-sectional  study 
of the lung function of Australians aged over 40 reported that COPD affects 7% of all 
Australians over the age of 45 and 30% of those aged over 75 [1]. According to the World 
Health Organisation (WHO), COPD is currently the fourth leading cause of death worldwide, 
killing 3.17 million people per year in 2015 (Figure 1.1-1) and the AIHW placed it as the 
fifth leading cause of death in Australia in 2014, responsible for 4.6% of all deaths in 
Australia and killing 7,025 people. It has been estimated that COPD prevalence is grossly 
underestimated, with 45-65% of cases remaining undiagnosed, as patients believe their 
symptoms are part of the natural aging process [2]. Although COPD is caused mainly by 
smoking tobacco products in developed countries, exposure to biomass smoke from cooking-
fires and the like also contributes in developing countries [3].  
The main clinical features of COPD are shortness of breath, which often worsens upon 
exertion, and a chronic cough which may or may not be productive. For a diagnosis of COPD 
to be made, a patient undergoing spirometry must exhibit less than 70%  predicted lung 
function, which is the ratio between the forced expiratory volume in one second and the 
forced vital capacity of the lung, and this must not be significantly improved following 
application of a bronchodilator [4]. As the disease progresses, patients also experience events 
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known as ‘acute exacerbations’ or, simply, exacerbations, which are sharp declines in lung 
function and health that necessitate a change in medication and management [5, 6]. COPD 
places a large burden on both the individual and the community.   
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1.1.1. Burden of COPD 
On an individual level, COPD can have enormous impact on the quality of life experienced 
by the affected person [7]. People may have difficulty breathing during light exercise or 
while doing mundane activities such as climbing stairs in earlier stages of disease. In later 
stages, as the disease worsens even simple activities such as getting dressed or showering can 
become difficult [8-10]. People experience less restful sleep, and overall emotional 
satisfaction and happiness decreases as the disease progresses[10]. The costs associated with 
treatment and living with the disease can also be prohibitive.  
At the level of the community, the impact is mainly in the financial sector. Between 2011 and 
2012 the average length of stay for hospitalisations resulting from chronic respiratory disease, 
including COPD, was 5 days  [11]  and according the AIHW, an average of 690,000 people 
over the age of 45 are hospitalised each year in Australia with COPD as the primary 
diagnosis (based on data from 2014-15). In 2011-2012, COPD was responsible for 398,000 
hospital patient days, which accounted for67% of the total hospital days for all chronic lung 
diseases [11]. COPD accounted for 3.4% of the total disability-adjusted life years (DALYs), a 
measurement which is used to represent the burden of disease, in Australia in 2010 [11] .  
Healthcare costs associated with COPD make it an extremely expensive chronic condition for 
a patient to have. In the UK a person with COPD spends up to £3,376 a year on treatment for 
the condition and related medical expenses, if adherent to combined long-acting beta-agonist 
and inhaled corticosteroid treatment [12]. Patients who are not adherent spend £2,373 a year 
on the disease; these values do not include monetary loss due to time off work and are purely 
expenses paid by the patient. In Finland in 2006 the direct and indirect cost of COPD totalled 
€107,705,570 [13] and in 2008 the economic cost of COPD in Australia was AU$8.8 billion 
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according to a report commissioned by Lung Foundation Australia [14]. Despite this burden, 
there is no cure for COPD, and treatments can only slow disease progression, not halt it. This 
is in part due to the fact that the underlying molecular mechanisms and cellular processes of 
COPD still remain to be elucidated.   
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Figure 1.1-1: WHO data for the leading causes of death worldwide. Top ten causes of 
death for 2015 are shown. COPD ranks fourth, with a total of 3.1 million deaths. It ranks 
below ischaemic heart disease (7.4 million) and stroke (6.7 million) and is only slightly 
overshadowed by lower respiratory tract infections, which may share some overlap with 
COPD, due to increased infection rates in COPD, as may the lung cancer statistics 
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1.1.2. Pathology of COPD  
Cigarette smoke exposure causes the majority of COPD cases in developed countries and 
smoking is the most important risk factor for the disease [4]. However, cigarette smoke’s 
highly complex chemical composition means that the mechanisms which cause COPD are 
still not fully explained. The large airways are classically considered the major site for the 
occurrence of lung cancers in COPD, however with the increased prevalence of 
adenocarcinomas in recent years, the small airways are now beginning to become the major 
site of cancer in COPD [15, 16]. However, the large airways are still an important site in the 
disease pathology, hosting a number of pathological changes in COPD, including luminal 
inflammation, mucus hypersecretion, airway wall and epithelial thickening and epithelial-
mesenchymal transition (EMT). 
Classically, COPD is defined as chronic inflammation in the bronchi, or bronchitis, 
accompanied by fibrosis or narrowing of the airways, especially in the small airways [17], 
and in later stages by destruction of the parenchyma and alveoli, emphysema. Squamous cell 
cancer, mucus hypersecretion and chronic luminal immune infiltration are commonly seen in 
the large bronchi, those in the upper part of the respiratory tree which are supported by 
cartilaginous structures, while the small airways, those lower in the bronchial tree and 
without cartilage, suffer from fibrotic destruction, adenocarcimonas and loss of elastic recoil 
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1.1.2.1. The healthy large airway 
When discussing pathology, it is useful to briefly describe the normal physiology and 
structure of the airways. Given the focus of the project, this will be the large airways; the 
small airways differ in a number of features from the large, however they are not of major 
importance to the current discussion. In healthy large airways, as elsewhere, the epithelial 
layer is the body’s primary defence against invading pathogens, foreign objects and noxious 
particles [19]. In the airways, it produces mucus which traps pathogens and particulates, and 
the cilia on the apical cell surface act to clear the mucus and invading bodies. The epithelium 
in healthy large airways is a pseudostratified layer, made up of ciliated epithelium and mucus 
producing goblet cells and glands [19]. However, due to its role as the first line of defence, 
the epithelium is exposed to any number of stimuli which can alter its growth, functionality 
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 Epithelial layer dysregulation 
One of the key changes in COPD, and the main focus of this thesis, is the epithelial lining of 
the large airways. Additional to the potential for malignancy described below, in section 
1.1.2.6, the airway epithelium in COPD exhibits squamous metaplasia, where in healthy 
lungs it forms a pseudostratified layer [20, 21]. As well as metaplasia, which causes epithelial 
thickening, the mucus producing goblet cells and sub-mucosal glands of the epithelium 
multiply and become over-active, producing thick mucus in the lumen which contributes to 
airway obstruction [22, 23], and there are also deficiencies in cilia length and function, which 
impede airway particulate clearance [24, 25]. Furthermore, there is evidence that the basal 
cells, from which the epithelial layer is renewed constantly, are dysregulated [26-30] and 
express mesenchymal markers such as S001A4, vimentin and α-smooth muscle actin [31-34]. 
This evidence suggests that EMT, which is the major focus of this thesis, may be active in 
COPD, and it has the potential to be a driver of fibrosis and the development of lung cancer 
in COPD [35], such as in the large airways, which are the main site of COPD-related 
squamous cell lung cancer [16].   
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1.1.2.2.  Small airway destruction and emphysema 
Loss and fibrosis of the small airways is strongly related to decline in lung function in COPD 
[17]. The exact mechanisms behind the remodelling and destruction of the small airways 
remains largely unclear. While inflammation in the small airways has been proposed to be 
major factors in airflow limitation [36], recent evidence has brought this into question, 
demonstrating hypocellularity of the small airway wall [37] and other mechanisms, such as 
EMT, are likely to play a role [38-40].  
In addition to changes in the airways, emphysematous changes occur in the lung parenchyma 
of around 50-60% % of people with COPD [41]. Emphysema is destruction of the alveoli and 
surrounding parenchymal tissue of the lungs and while it also correlates strongly with 
worsened lung function [17], it is not the predominant cause of lung function decline in early 
stages of COPD. However, both emphysema and small airway changes fall beyond the scope 
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Respiratory infection rates in patients with COPD are increased compared to the general 
population [42]. Viral and bacterial infections are known to trigger exacerbations, with 30-
55% of hospitalised exacerbations presenting with viral or bacterial infections [43-46]. 
However, the exact mechanism behind this relationship is unknown. Acute infections are not 
the only concern in COPD; around 40% of people with COPD are estimated to have chronic 
and persistent colonisation of the airways and lungs, which likely contribute to acute 
exacerbations [42]. Haemophilus influenzae, Staphylococcus aureus, Streptococcus 
pneumoniae and Pseudomonas aeruginosa, are all common bacterial pathogens in COPD, 
although H. influenzae appears more frequently than the others [42, 43, 47, 48], and once 
established the infections can be near-impossible to eradicate. The method by which these 
infections persist, and why these particular species are so overrepresented in COPD is 
currently unclear, although there is evidence that the ability of H. influenzae and S. 
pneumoniae  to adhere to platelet-activating factor receptor (PAFr) on the airway epithelium 
may play a key role in their success [49-52], which is discussed in more detail in Chapterpter 
7. While high rates of infection and persistent colonisation of the lungs by pathogens might 
indicate underactivity or suppression of the immune system, the longstanding view of the 





NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 




Inflammation has been classically thought to play a key role in COPD, with high levels of 
neutrophils, macrophages and other inflammatory cells seen infiltrating the airway walls, 
parenchyma, and airway lumen [53]. In particular, CD28 positive inflammatory cells and 
neutrophils are known to be upregulated in COPD and are thought to contribute to the 
commonly-observed glucocorticosteroid resistance seen in COPD [54-56]. Chronic 
inflammation has also been suggested to promote the development and growth of lung cancer 
[35, 57] and is known to promote the development of fibrosis in other diseases [58, 59]. 
However, the inflammation story is not clear-cut [60], as recent work has also demonstrated 
that the airway walls in COPD are actually hypocellular, which challenges this long-held 
view that inflammation in the airway wall is a major contributor to the airway wall pathology 
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Fibrosis, airway remodelling and small airway obliteration are key features of COPD and 
have been shown to occur in areas with chronic inflammation in a number of other tissues, 
including the kidney and liver [58, 59]. It is proposed that in pathological fibrosis the normal 
cellular repair mechanisms are dysregulated and these healthy processes become damaging 
due to their continued activation [59]. Pro-inflammatory and pro-fibrotic cytokines such as 
tumour necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) are known to be 
unregulated in non-COPD related fibrosis [62-65]. In COPD airways, there are a number of 
similar cytokines upregulated, including TNF-α, IL-1, IL-8 and IL-10, [66] however it is still 
unclear precisely what effect they have in COPD. Possibilities include upregulation of 
extracellular matrix (ECM) production by existing fibroblasts or increased numbers of 
fibroblasts, which in turn results in higher levels of ECM production. Alterations at the 
cellular level in diseases such as these may open the door to more malignant changes, such as 
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1.1.2.6.  Lung cancer 
People with COPD have a six-fold increased risk of developing lung cancer [67, 68]. This 
risk is independent of their age, gender and current smoking status, which indicates that 
COPD itself is an independent predictor of lung cancer risk. In particular, while people with 
COPD are classically more prone to developing squamous cell and small-cell carcinomas 
than adenocarcinomas [69-71], there is evidence that adenocarcinomas are surpassing 
squamous cell carcinoma rates[16]. There is also evidence to suggest that adenocarcinomas 
are more common at GOLD Stage I, with later GOLD Stages being more prone to squamous 
cell carcinoma [72], and there is a difference in the rates of mortality due to lung cancer at 
these stages as well, with 55% of mild COPD deaths being due to lung cancer, while only 
33% of severe-stage COPD deaths attributable to the same [16]. Both squamous and small-
cell carcinomas occur most frequently in the central large airways [16]. The reasons behind 
this increased risk of lung cancer are largely unknown; it was thought to be due to the fact 
that the majority of people with COPD are smokers, however with the revelation that COPD 
predicts lungs cancer independently of smoking status, it would appear that some mechanism 
involved in COPD pathogenesis promotes or even causes the development of lung cancer. 
Along these lines, it has been proposed that susceptibility to COPD is related to susceptibility 
to lung cancer [73]. Metastatic cancers, including lung cancers, are shown to undergo a 
process called epithelial-mesenchymal transition (EMT) [74] and according to Cancer 
Research UK and the National Institute of Health (NIH) Surveillance, Epidemiology and End 
Results fact sheets, epithelial cancers, or carcinomas, comprise 85-99% of all human cancers 
[75, 76], which suggests that the epithelium is particularly susceptible to malignant changes.   
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1.2. Epithelial-mesenchymal transition 
1.2.1. What is EMT? 
Epithelial-mesenchymal transition (EMT) is a process that occurs naturally as part of human 
development. There are three ‘types’ of EMT, which occur at different points in development 
or in response to different stimuli (Figure 1.2-1). During embryogenesis, Type 1 EMT causes 
the formation of the mesodermal ridge and allows the original embryonic epithelial cells to 
differentiate into the many types of mesenchymal structures in the body [77, 78]. However, 
EMT occurs even after development is complete; Type 2 EMT is involved in wound-healing 
and repair. It allows epithelial cells to migrate to the site of injury and close wounds, as well 
as promoting the formation of scar tissue via fibrosis. Both Type 1 and Type 2 EMT are 
normal and not pathogenic.  
However, Type 3 EMT is associated with a number of pathogenic processes. Similar to Type 
2 EMT but made distinct by the presence of hypervascularity, Type 3 EMT is associated with 
cancer metastasis [35] and a number of fibrotic diseases [65, 79-82] and is the major focus of 
this project. 
EMT occurs when the epithelial layer loses coherence and becomes disorganised. Cell-to-cell 
contacts which use E-cadherin are replaced by N-cadherin junctions, and other adherent 
molecules such as occludins and caludins are downregulated [83]. Additionally, the cells 
undergo remodelling of their cytoskeletal structures, losing cytokeratin and upregulating 
expression of mesenchymal proteins such as vimentin, α-smooth muscle-actin and S100A4. 
The cells gain motility and lose their ability to form the tight barrier layer characteristic of 
epithelial cells. They also change their structure, losing apical-basal polarity and instead 
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gaining an elongated, motile phenotype. Cells undergoing EMT may also begin to produce 
extracellular matrix remodelling proteins such as fibronectin, matrix-metalloproteases and 
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Figure 1.2-1: The three types of epithelial-mesenchymal transition (EMT). Type 1 EMT occurs during 
embryogenesis and is responsible for forming the mesodermal ridge and the later formation of the 
mesodermally-derived tissues and organs. Type 2 EMT is active in adult tissues and allows for wound 
healing and repair of damaged epithelial layers via migration of new cells. Type 3 EMT is associated 
with malignant and pathogenic processes such as metastasis in cancer and fibrotic diseases. Type 3 
EMT is the only one of the three types of EMT which is associated with hypervascularity in the area.  
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1.2.2. What causes EMT? 
EMT can be driven by a number of different processes, and within disease its precipitating 
factors are often unclear, and are likely to be multifaceted. The intracellular processes by 
which EMT occurs appear to be centred around the activation and regulation of the 
transcription factors Snail and Slug, TWIST and zinc-finger E-box binding transcription 
factors [83]. These pathways are not unique to EMT; they control a number of other vital 
processes and can be triggered by a number of different factors, both internal and external to 
the cell. Thus, while these pathways are clearly indicated as involved in EMT development 
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1.2.2.1. The role of TGF-β in EMT 
One of the most widely-studied inducers of EMT, both in vivo and in vitro, is transforming 
growth factor-β1 (TGF-β) [83]. TGF-β has shown to be linked to EMT in hepatic fibrosis [65, 
80], kidney fibrosis [79, 81] and non-COPD-related pulmonary fibrosis [82], in addition to 
endothelial-mesenchymal transition in cardiac fibrosis [84]. It is also known to be 
upregulated in the small airways of people with COPD [85, 86]. TGF-β acts on TGF-β 
receptors 1 and 2 to form a complex. This complex then activates the Smad2/3 complex via 
phosphorylation, and the phosphorylated Smad2/3 can then either bind Smad4 and move into 
the nucleus to act as a transcription factor, or Smad6 or Smad7 can bind the complex and 
prevent transcription [87-89] (Figure 1.2-2). The Smad pathway is the most extensively 
studied of the pathways through which TGF-β acts, although there is evidence to suggest that 
the MAPK pathway, which can be activated by exposure to TGF-β and also to cigarette 
smoke, may play a role in inflammation in COPD [90]. Even under in vitro conditions TGF-β 
can induce EMT in bronchial epithelial cells [33, 91].  
One of the transcription factors which the Smad pathway regulates via the MAPK pathway 
[92] and which is capable of promoting EMT, along with the Snail/Slug and ZEB families, is 
TWIST [93]. TWIST is a helix-loop-helix transcription factor which has been demonstrated 
to promote EMT in metastatic cancer [94]. It is not expressed commonly in healthy adult 
tissues [95], and has been proposed as an attractive target for potential pathway blocking 
therapeutics in breast cancer [96]. TWIST is an e-box binding transcription factor and is 
naturally involved in embryonic development and differentiation, but in adult tissues 
promotes EMT via the down-regulation of E-cadherin [92, 95].  
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Factors other than TGF-β can induce EMT, although TGF-β is considered to be a major 
contributor to pathological EMT. TNF-α induces EMT in bronchial epithelial cells, and can 
enhance the EMT-inducing effects of TGF-β in-vitro [91]. EMT can also be induced by 
estradiol and the surface glycoprotein CD44 in breast cancer, which shows that drivers of 
EMT can be tissue-origin specific [97, 98]. EMT, whether induced by TGF-β or not, plays 
not only a role in development but is also involved in a number of disease pathologies.   
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Figure 1.2-2: Transforming growth factor-β1 (TGF-β) activation of the Smad pathway. TGF-β binds 
to TGF-β receptor II (top panel). Following the binding of TGF-β, TGF-β receptor II dimerises with 
TGF-β receptor I. Once the dimer is formed, TGF-β receptor I phosphorylates the Smad2/3 complex 
(middle panel). If the Smad signalling pathway activates successfully (bottom-left panel) then Smad4 
binds the phosphorylated Smad2/3 complex and the active complex translocates to the nucleus, where it 
acts as a transcription factor. If the Smad signalling pathway is inhibited, instead of Smad4 binding the 
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1.2.3. EMT in COPD 
While EMT is especially well-recognised to occur in many forms of metastatic cancer, 
including lung, gastric and breast cancers [99-102] and is also known to occur prior to 
kidney, hepatic and pulmonary fibrosis [65, 79-82], the potential for its presence in the 
development of COPD was not considered until relatively recently. In 2010 Sohal and 
colleagues noticed fragmentation of the reticular basement membrane in the airways of 
people with COPD [31]. Along with this fragmentation, they noted cells appeared within 
these clefts; however the reticular basement membrane is normally acellular. These cells 
stained positive for the epithelial cell marker cytokeratin 5, suggesting that they may have 
originated in the epithelial layer. However, they also stained positive for mesenchymal cell 
markers, including S100A4 and matrix metalloproteinase-9 (MMP9), as did some cells in the 
epithelial layer. Based on these observations, Sohal and colleagues proposed that EMT may 
be occurring in the airways of people with COPD and provided further support for these 
findings with additional cellular counting of immunohistochemically stained tissue in 2011 
[32]. 
These findings were later corroborated by Milara and colleagues in 2013, who demonstrated 
that primary human bronchial epithelial cells (pHBECs) underwent EMT in response to 
exposure to cigarette smoke extract (CSE) in both submerged and air-liquid interface (ALI) 
cultures, in addition to exhibiting decreased cell-to-cell contact as demonstrated bydecreased 
trans-membrane electrical conductance [33]. Milara and colleagues confirmed that the EMT 
pathway in pHBECs appeared to be at least partially Smad dependant, and that cigarette 
smoke exposure induced these cells to release increased levels of TGF-β and undergo EMT. 
They also demonstrated that the phosphodiesterase 4 (PDE4) inhibitor roflumilast-N-oxide 
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can prevent EMT in response to cigarette smoke, suggesting a potential treatment and an 
alternative non-TGF-β reliant mechanism of action of EMT in COPD [103]. 
More recently, Nishioka and colleagues have shown that soluble factors secreted by 
fibroblasts in COPD can induce EMT in healthy epithelial cells. While they did not identify 
the specific factors responsible, these findings provide further weight to the theory that EMT 
may occur in COPD airways, and raise the need for further study of the process in COPD 
[34].  
Overall there is a clear picture emerging that EMT is occurring in COPD and in direct 
response to cigarette smoke exposure. The precise mechanism by which the process is 
activated remains unclear, and it is highly likely that there are a number of mechanisms that 
trigger its progression, including Smad [33], PPAR [104-106], cholinergic [107-110] and 
Wnt pathway signalling [104, 111, 112]. Further research into the role of EMT in COPD is 
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1.2.3.1. EMT in lung cancer  
As mentioned previously, people with COPD have a six-fold increased risk of developing 
lung cancer [67, 68]. The mechanism behind this increased prevalence is currently unknown, 
however the discovery of EMT in COPD and smokers’ airways may shed light on the 
phenomenon. EMT is one of the key processes involved in cancer development and 
malignancy, and 85-99% percent of all cancers are derived from the epithelium [75, 76], 
which suggests a particular susceptibility to malignancy. In particular EMT is strongly linked 
to the metastatic potential of a number of different cancers, including ovarian [113], breast 
[101], lung [114] and prostate [115, 116]. The process as it occurs in lung cancer is of 
particular relevance to COPD and the relationship between the two diseases. Lung cancers 
exhibit EMT during metastasis and a tumour’s ability to metastasise and invade surrounding 
tissues correlated with the degree of EMT [102, 117].  
EMT in lung cancer is thought to be driven at least in part by TGF-β [118-122] and cytokines 
such as interleukin-17 [123], acetylcholine [124] and Williams syndrome transcription factor 
[114]. An inflammatory microenvironment in the airways has been linked to the development 
of cancer, supporting the role of inflammatory cytokines as potential drivers of EMT [35, 57, 
125]. However it is not known if these same molecules drive EMT in COPD.  
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
24 
 
1.3. Modelling human disease and mechanisms in vivo and in vitro 
When studying disease, it can often be challenging to look at the process in patients. This 
may be due to any number of reasons, including the rarity or lethality of the disease, the 
invasiveness of the procedures required to study the affected organs or the inability to detect 
the early stages of disease progression, which limits the ability to study and preventdisease 
development. In these cases, it is desirable to model the disease or process and utilise the 
model to identify key pathways which can become the target of therapy. There are two types 
of model systems available in the study of disease: in vivo and in vitro models. In vivo models 
of respiratory disease typically utilise mice, rats, guinea pigs or, rarely, dogs [126-128]. 
These models are useful for examining the complex intra-cellular interactions seen in human 
disease, however they are costly and time-consuming to produce and often do not recapitulate 
the precise pathology seen in human disease.  
In vitro cell-based models have the advantage over animal models in that they are sourced 
directly from human tissue and thus are more likely to be accurate representations of the 
human condition (Figure 1.3-1). However culture-based models lack complexity and 
intracellular interactions, which makes them less relatable to the human condition as a whole. 
While there are some culture models which allow multiple cell types to be grown 
concurrently [34, 129-131], they still only model a fraction of the complexity of the human 
body. Additionally, culture conditions can impact cell phenotypes, and there are marked 
differences between commercially available immortalised cell lines and cells taken directly 
from patients with the disease of interest [132]. Immortalised and primary cells have different 
advantages and disadvantages in the study of disease, (Figure 1.3-2) and it is important to 
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consider these when choosing a model. Despite their drawbacks, both in vitro and in vivo 
models can shed light on different aspects of the disease of interest.   
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Figure 1.3-1: Comparison of advantages and disadvantages of in vitro models versus in vivo 
animal models. Both cell-based models and models of disease induced in animals have advantages 
and disadvantages. Cell models (left) can be isolated from humans and specifically from diseased 
individuals, however lack the complex interactions of the extracellular milieu and do not provide 
structural information. In contrast, animal models allow for examination of histology and systemic 
effects, however structural differences between the model and humans are an issue.  
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1.3.1. Current models of COPD 
1.3.1.1. In vivo models 
Briefly, in vitro models of COPD are commonly induced in rats and mice, with a number of 
guinea pig models also being used [133-135]. There are three main methods of induction, 
these being genetic, exposure to exogenous elastase and exposure to cigarette smoke or other 
airway irritants. Genetic models of COPD [136-138] and elastase induced models [43, 139-
143] typically more closely resemble human alpha-1-antitrypisn (AAT) deficiency caused 
COPD, which is distinct from smoke induced COPD [144-146]. Even in cigarette smoke 
induced rodent models [133, 136, 140, 147-154], the endpoint which is typically used as the 
measure of COPD induction is emphysema [126]. This is problematic, since emphysema only 
occurs in half of all human COPD cases, and is a late-stage development [41].  
Additionally, structural differences between human and rodent airways [127, 133, 134] mean 
that key COPD indicators in humans such as mucus cell hyperplasia and fibrosis are often not 
measured. Small airway changes, which are key to loss of lung function in humans [36] are 
also difficult to measure, as mice lungs do not possess terminal bronchioles, and the closest 
analogous airway structure to the large airways in humans is actually the trachea, making 
physiological comparisons challenging [135]. Despite these drawbacks, rodent models of 
COPD have furthered understanding of COPD drivers, indicating the potential roles of 
pathways including PDGFR signalling via Sestrin-2 [136], angiotensin receptor signalling 
[151] and GSK-3 activation [155]. However, to understand complex, human-specific diseases 
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1.3.1.2. BEAS-2B and other immortalised cells 
Immortal cell lines derived from people with COPD are not available commercially, and even 
commercially available airway and lung derived epithelial cell lines tend to have limited data 
on the health status of the donors. The most common models of airway epithelium are the 
A549 cell line, derived from cancerous alveoli epithelia, the 16HBE cell line, derived from 
human bronchial epithelia and the BEAS-2B cell line, derived from healthy human bronchial 
epithelia. None of these cell lines are taken from patients with COPD, and given the extent of 
their culturing it is likely that even if they had been, they would not accurately represent the 
in vivo condition [132]. However, they are useful for studying specific pathways that may be 
present in airway epithelium and active in COPD.  
The BEAS-2B cell line is of particular relevance to this thesis. Regarded as ‘normal’, this 
cells line is an SV-40 adenovirus modified cell line taken from healthy human bronchi [156]. 
When studying airway epithelium, in the absence of primary cells the BEAS-2B cell line is 
considered an acceptable alternative, and its use in research has been and still is widespread 
[90, 157-177]. However, BEAS-2B cells clearly have an altered phenotype, evidenced by 
their immortality, their inability to differentiate into a fully formed epithelium when grown at 
an air-liquid interface [168] and their tendency to terminally differentiate when exposed to 
serum [178]. These characteristics raise the question: what else about their phenotype is 
different from primary epithelial cells extracted from healthy airways? With regards to EMT 
the two cell types, BEAS-2B and primary cells, have never been directly compared, since the 
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1.3.1.3. Primary cells 
While immortalised cell lines can shed light on diseases, particularly if there is a specific 
triggering element or condition which can be applied to the cells, in cases such as COPD 
where the exact mechanisms and causes are unclear, primary cells taken from the airway 
epithelium of patients with COPD theoretically provide a more complete insight into the 
disease. While COPD is caused mainly by cigarette smoke in developed countries such as 
Australia and America, the exact components which trigger the pathological processes are 
unknown, as are the factors within the affected person which cause them to be susceptible. 
Indeed, even the mechanisms by which the disease develops and progresses remain largely 
unclear, although there have been large advances made in recent years, and it is becoming 
obvious that there are multiple cell types which play different roles in the disease. Since it is 
therefore difficult to induce an accurate model of COPD in a healthy cell line, particularly 
given the contribution of numerous different cell types to the disease, when studying 
bronchial epithelial cells and their role in COPD it may be simpler to take cells from people 
with COPD to study rather than attempting to artificially induce the full disease state in 
healthy cells. However, it is completely possible to induce certain mechanisms and changes 
which may drive disease progression, such as EMT, in healthy cells and thus it is possible to 
examine particular mechanisms behind diseases, albeit without the complete context of the 
disease itself.  
Work has been done on a number of different cell types in COPD, including lymphocytes 
[54, 179], T-cells [55, 180-182], macrophages and natural killer cells [56, 183-188], lung-
derived fibroblasts [189, 190] and, most importantly for this thesis, epithelial cells [25, 103, 
189, 191-196]. Primary lung epithelial cells can be grown in submerged culture [103, 185, 
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193, 196], however for further applicability to the lung environment, they can also be grown 
in an air-liquid interface (ALI) culture system, which allows them to form a differentiated 
epithelial layer with cilia and mucus production [103, 189, 193-195]. There has been 
evidence that epithelial cells derived from people with COPD do not survive as well as those 
from non-smokers or people without COPD, nor do they differentiate as readily at ALI as 
healthy epithelial cells [30], which can make using them as a model difficult. There is 
evidence that the major site of dysregulation occurs in the basal stem cells of the epithelial 
layer [26-30, 135, 197, 198], suggesting that submerged culture, which produces similarly 
‘basal’ cells, can be exceptionally useful in studying these mechanisms.  
Despite the challenges, epithelial cell culture models of COPD have revealed a number of 
insights into the disease. Smoking and COPD decrease the length of the airway cilia, possibly 
reducing clearance of bacteria and damaging particles from the lungs [25]. Heterogeneity of 
CFTR, an ion channel whose dysfunction is responsible for cystic fibrosis and which was 
speculated to contribute to chronic bronchitis in COPD, does not appear to impact ion 
transportation in COPD more than in non-COPD patients [195], and although the work was 
not performed in COPD-derived cells, there is evidence that exposure to cigarette smoke 
promotes autophagy in airway epithelial cells, which may play a role in COPD [194]. There 
is also evidence from cell culture that platelet-activating factor and the PI3K-p110α pathway 
may play roles in the increased rates of bacterial and viral infections seen in COPD lungs 
[191, 199].  However, the models which are most relevant to this thesis are the models which 








Figure 1.3-2: Comparison of the advantages and disadvantages of immortalised cell versus primary cell models systems. In vitro models are 
valuable for studying pathways and mechanisms, as well as testing potential therapies. Immortalised cell lines are easier to obtain and culture than 
primary cells, however often exhibit abnormal phenotypes compared to primary cells.  
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1.3.2. Current models of EMT  
1.3.2.1. In healthy human bronchial epithelial cells 
As has been shown in a number of other epithelial cell lines derived from various origins, 
EMT can be induced by application of exogenous TGF-β [62, 200, 201]. It comes as little 
surprise, in that case, that human epithelial cells derived from the alveoli (the A549 cell line) 
and the bronchi (the BEAS-2B cell line) undergo EMT in response to stimulation with TGF-β 
[163, 165, 175, 202]. Perhaps of more obvious relevance to the question of EMT in COPD, it 
has been demonstrated that nicotine can directly induce EMT when applied to cells, and 
appears to act through the Wnt/β-catenin signalling pathway [112]. However, as discussed 
previously (1.3.1.2), immortalised cell lines exhibit numerous changes from their original 
phenotypes, and thus it is important to know if these changes also occur in primary cells 
derived directly from human lungs.  
Primary human bronchial cells (pHBECs) are epithelial cells taken directly from the airway 
walls via brushings during bronchoscopy, or grown out from biopsy samples. They have 
finite lifespans and are more difficult to obtain than commercially available cell lines, 
however they are theoretically more closely representative of the physiology of their origin 
than immortalised cell lines. While cell lines are useful, it is important to know if pHBECs 
are capable of undergoing EMT before making firm claims regarding the potential role of 
EMT and pathways which induce it in COPD based on cell culture work. EMT can be 
induced in primary human bronchial epithelial cells via application of TGF-β and tumour 
necrosis factor-alpha (TNF-α) separately, and there is a synergistic effect when  the two are 
applied in combination [91]. Furthermore, application of cigarette smoke extract (CSE) not 
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only induces EMT in pHBECs, it also appears to activate the Smad pathway, which is one of 
the major TGF-β related pathways [33], and is capable of inducing EMT in alveolar-derived 
primary epithelial cells [203]. This suggests that TGF-β and its associated pathways may play 
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1.3.2.2. In COPD-affected bronchial epithelial cells 
There have been no animal models to date which have looked for EMT changes in COPD 
airways, however there have been a number of human-derived in vitro cell models. Although 
EMT can be induced in epithelial cells derived from the airways and alveoli, as discussed 
previously, it is all for nothing if it does not mimic the EMT seen in COPD. While biopsies 
from patients can reveal some mechanistic information, they do not readily allow the testing of 
different treatments or the inhibition of pathways, which allows one to mine further information 
about the process of interest, although it can be done [204]. Cell culture allows these things to 
be done more easily, and the most reliable way to get the most accurate culture models of EMT 
in COPD is to culture epithelial cells directly from the airways of people with well-documented 
disease.  
As early as 2006, it was suggested that there were some issues with epithelial cell deregulation 
and altered functioning that may be playing a role in COPD, beyond simple hyperplasia [205], 
however it was not until 2010 that evidence was provided for the possibility of EMT in COPD 
airways [31]. Despite being able to induce EMT in bronchial epithelial cells via the application 
of endogenous cytokines, growth factors and other stimulants such as cigarette smoke extract 
[77, 78, 82, 91, 163, 165, 202, 206], it was only in 2010 that Milara and colleagues 
demonstrated EMT in unstimulated cultured cells taken directly from people with COPD [33]. 
Since then, there have been a number of models of EMT in bronchial epithelial cells used to 
study EMT in COPD, both in primary cells derived from COPD and immortalised cell lines 
induced to exhibit EMT [34, 125, 197, 203, 207]. However there appears to have been little 
work done to answer a very basic question: in the absence of primary cells taken from people 
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with COPD, can immortalised cells truly recapitulate EMT as seen in COPD, or are they 
modelling a process which may appear superficially similar but where the underlying 
mechanisms are fundamentally different? There is also the question of whether EMT occurs 
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1. To determine if EMT is present in primary bronchial epithelial cells sourced from non-
smokers, smokers with normal lung function and people with airflow limitation or pre-
COPD.  
o To collect and characterise a bio-bank of primary bronchial epithelial cells 
(pHBECs) taken from healthy non-smokers, smokers with normal lung function and 
people with airflow limitation, with a focus on EMT markers and the pathogen 
adhesion molecules I-CAM-1 and platelet activating factor receptor (PAFr). 
o To compare the expression of EMT-related proteins and mRNA in cultured 
pHBECs with the expression of the same markers in matched biopsy tissue in order 
to examine the effects of culture on the cells’ expression profiles. 
o To compare the expression profiles of pHBECs from people with normal lung 
function and pre-COPD with regards to the expression of the lung cancer marker 
brachyury to determine if pre-COPD-derived epithelial cells exhibit increased 
expression of this lung cancer marker. 
2. To assess the suitability of the BEAS-2B cell line as a model for pHBECs, with particular 
focus on EMT.  
3. To induce EMT in pHBECs and immortalised cells via application of cigarette smoke 
extract and transforming growth factor-β, and determine whether cigarette smoke extract 
induced EMT occurs in healthy epithelial cells taken from non-smokers.  
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4. To assess the effect of current late-stage COPD treatment drugs, including corticosteroids, 
long-acting muscarinic-antagonists and long-acting β-agonists on EMT in early pre-clinical 
COPD.  
o To determine if the drugs have similar effects on induced EMT as on EMT in cells 
isolated from people with airflow limitation. 
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2. Materials and Methods 
NOTE: Unless otherwise specified, procedures were performed under aseptic conditions in 
the PC2 laboratory at the Menzies Research Institute. All cell culture was performed in an 
appropriately sterilised laminar flow biosafety cabinet which was exposed to UV radiation for 




NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 




2.1. List of Abbreviations 
2.1.1. General abbreviations 
COPD – chronic obstructive pulmonary disease 
CS – current smoker 
CSE – cigarette smoke extract 
ELISA – enzyme linked immunoabsorbance assay 
ES – ex-smoker 
FIJI – FIJI is just ImageJ 
GOLD – Global Initiative for Chronic Obstructive Lung Disease 
ICS – inhaled corticosteroid 
IL - interleukin 
LABA – long acting beta agonist 
LAMA – long acting muscarinic antagonist 
NLFS – smoker with normal lung function 
NNS – non-smoker 
p# – passage number 
PAFr – platelet activating factor receptor 
PBFs – primary bronchial fibroblasts 
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pHBECs – primary human bronchial epithelial cells 
SEM – standard error of the mean 
TGF-β – transforming growth factor beta-1 
TJP1 – tight junction protein-1 
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2.1.2. Abbreviations for materials and methods 
AmpB – amphotericin B 
BEBM – bronchial epithelial basal medium 
BEGM – bronchial epithelial growth medium 
BSA – bovine serum albumin 
DAB – 3’3’-diaminobenzadine 
DMEM – Dulbecco’s modified Eagle medium 
DMSO – dimethyl sulphoxide 
EDTA – ethylene diamine tetra-acetic acid 
ECS – eight-chambered slide 
FBS – foetal bovine serum 
FEF25-75 - forced expiratory flow 25-75% 
FEV1 – forced expiratory volume in 1 second 
FVC – forced vital capacity 
HRP – horseradish peroxidase 
PBS – phosphate buffered saline 
penstrep – penicillin/streptomycin 
PVP – polyvinyl pyrrolidone  
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qPCR – quantitative real-time PCR 
RHH – Royal Hobart Hospital 
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2.2. Recruitment and subject demographics 
2.2.1. Recruitment methods 
Recruitment and collection of samples was approved by the Tasmanian Health and Medical 
Human Research Ethics Committee (H0013051). 
Volunteers who responded to a newspaper advertisement for the study were recruited and 
screened by a practice nurse, before attending the Royal Hobart Hospital (RHH) for a 
bronchoscopy. Volunteers were sedated by a trained anaesthesiologist and local anaesthetic 
applied to the nasal passages prior to insertion of the bronchoscope. All procedures were 
performed by fully trained staff within the RHH. The bronchoscope was inserted via a nostril, 
travelling down through the larynx and into the upper bronchi. Excess mucus and blood was 
cleared by flushing the airways with a sterile saline solution. Brushings were taken from the 
large airways and placed in bronchial epithelial growth media (BEGM) for culture into 
bronchial epithelial cells. Following the brushings, a small clamp was inserted into the 
airways. Four biopsies were removed and placed in 4% paraformaldehyde for embedding in 
wax blocks, and a single biopsy was removed and placed in Dulbecco’s modified Eagle 
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2.2.2. Volunteer demographics 
The volunteers who participated in this study responded to an advertisement requesting 
smokers and non-smokers. They were recruited and assigned to the study groups on the basis 
of airflow obstruction and smoking status. It was expected, based on prior experience by the 
group in which this study was undertaken, that there would be enough volunteers with COPD 
as defined by the GOLD criteria [208]. However, while the volunteers presented with airflow 
obstruction, all but two failed to meet the clinical criteria for a diagnosis of COPD under the 
GOLD guidelines (FEV1/FVC ratio <70%) [208]. However, there was evidence of significant 
airflow limitation and obstruction in a subset of 17 volunteers (Table 2.2-1). These volunteers 
exhibited significantly lower forced expiratory volumes over one second (FEV1), as well as 
reduced maximum mid-expiratory flow (also called forced expiratory flow 25-75% or FEF25-
75%) and reduced FEV1/FVC ratios as compared to those volunteers with normal lung 
function, as determined by ANOVA. For the purposes of this study, these patients were 
considered to have chronic airflow limitation, or ‘pre-COPD’, as they exhibited significant 
airflow limitation, and are referred to as ‘COPD’ for the remainder of this work.  
Overall, this study successfully recruited 46 volunteers out of 117 people who responded to 
the advertisement (Figure 2.2-1). In addition, four volunteers who were already undergoing a 
bronchoscopy for medical reasons were recruited at a later stage in the study. The final 
breakdown of volunteers was 19 non-smokers, 12 ex-smokers with chronic airflow 
limitation/COPD, 5 current smokers with chronic airflow limitation/COPD and 10 current 
smokers with normal lung function.    
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95.5 (16.8) *80.4 (10.5) *40.2 (10.3) 35.8 (12.3) *64.4 (23.7) 
Table 2.2-1: Demographic information for the volunteer groups which provided samples. Data were presented in the format: mean (standard deviation), except for 
gender, which was presented as total females/total males. One pack-year is equivalent to smoking 1 pack (20 cigarettes) per day for 1 year. Numbers in bold are 
significantly different from non-smokers (one-way ANOVA p<0.05), numbers preceded by an asterisk (*) are significantly different from smokers with normal lung 
function (one-way ANOVA p<0.05), numbers preceded by a cross (†) are significantly different from current smokers with COPD (one-way ANOVA p<0.05). 
 
KEY: NNS= non-smokers; NLFS=smokers with normal lung function; COPD= chronic obstructive pulmonary disease; COPD-CS= current smokers with COPD; 
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Figure 2.2-1: Flowchart of volunteer recruitment and retention.  
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2.3. General cell culture methods 
2.3.1. Flask, slide and plate coating procedure 
Flasks were coated with a solution of 1:30 bovine collagen (Type I; Life Technologies, cat# 
A10644-01) in PBS (Life Technologies, cat# 10010-023). The collagen mixture was applied 
to the culture surface of the flasks, plates or slides used, and placed in a humidified incubator 
at 37°C and 5% CO2 for a minimum of an hour and a maximum of two hours. Following 
incubation, the collagen solution was removed by tapping the culture vessel hard on its side 
and aspirating or pouring the coating media off. The culture surface was washed two times 
with sterile PBS, except in the case of eight-chambered slides, where no washing occurred 
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2.3.2. EMT induction methods 
2.3.2.1. Exposure to transforming growth factor-β1 (TGF-β) 
The transforming growth factor β-1 (TGF-β) stock solution (Abcam (Sapphire), cat# 
ab50036; prepared in water) was dissolved in BEGM at a ratio of 1:1,000 to give a working 
concentration of 10ng/μl, which would be more than sufficient to induce EMT [91]. All cells 
had their media poured off and disposed of. The TGF-β solution was applied to the cells in 
the amounts as follows: T-25 flasks required 4ml of solution, T-75 flasks 7ml of solution, 
6WPs 2ml of solution, 12WPs 1ml of solution, 24WP 0.5ml solution and ECSs 200μl of 
solution.  
Cells that were not being treated had fresh BEGM applied in the same amounts. All cells 
were incubated at 37°C and 5% CO2 in a humidified incubator. Images were taken on a 
DMIL (Leica) microscope using a Leica DFC320 camera and the imaging program FireCam 
(version 3.4.1) at 4x and 10x objective magnification both prior to and at the conclusion of 
treatment. Treatment was commenced when cells were approximately 80-90% confluent for 
BEAS-2Bs, and five days after being thawed for pHBECs, and was maintained for 72 hours.   
2.3.2.2. Exposure to cigarette smoke extract (CSE) 
Cigarette smoke extract was generously provided by the Edvinsson group at Lund University, 
Sweden [209]. The extract was transported dried on filter paper – extraction was achieved by 
soaking the filter paper overnight in DMSO (1ml). For treatment of cells, based on previous 
dose response work by Jessica Kregor within the author’s group, CSE was applied to cells at 
0.1% in complete BEGM for four hours. 0.1% CSE worked out as roughly equivalent to 
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0.3% of a single cigarette and with 0.8mg of nicotine per cigarette [199, 209], an expected 
total of approximately 7.2µg2µg nicotine in a single exposure. Standardisation of cigarette 
smoke is, however, difficult due to the variable composition of cigarettes between brands, as 
well as the variability in what individuals are exposed to while smoking.   
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2.3.3. Drug treatments 
2.3.3.1. Salmeterol xinafoate 
4.5mg of salmeterol xinafoate (Sigma-Aldrich, cat# S5068-10MG) was measured out and 
diluted in 745μl DMSO (Sigma-Aldrich, cat# D8418-50ML) to obtain a 10mM stock 
solution. It was stored at room temperature in the dark. Salmeterol has a pharmacological Kd 
value (the concentration at which the substrate occupies 50% of available receptors) of 1-
2nM [210]. 
2.3.3.2. Fluticasone proprionate 
5mg of fluticasone proprionate (Sigma-Aldrich, cat# F9428-5MG) was diluted directly in the 
bottle with 1,000μl DMSO (Sigma-Aldrich, cat# D8418-50ML) to obtain a 10mM stock 
solution. It was stored at room temperature in the dark. Fluticasone has a pharmacological Kd 
value of 42.5-19.5 nM [211]. 
2.3.3.3. Tiotropium bromide 
5.3mg Tiotropium bromide monohydrate provided by Boehringer Ingelheim was diluted in 
1,120μl DMSO (Sigma-Aldrich, cat# D8418-50ML) to obtain a 10mM stock dilution. It was 
stored at room temperature in the dark.Tiotropium has a pharmacological Kd value of 0.1-0.3 
nM [212]. 
2.3.3.4. Treatment procedure 
Unless otherwise stated, all drugs were delivered at a 10μM dilution (1:1000 dilution from 
stock) in cell growth medium for 24 hours. This dosage was decided upon following personal 
communication with Dr. Mathew Eapen, also in the Centre for Research ExcellenceCRE, 
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who had previously worked in industry and recommended the dosage as a standard starting 
point. The dosage was also consistent with the experiences in early-career pharmacological 
studies on airway tissue in vitro of Professor E.H. Walters, and the concentration is far above 
the Kd of the three drugs, ensuring saturation of receptors. Drugs were started 20 hours prior 
to treatment with cigarette smoke extract (CSE) or after 48 hours of treatment with TGF-β (if 
applicable) and were applied concurrent with the treatments. Controls for these samples had 
DMSO added to the growth medium at 0.3% v/v.    
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2.3.1. Collection of supernatant for ELISA 
24 hours before the end of treatment the culture media was removed and replaced with fresh 
media. If treatments were less than 24 hours, no replacement occurred. Following the 
remainder of the treatment, the supernatant from the cells was collected and centrifuged at 
1,500g for 10 minutes at 4°C (Beckman-Coulter Allegra X-12R or Centurion Scientific K3 
Series centrifuge). Following centrifugation, the supernatant was removed and stored in 1ml 
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2.4. Cell culture (PHBECs) 
NOTE: Prior to cryopreservation, BEGM contained all supplements supplied in the Lonza 
SingleQuots kit (cat# CC3170), in addition to 2.5μg/ml Amphotericin B (AmpB) (Sigma-
Aldrich, cat# A2942-50ML) and 1 unit penicillin and 1ug/ml streptomycin (using a stock of 
penicillin/streptomycin (penstrep) (Sigma-Aldrich, cat# P4333-100ML)). Following 
cryopreservation and thawing (passage 2 and beyond), BEGM contained all supplements 
supplied in the Lonza SingleQuots kit (cat# CC3170) without additional antibiotics. 
2.4.1. General methods 
2.4.1.1. Collection of samples 
Brushings were used to culture PHBECs. A small wire brush was passed down through the 
tube attached parallel to the bronchoscope, and was scraped repeatedly against the wall of the 
bronchi. The brush was withdrawn and the end placed in BEGM. Four brushes were 
collected, each placed in separate tubes. Samples and culture media were exposed to air for 
the least amount of time possible. All collection and transport occurred at ambient 
temperatures.  
2.4.1.2. Culture set up 
Once collected, the brushes were transferred to the Menzies Research Institute. The brushes 
were vigorously agitated within the media to place as many cells as possible into suspension, 
before the brushes themselves were placed in a coated T-25 flask with BEGM (4ml). The 
media containing the cells was centrifuged in a Heraeus Megafuge 2.0 centrifuge at 1,500rpm 
for five minutes. The supernatant was discarded and the cell pellet resuspended in BEGM 
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(1ml). Each cell pellet was placed into a separate coated T-25 flask, with additional BEGM 
(4ml). All flasks were incubated at 37°C and 5%CO2 in a humidified incubator. These cells 
were designated passage number 0 (p0). 
2.4.1.3. Maintenance 
Cells were fed two to three times weekly. ‘Feeding’ consisted of aspirating or pouring off the 
old, used media and applying fresh media. T-25 flasks required 4ml of BEGM, T-75 flasks 
7ml of BEGM, 6-well plates (WPs) 2ml of BEGM, 12WPs 1ml of BEGM, 24WP 0.5ml 
BEGM and ECSs 200μl of BEGM. 
Upon cells becoming approximately 80-100% confluent, images were taken on a DMIL 
(Leica) microscope using a Leica DFC320 camera and the imaging program FireCam 
(version 3.4.1) at 4x and 10x objective magnification. The media was discarded or collected 
for ELISA (see 2.10.1), and trypsin/EDTA (Sigma-Aldrich, 0.25% trypsin, 0.02% EDTA, 
cat# T4049) was applied to the cells. The cells were incubated at 37°C and 5% CO2 in a 
humidified incubator until they were detached from the culture surface, at which time BEGM 
equal to four times the volume of trypsin/EDTA (Sigma-Aldrich, 0.25% trypsin, 0.02% 
EDTA, cat# T4049) was added to the cells. The cell solution was swirled in the flask to 
encourage all the cells to detach, before being centrifuged at 1,500rpm for five minutes. The 
supernatant was discarded and the cell pellet resuspended in BEGM. For cells at p0, 
resuspension was in BEGM (1ml); for other passage numbers the volume varied depending 
on the intended use (see the appropriate section for further details). The cells were seeded 
into the appropriate coated culture vessels and the passage number increased by one. Cells at 
p0 in a single T-25 flask were seeded into two T-75 flasks and became p1 cells, for example.  
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 





Cells were trypsinised as described in 2.4.1.3. Following centrifugation the cell pellet was 
resuspended in cryoprotectant comprised of 10% DMSO in FBS. Cell pellets obtained from 
T-25 flasks were resuspended in 2ml of cryoprotectant, and cell pellets from T-75 flasks in 
3ml. The only exception was when half of the flask was taken for RNA extraction, at which 
point cells were resuspended in 1ml and 2ml respectively. The cell solution (1ml) was placed 
into Nalgene 1.5ml cryovials (Sigma-Aldrich, cat# V4757) and placed in a Nalgene Mr. 
Frosty cryo-cooler device (Sigm-Aldrich, ca# C1562). The Mr. Frosty was stored at -80°C 
overnight (occasionally for longer, no more than 72 hours, if noted), after which the cryovials 
were transferred to vapour phase liquid nitrogen storage.  
2.4.1.5. Reviving cryopreserved cells 
Frozen cells were retrieved from the liquid nitrogen storage on ice, and then rapidly thawed 
by hand, or in a water bath heated to 37°C for large numbers of vials. The cells were quickly 
placed into excess BEGM (9ml) and centrifuged at 1,500rpm (Heraeus, Megafuge 2.0) or 
130g (Beckman Coulter, Allegra X-12R) for five minutes. The supernatant was discarded, 
and the cells resuspended in BEGM (1ml). Cells were either seeded into one coated T-75 
flask with BEGM (7ml) or into three T-25 flasks with BEGM (4ml). Flasks were incubated at 
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2.4.2. Culture for immunocytochemistry 
2.4.2.1. Cell culture on coverslips 
Coverslips were placed in a 12-well plate, one slip per well. Bovine Type I collagen (Life 
Technologies, cat# A10644-01) was dissolved to a final dilution of 1:30 in ethanol (30% in 
water). The collagen solution was applied to the bottom of the wells in an amount sufficient 
to cover the slips and the surface of the well and left overnight to evaporate. However, due to 
issues with cell growth on the coverslips and overall difficulty with staining and handling of 
the coverslips, this method was abandoned. 
Cells were brought up from storage (2.4.1.5), grown and passaged as described in 2.4.1.3. 
Following trypsinisation, cells were seeded into the coated wells containing coverslips (2.3.1) 
and incubated with fresh BEGM at 37°C and 5% CO2. Cells were grown until 95-100% 
confluency before being used for immunocytochemistry. 
2.4.2.2. Cell culture on eight-chambered slides 
Cells were brought up from storage (2.4.1.5) and seeded into the wells coated with 1:30 
bovine collagen (Type I; Life Technologies, cat# A10644-01) in PBS (Life Technologies, 
cat# 10010-023) (2.3.1). A single cryovial (1ml of cells) was used to seed 9 wells. Cells were 
incubated with fresh BEGM at 37°C and 5% CO2 for five days, and either treated as 
described in section 2.3.2 and 2.3.3 or left untreated. Following treatment, cells were 
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2.5. Cell culture (PBFs) 
NOTE: DMEM was supplemented with 10% FBS and contained 2.5μg/ml AmpB (Sigma-
Aldrich, cat# A2942-50ML) and 1 unit penicillin and 1ug/ml streptomycin (Sigma-Aldrich, 
cat# P4333-100ML). 
2.5.1. Collection of samples 
A bronchoscopy was performed as described in 2.4.1.1, with a single biopsy taken and placed 
in DMEM supplemented with 10% FBS.  
2.5.2. Culture set up 
Biopsies were ‘wounded’ by gently cutting with a scalpel blade, passing through a 1000μl 
pipette tip or abrading on a filter. Wounded biopsies were then placed in a coated T-25 flask 
with DMEM supplemented with 10% FBS (4ml) and incubated at 37°C and 5% CO2 in a 
humidified incubator.  
2.5.3. Maintenance 
Upon formation of a monolayer extending some distance from the biopsy, the media was 
decanted and trypsin/EDTA applied (Sigma-Aldrich, 0.25% trypsin, 0.02% EDTA, cat# 
T4049). The cells were incubated at 37°C and 5% CO2 in a humidified incubator for fifteen 
minutes and DMEM with 10% FBS was added (4ml). The cells were centrifuged at 1,500rpm 
in a Heraeus, Megafuge 2.0 centrifuge for 10 minutes, following which the cell pellets were 
resuspended in DMEM with 10% FBS (1ml) and placed in a fresh coated T-25 flask with 
DMEM/FBS (4ml). Cells were incubated at 37°C and 5% CO2 in a humidified incubator, 
however no further growth was observed and the cells were abandoned. 
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2.5.4. Brief discussion of fibroblasts 
Attempts were made to culture fibroblasts from biopsies collected with the brushings and 
stored in DMEM, however all but one sample failed to proliferate fibroblasts, and following 
passage that sample failed to grow and died. A total of two flasks taken from brushings 
became spontaneously overrun with what appeared at the gross phenotypic level to be 
fibroblasts (Figure 3.2-1), one flask at passage zero and, interestingly, one flask at passage 2 
following cryopreservation and thawing, both growing in bronchial epithelial growth media 
(BEGM). The flask at passage 0 was given to Mathew Eapen, a fellow PhD student who was 
intending to culture fibroblasts as part of his study, however they subsequently died. The 
flask which was overrun at passage 2, which was especially interesting since it was taken 
from a different volunteer from the initially overrun flask and both prior to freezing and for 
some time after thawing appeared phenotypically identical to the other epithelial cells, was 
grown successfully in BEGM and frozen in the same manner as the epithelial cells (2.4.1.4). 
No tests were performed on these cells, although they remain in storage.  
It was unclear why culturing fibroblasts from explants was unsuccessful – potentially, 
supplementation of the media with additional serum or growth factors may be recommended. 
In cases where the fibroblasts overtook the epithelial cell cultures, they proved to be hardy 
and prolific, however in these cases it is probable that the cultures would still remain mixed. 
If required to utilise these fibroblasts, it would be recommended that some form of cell 
sorting, possibly using flow cytometry, be performed to ensure pure cultures of fibroblasts 
without epithelial cell contamination. In conclusion, the attempted culture of paired 
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fibroblasts from biopsies matched to epithelial cultures was a failure, although the reasons for 
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2.6. Cell culture (BEAS-2B) 
NOTE: BEGM contained all supplements supplied in the Lonza SingleQuots kit (cat# 
CC3170) with no additional antibiotics.  
2.6.1. Creating a working stock of BEAS-2B cells 
2.6.1.1. Coating procedure 
The flasks for this procedure were coated with FCS mix, which was a 0.01mg/ml fibronectin, 
0.03mg/ml collagen-1, 0.01mg/ml bovine serum albumin mix made up in culture growth 
media (bronchial epithelial growth media without the AmpB SingleQuot). The mix (4ml) was 
placed on the flasks for 2 hours at 37°C, 5% CO2 then removed and the flasks were air-dried 
overnight in the biosafety hood before use. 
2.6.1.2. Thawing and culture maintenance 
A single vial of BEAS-2B cells at passage 4 (p4) was obtained from the American Type 
Culture Collection (ATCC, cat# CRL-9609) and stored in vapour phase liquid nitrogen. The 
cells (1ml) were rapidly thawed, placed in bronchial epithelial growth media (9ml, BEGM, 
without the AmpB SingleQuot) centrifuged at 1,500rpm for 10 mins (Beckman-Coulter, 
Allegra X-12R), following which the cells were resuspended in fresh BEGM and placed into 
a single T-75 flask (Corning via Sigma-Aldrich, cat# CLS430641) coated with FCS in 
BEGM (7ml), as per the commercial instructions for the cells. The thawing procedure was the 
same for subsequent passages of cells. 
During growth, the cells were incubated at 37°C, 5%CO2 until they reached approximately 
90% confluence, with BEGM (7ml) being replaced every Monday and Friday. Upon reaching 
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90% confluence, the media was removed from the cells and a trypsin/EDTA/polyvinyl 
pyrroline (2ml, Sigma-Aldrich, 0.25% trypsin, 0.02% EDTA, cat# T4049; Sigma-Aldrich, 
0.5% PVP, cat# P0930) solution was applied to the cells until they detached from the flask, as 
per commercial instructions. The cell solution was placed in BEGM (8ml) and centrifuged at 
130g for 5 mins (Beckman-Coulter, Allegra X-12R), before being resuspended in BEGM 
(7ml) and split into seven coated T-75 flasks. Cells were grown to passage 5 and all flasks 
were frozen down to create a master stock of cells, with each vial containing cells at the 
concentration of 1x105cells/ml.  
From the master stock, a single vial was thawed. The vial was thawed and grown as described 
above and passaged into seven T-75 flasks. Those flasks were then grown, passaged and the 
cells cryopreserved, at a final concentration of 1x106cells/ml.  
2.6.1.3. Cryopreservation 
Following trypsinisation, the cells were centrifuged at 130g for 5 mins (Beckman-Coulter, 
Allegra X-12R), before being resuspended in a cryoprotectant mix comprised of 10% DMSO 
and 90% BEGM. The cells were resuspended to a concentration of 1x105cells/ml for the 
master stock (due to a calculation error) and 1x106cells/ml for the working stock. Vials were 
then placed in a -80°C freezer in a Nalgene Mr. Frosty cryo-cooler (Sigma-Aldrich, cat# 
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2.6.2. General methods 
2.6.2.1. Reviving cryopreserved cells 
Frozen cells were retrieved from the liquid nitrogen storage on ice, and then rapidly thawed 
by hand. The cells were quickly placed into excess BEGM (9ml) and centrifuged at 300g for 
five minutes. The supernatant was discarded, and the cells resuspended in BEGM (1ml). 
Cells were seeded into one coated T-75 flask with BEGM (7ml) and incubated at 37°C and 
5% CO2 in a humidified incubator. 
2.6.2.2. Maintenance 
Cells were passaged twice a week upon reaching approximately 80% confluence. The old 
media was removed from the cells and trypsin/EDTA/PVP applied (0.25% trypsin, 0.02% 
EDTA, 0.5% PVP). During 2016/17, cell growth was greatly diminished and cells were 
passaged approximately once a month, upon reaching 80-90% confluence.  
Cells were incubated at 37°C and 5% CO2 in a humidified incubator until most cells had 
detached from the culture surface. BEGM equal to four times the amount of 
trypsin/EDTA/PVP was added, and the solution swirled gently to encourage any remaining 
cells to detach. The cell suspension was centrifuged at 300g in an Allegra 12-XR (Beckman 
Coulter) centrifuge for five minutes. Cells were split one in seven to seed a new coated T-75 
flask, with the remainder used to seed coated culture vessels appropriate for the experiments 
to be performed (see the relevant sections for more detail).  
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During experimentation, cells were not synchronised in cell cycle by serum starvation, 
however cells were utilised following a set period of growth after passaging (five days) and 
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Cells were trypsinised and centrifuged as described in 2.6.2.2. Following centrifugation, the 
cells were resuspended in cryoprotectant comprised of 7.5% DMSO and 92.5% BEGM to an 
approximate concentration of 1x106 cells/ml. The cell solution (1ml) was placed into Nalgene 
1.5ml cryovials (Sigma-Aldrich, cat# V4757) and placed in a Nalgene Mr. Frosty cryo-cooler 
device (Sigma-Aldrich, cat# C1562). The Mr. Frosty was stored at -80°C overnight, after 




NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 




2.6.3. Culture for RNA and intra-cellular protein extraction 
Cells were brought up from storage (2.6.2.1), grown and passaged as described in 2.6.2.2. 
Following trypsinisation, cells used for RNA extraction were resuspended in ice cold PBS 
(1ml; Life Technologies, cat# 10010-023). Cells were centrifuged at 130g for five minutes 
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2.6.4. Culture for immunocytochemistry 
Cells were brought up from storage (2.6.2.1) and seeded a single T-75 flask coated with 1:30 
bovine collagen (Type I; Life Technologies, cat# A10644-01) in PBS (Life Technologies, 
cat# 10010-023) (2.3.1). Cells were incubated with fresh BEGM at 37°C and 5% CO2 until 
they reached 80% confluence and then were passaged as described in section 2.6.2.2. Cells 
were split with 2/7 of the total seeded into 2x T-75 flasks coated with 1:30 bovine collagen 
(Type I; Life Technologies, cat# A10644-01) in PBS (Life Technologies, cat# 10010-023) 
(2.3.1) and the remainder seeded into 6x ECS. Cells were incubated with fresh BEGM at 
37°C and 5% CO2. The cells in ECSs were grown for
 five days and either treated as described 
in sections 2.3.2 and 2.3.3 or left untreated. Following treatment, cells were prepared as 
described in section 2.9. 
Further cells for immunocytochemistry were obtained from the continued T-75 flasks, which 
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2.7.1. Collection, processing and storage 
Biopsies were collected as described in section 2.2.1 and placed in 4% paraformaldehyde at 
room temperature. The biopsies were fixed at room temperature for 2 hours before being 
removed from the paraformaldehyde, sandwiched between folded filter paper and then 
between two pieces of foam, inserted into a plastic embedding cassette and placed in 50% 
ethanol. The biopsies were stored in a sealed container in 50% ethanol overnight, before 
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Table 2.7-1: Protocol settings for the Leica  ASP200S autoprocessor for fixing bronchial biopsies. All steps 
were set with the fast drain time (80 seconds). P/V cycles are filling (vacuum) and draining (pressure). 
Reagent Temperature (°C) Time (minutes) Pressure/Vacuum (kPa) 
70% ethanol 37 20 -- 
95% ethanol 37 20 -- 
100% ethanol 37 20 -- 
100% ethanol 37 10 -- 
100% ethanol 37 10 -- 
100% ethanol 37 20 -- 
Xylene 37 40 -- 
Xylene 37 40 35/-70 
Paraplast wax 60 15 35/-70 
Paraplast wax 60 25 35/-70 
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Following processing the biopsies were embedded in Surgipath Paraplast wax (Leica) using 
an embedding station to melt, dispense and chill the wax. Generally three to four biopsies 
were embedded out of the four collected at bronchoscopy, however more or less were 
sometimes obtained due to breakdown and fragmentation of the tissue during collection and 
processing.  
Prior to cutting, biopsies were stored at 4°C. Cut sections were stored at room temperature.  
2.7.2. Detection of intra-cellular protein 
Biopsies were cut to a thickness of 3μm by Steve Weston and placed on slides. Sections were 
dewaxed by placing slides in xylene (100%) for 5 minutes, following which slides were 
transferred to fresh xylene (100%) for 5 minutes. Slides were then placed in ethanol solutions 
of 100%, 95% and 70% ethanol for five minutes each time, in the specified order, before 
being transferred to tap water. Sections then underwent antigen retrieval using High pH 
FLEX Target Retrieval Solution (pH9; Dako, cat# K8004) in a Dako PT-Link at 97°C for 15 
minutes.  
Following heat retrieval, slides were briefly rinsed with deionised water and placed in the 
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For negative control slides, the primary antibody was replaced with an isotype control 
consisting of species appropriate IgG. Slides were rinsed with water and placed in Meyer’s 
haematoxylin for 5 minutes. Excess haematoxylin was rinsed off under running tap water 
until the water ran clear rather than blue or purple. Haematoxylin staining was fixed by 
placing the slides into ammoniated water for a minimum of 3 minutes.  
Following nuclear staining, slides were dehydrated by moving them through a series of 
dehydrating solutions. In order, the solutions were: 95% ethanol, 100% ethanol (two different 
batches), 100% xylene (two different batches). The slides were exposed to the initial three 
solutions (ethanol-containing) for five minutes each and were exposed to the final two 
solutions (xylene) for two minutes per solution. The slides were manually mounted using 
Dako hard-set mounting media (Dako, cat# CS703), with unmounted slides left in the final 
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RNAScope was attempted on biopsies collected in section Collection, processing and 
storage2.7.1 using the RNAScope 2.5HD Detection Reagent BROWN kit (Advanced Cell 
Diagnostics, cat# 322370). The procedure was performed according to the manufacturer’s 
instructions, and utilised Peptidylprolyl Isomerase B (PPIB) as the positive control probe 
(Advanced Cell Diagnostics, cat# PN 313901). Briefly, the samples were baked for 1 hour at 
60°C before being deparaffinised by placing the slides sequentially into two xylene (100%) 
and then two ethanol (100%) baths, with the xylene baths lasting for 5 minutes and the 
ethanol baths for 1 minute.  
The slides were air dried, and 8 drops of RNAScope hydrogen peroxide were added to the 
sample and were incubated at room temperature for 15 minutes. Following incubation the 
hydrogen peroxide was removed and the slides washed twice in distilled water. The slides 
were then submerged in boiling RNAScope Target Retrieval Solution. In the initial attempt, 
slides were submerged for 15 minutes, however the Target Retrieval Solution only returned 
to the boil for the final five minutes of submersion. Two additional attempts were made to 
optimise the RNAScope, one submerging the slides for 30 minutes and the other submerging 
the slides and waiting until the Target Retrieval Solution has returned to boil before starting 
the 15 minute timer.  
Following target retrieval the slides were washed in distilled water four times before being 
rinsed with ethanol (100%) and allowed to air dry. A hydrophobic barrier was drawn around 
the sample using an Immedge hydrophobic barrier pen and allowed to dry overnight.  
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Slides were placed in the HybEZ oven with 5 drops of RNAScope Protease Plus and 
incubated at 40°C for 30 minutes. The Protease Plus was removed from the slide following 
incubation and the slides were washed four times in distilled water.  
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Table 2.7-3: RNAScope hybridisation and amplification incubation periods. All incubations except for the 
Amp6 step were performed in the HybEZ oven. 
Probe Exposure time (min) Temperature (°C) 
PPIB/Negative control 120 40 
Amp1 30 40 
Amp2 15 40 
Amp3 30 40 
Amp4 15 40 
Amp5 30 40 
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Between each step in Table 2.7-3 slides were washed twice for 2 minutes in RNAScope 
Wash Buffer before continuing with the next step. Following the washes after Amp6 
treatment, the RNAScope DAB-A and DAB-B reagents were combined, two drops of each 
reagent per sample on the slide, and then applied to the slides. Slides were incubated for 10 
minutes at room temperature before being rinsed four times with tap water. Following the 
rinses, the slides were placed in Meyer’s haematoxylin for 5 minutes. Excess haematoxylin 
was rinsed off under running tap water until the water ran clear rather than blue or purple. 
Haematoxylin staining was fixed by placing the slides into ammoniated water for a minimum 
of 7 minutes.  
Following nuclear staining, slides were dehydrated by moving them through a series of 
dehydrating solutions. In order, the solutions were: 95% ethanol, 100% ethanol (two different 
batches), and 100% xylene. The slides were exposed to each solution for five minutes. The 
slides were manually mounted using Dako hard-set mounting media (Dako, cat# CS703), 
with unmounted slides left in the final xylene bath until mounting. Mounted slides were air-
dried overnight at room temperature. 
However, despite attempts at optimisation described above RNAScope failed to produce 
DAB staining of the housekeeping gene in sample biopsies, although staining was present in 
the HeLa cell pellet (Advanced Cell Diagnostics, PN 310045) provided as a control, 
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2.7.4. Analysis of staining 
2.7.4.1. ImageJ vs. Image Pro Plus 
Previous work within the group had been done using Image Pro Plus software to analyse 
biopsy images, however the free-to-use ImageJ software had a plugin designed for isolating 
DAB staining in colour images, allowing for easy quantification via the in-built ‘threshold’ 
function. A brief assessment of the two programs was undertaken to determine whether one 
was better suited to the task of analysis.  
An example of high-staining (cytokeratin) and low staining (S100A4) was used. As seen in 
Figure 2.7-1 and Figure 2.7-2, the percentage of the epithelium stained was approximately the 
same between both programs, with ImageJ being slightly more sensitive to low, discrete 
staining such that seen as in S100A4 stained biopsies. As both programs appeared similar in 
capability, the decision was made to utilise ImageJ and its successor FIJI Is Just ImageJ (FIJI) 
for analysis of immunohistochemical and immunocytochemical staining. Analysis of 
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Figure 2.7-1: A comparison of cytokeratin staining in airway epithelium as measured using Image Pro Plus 
software versus the ImageJ IHCToolbox. Four random images were selected from a single sample and the amount 
of staining quantified in both Image Pro Plus and ImageJ. Images were first measured in Image Pro Plus, where 
the epithelial area of interest was defined – every effort was taken to match the area in ImageJ. The blue line in the 
top row of images denotes the length of the reticular basement membrane, as seen in Image Pro Plus. The bottom 
row of images shows the total area of epithelium measured, taken from ImageJ. Area stained is expressed as a 
percentage of total area of the epithelium.  
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Figure 2.7-2: A comparison of S100A4 staining in airway epithelium as measured using Image Pro Plus 
software versus the ImageJ IHCToolbox. Three random images were selected from a single sample and the 
amount of staining quantified in both Image Pro Plus and ImageJ. Images were first measured in Image Pro 
Plus, where the epithelial area of interest was defined – every effort was taken to match the area in ImageJ. The 
blue line in the top row of images denotes the length of the reticular basement membrane, as seen in Image Pro 
Plus. The bottom row of images shows the total area of epithelium measured, taken from ImageJ. Area stained is 
expressed as a percentage of total area of the epithelium.  
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2.8. q-PCR analysis 
2.8.1. RNA extraction 
2.8.1.1. Promega ReliaPrep 
Following trypsinisation, cells used for RNA extraction were resuspended in ice cold PBS 
(1ml; Life Technologies, cat# 10010-023). RNA was extracted according to the 
manufacturer’s instructions. Brieflyie, cells were centrifuged at 1,300g for five minutes 
(Heraeus Pico21 Centrifuge). Combined thioglycerol (2.5μl) and buffer BL (247.5μl) was 
added to the resulting cell pellet. Isopropanol (85μl) was added to sample, mixed well, and 
the resulting mixture was transferred to a ReliaPrep mini-column.  
The sample was centrifuged at 13,000g for 1 minute and RNA wash buffer (500μl) was 
added to the column membrane. The sample was centrifuged for a further minute at 13,000g 
while Yellow Core Buffer (24μl), MnCl2 (3μl) and DNaseI (3μl) were combined. The DNase 
solution was added to the column membrane and incubated at room temperature for 15 
minutes.  
Following incubation, column wash buffer (200μl) was added to the column and the sample 
was centrifuged at 13,000g for 1 minute. RNA wash buffer (300μl) was added to the column 
and centrifuged through at 13,000g for 1 minute. Additional RNA wash buffer (500μl) was 
added to the column and the sample centrifuged at 21,100g for 2 minutes to dry the column 
membrane. Nuclease free water (30μl) was applied to the column and the RNA was eluted 
into a clean tube and stored at -80°C until use.  
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RNA was quantified using a Nanodrop8000 and diluted to a concentration of 50ng/μl prior to 
use, or was used undiluted if the initial concentration was less than 50ng/μl. 
Samples used for pilot data and testing were collected utilising this method, however in order 
to collect both protein and RNA from primary cell samples with limited availability, for the 
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2.8.1.2. QIAgen RNA/Protein AllPrep 
Cells were grown in 12-well plates as described in section 2.4.1 for pHBECs and 0 for 
BEAS-2B cells. RNA extraction was performed using the AllPrep RNA/Protein kit (QIAgen, 
cat# 80404), as according to the manufacturer’s instructions. Briefly, the cells were washed 
with PBS and buffer APL (200μl) was added to each well and allowed to incubate at room 
temperature for five minutes. Following incubation the well bottom was scratched vigorously 
with the tip of a micropipette and the lysate transferred to an AllPrep spin column after being 
pipetted up and down several times in order to further help lysis. The homogenate was spun 
through the column at 8,500g (Heraeus Pico21 centrifuge). For the first 24 samples, protein 
extraction was performed first, however for all subsequent samples RNA extraction was 
performed first. 
Buffer RLT (350μl) was added to the AllPrep spin column and centrifuged at 8,000g for 1 
minute (Heraeus Pico21 centrifuge). Ethanol (70%, 350μl) was added to the resultant flow 
through and mixed, before the entire volume was transferred to an RNeasy spin column and 
centrifuged at 8,000g for 1 minute. Buffer RW1 (700μl) was added to the column and 
centrifuged at 8,000g for 30 seconds. Buffer RPE (500μl) was added to the column and 
centrifuged at 8,000g for 30 seconds, two times in succession. The empty spin column was 
then centrifuged at 21,100g for 2 minutes to dry the column, before nuclease free water 
(30μl) was added to the column membrane. RNA was eluted by centrifuging at 8,000g for 1 
minute and was stored at -80°C until use. 
RNA was quantified using a Nanodrop8000 and diluted to a concentration of 50ng/μl prior to 
use, or was used undiluted if the initial concentration was less than 50ng/μl. 
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2.8.2. Reverse transcription 
Reverse transcription of RNA samples was performed according to the manufacturer’s 
instructions for the GoScript Reverse Transcription kit (Promega, cat# A5001). Briefly, a 
reverse transcription master mix containing (per sample) nuclease free water (5μl), 5x 
Reaction Buffer (4μl), MgCl2 (5μl) and 1μl each of nucleotide mix, random primers, primer 
oligo(dT)s and reverse transcriptase was mixed. The master mix (18μl) was added to the 
RNA (2μl, 100ng) and the mixture heated on a BRESATEC PRC-100 heat block. The 
heating steps were: 
o 25°C for 5 minutes. 
o 42°C for 60 minutes. 
o 70°C for 15 minutes. 
Samples were then diluted 1:100 to achieve a final concentration of cDNA of 1ng/μl and 
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Quantitative real-time PCR was performed on a LightCycler480 (Roche) in 96-well plates. 
Reactions were 25μl total, consisting of nuclease free water (9μl), QuantiTect SYBR Green 
PCR Master Mix (12.5μl; QIAgen, cat# 204145), QuantiTect Primer Assay (2.5μl; QIAgen, 
see TABLE) and cDNA (1μl, 1ng/μl). QuantiTect Primer assays are designed by QIAgen to 
cross intron-exon boundaries, which removes the need for a no-reverse-transcription control 
as they cannot amplify gDNA. Although including a control would be best practice, due to 
limitations on time and samples it was not possible.  
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Table 2.8-1: Roche LightCycler480 qPCR program specifications. 
Name of step Temperature (°C) Duration Number of cycles 
Activation 95 15 min 1 
PCR 
94 15 sec 
45 55 30 sec 
72 30 sec 
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Analyses of qPCR data were performed using the method described by Pfaffl [214]. 
Efficiency of the primer sets was determined from the slope of the line fitted to a standard 
curve created via serial dilution of a known concentration of sample. Reference samples from 
the standard curve were run on each plate and the raw data were corrected according to 
changes in the reference sample compared to the standard curve. All data were normalised to 
the expression of the housekeeping gene β-actin. In all data sets, each point represents an 
individual experimental sample. Analysis of the data consisted of a two-way ANOVA 
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2.8.5. Brief discussion of brachyury qPCR 
As previously discussed (1.1.2.6), a person having COPD has, irrespective of their current 
smoking status, a six-fold increased risk of lung cancer compared to a person without COPD 
[67, 68]. In the large airways, people with late-stage COPD see predominantly squamous cell 
carcinomas, while people with Stage I COPD tend to see a predominance of adenocarcinomas 
[16, 72].  
Brachyury is a T-box transcription factor which has been shown to be expressed in 41% of 
primary lung tumours [212]. In the study by Roselli and colleagues, brachyury was expressed 
by 48% of adenocarcinomas and 25% of squamous cell carcinomas. Brachyury is also 
expressed in breast and prostate cancers [213-215].  A feature which makes brachyury 
especially useful to examine potential links between lung cancer and COPD is the fact that it 
is not expressed at detectable levels in normal lung tissue, or even in the majority of normal 
tissues outside of the prostate [216], which makes it a neat binary marker. Of further 
importance to COPD, brachyury is closely associated with an EMT phenotype in breast 
cancer [213, 217], and may potentially be a link between EMT in chronic airflow limitation 
which is not yet clinical COPD and the increased risk of lung cancer in COPD.  
The initial standard curve for the qPCR failed to show expression of brachyury, except in one 
sample in the middle of the concentration curve. The source of this peak is unknown but 
expected to be a random artefact, possibly due to point contamination of the well rather than 
a true signal based on the fact that higher concentrations of RNA did not show expression. It 
is highly likely this lack of signal was due to the fact the XPressRef Universal RNA from 
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QIAgen is sourced from normal, non-diseased cells, and these are unlikely to express 
brachyury at a detectable level [216].  
Several cell lines, including the prostate cancer cell line LNCAP and the breast cancer cell 
line MDA-MB-231 are known to be susceptible to brachyury-mediated immune responses in 
their baseline state [214]. A fellow PhD student, Emma Wilkinson, had access to RNA taken 
from MDA-MB-231 cells, of which she donated a small amount for use as a standard curve. 
However, despite expected expression of brachyury in this cell line, no expression was seen 
in qPCR. 
A small number of samples, including two at random from the standard curves utilising 
universal RNA and RNA from the MDA-MB-231 cell line, showed Ct values, however with 
Ct values of greater than 35 cycles it is unlikely that these signals represented true expression. 
This was further backed up by the melt curves for the unknown samples, which did not 
exhibit neat peaks at identical positions on the graph   
Primers for brachyury, like all the primer assays used in this study, were obtained 
commercially from QIAgen and are therefore confirmed to amplify product when present. 
Optimisation of reaction temperature was not possible for this primer set due to lack of 
reagents and time, which may have been a contributing factor to the lack of results. Improper 
annealing temperatures can affect primer binding and reduce or eliminate signal, even when 
product is present in the sample. It is likely, however, that brachyury was simply not 
expressed in the samples. As previously discussed, the universal RNA came from non-
diseased normal tissue, and thus was unlikely to express brachyury [216], and the paper 
which was used to suggest the MDA-MB-231 cell line looked at an indirect measure of 
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protein expression [214], which may not indicate expression at the transcript level. Finally, 
although COPD is associated with an increased risk of lung cancer, and specifically 
adenocarcinoma in the large airways [16, 72], where the samples were taken from, brachyury 
is only expressed in 50% of adenocarcinomas [212] and thus may not be present in the 
samples. There is also the possibility that brachyury may be expressed only in established 
adenocarcinomas, and may not be present in cases of non-COPD airflow limitation, hence the 
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2.9.1. Immunocytochemical staining 
2.9.1.1. Staining procedure 
Media was removed from the cells and replaced with ice-cold acetone (dried with Molecular 
Sieve type 4A beads (ProSciTech, cat# C830)) for 5 minutes to fix cells. Following fixation, 
cells were washed with tris-HCl (0.5M, made up as described in section 2.12.1). Heat 
retrieval of the antigens was performed in High pH FLEX Target Retrieval Solution (pH9; 
Dako, cat# K8004) in a Dako PT-Link at 97°C for 15 minutes.  
Following heat retrieval, slides were briefly rinsed with deionised water and placed in the 
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For negative control slides, the primary antibody was replaced with an isotype control 
consisting of species appropriate IgG. Slides were rinsed with water and placed in Meyer’s 
haematoxylin for 5 minutes. Excess haematoxylin was rinsed off under running tap water 
until the water ran clear rather than blue or purple. Haematoxylin staining was fixed by 
placing the slides into ammoniated water for a minimum of 7 minutes.  
Following nuclear staining, slides were dehydrated by moving them through a series of 
dehydrating solutions. In order, the solutions were: 95% ethanol, 100% ethanol (two different 
batches), 100% xylene (two different batches). The slides were exposed to the initial three 
solutions (ethanol-containing) for five minutes each, and were exposed to the final two 
solutions (xylene) for two minutes per solution. The slides were manually mounted using 
Dako hard-set mounting media (Dako, cat# CS703), with unmounted slides left in the final 
xylene bath until mounting. Mounted slides were air-dried overnight at room temperature. 
2.9.1.2. Imaging procedure 
Slides were imaged using either an Olympus Virtual Slide Imager VS120 or an Axio Lab.A1 
(Zeiss) microscope with attached AxioCam ICc5 (Zeiss). Images taken using the VS120 slide 
scanner utilised the bundled imaging software, while the AxioCam utilised Zen (Blue 
Edition, v 2.3).  
The Olympus scanner was set to take an image of size 6mm x 6mm from each well at 20x 
objective magnification. The Axio Lab.A1 was used at 20x objective magnification to image 
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2.9.2. Converting image files to usable formats and size 
The Olympus Virtual Slide Imager VS120 created all image files in a proprietary filetype 
(.vsi), which was not readable by most imaging programs. Although FIJI Is Just ImageJ (FIJI) 
could open these files using the Bioformats plugin, due to the size of the images (>1GB) it 
was nearly impossible to analyse the images using available equipment. 
To aid in analysis, a macro was written to firstly open every image (around 700-750 images) 
and convert it into the .tiff file format, allowing the images to be opened easily by FIJI 
without the use of the Bioformats plugin (see Appendix 1: FIJI and ImageJ Macros (Raw 
Code) for macro codes). A second macro was then written to take each .tiff file, convert it 
into RGB colour (to allow analysis of staining, discussed in the next section) and then select 
16 non-overlapping fields of view and save each field of view as a separate image. The fields 
of view were selected at fixed locations spread across the whole image and were positioned 
identically in every image, to prevent bias when selecting areas to analyse. This produced 
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2.9.3. Image analysis 
Image analysis of immunocytochemical stainingstaining was performed using a combination 
of ImageJ and FIJI. From each well (16 images total), five images were randomly selected by 
random number generator (using the website https://www.random.org/) and the nuclei in 
these images were manually counted using the point selection tool in ImageJ or FIJI.  
Initially (for 9 slides – a total of 360 images) the staining in each cell was measured utilising 
the ImageJ plugin IHCToolbox [210]. However the scale of the analysis required automation. 
Dr. Jo-Maree Courtney wrote a macro for FIJI which randomly selected five images from 
each well and opened them sequentially without user input. The nuclei could then be counted 
manually for each image, following which the macro would apply colour deconvolution to 
the image. Colour deconvolution is an in-built FIJI function which can separate DAB and 
haematoxylin staining into individual channels, allowing the user to utilise the ‘threshold’ 
function of FIJI to select and measure the area stained with DAB without selecting 
haematoxylin-stained areas.  
This macro was used to analyse the remaining images, although it required user-coded 
changes to accurately select the area stained and to ensure the proper scale was set for each 
image (see Appendix 1: FIJI and ImageJ Macros (Raw Code) for macro code). Data were 
expressed as area stained/cell, a measurement which was obtained by dividing the total area 
stained in an image by the number of nuclei present. Analysis of the data consisted of a two-
way ANOVA applied to the three pHBEC groups treated with drugs, and all other data were 
analysed with one-way ANOVAs.   
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2.10. Enzyme linked immunoabsorbance assays 
2.10.1. Collection of samples 
2.10.1.1. Cell culture supernatant 
Twenty four hours prior to collection of the cells the media was changed. The supernatant 
was decanted following twenty four hours (in the case of CSE treated cells the media was 
collected after 4 hours) and centrifuged at 1,500rpm for ten minutes at 4°C. Following 
centrifugation the supernatant was split into aliquots (1ml) being careful not to disturb the 
pellet and stored at -80°C. 
2.10.1.2. Intra-cellular protein in PBS 
Cells were grown in 12-well plates as described in section 2.4.1 for pHBECs and section 
2.6.3 for BEAS-2B cells. RNA extraction was performed using the AllPrep RNA/Protein kit 
(QIAgen, cat# 80404), as according to the manufacturer’s instructions. Briefly, the cells were 
washed with PBS and buffer APL (200μl) was added to each well and allowed to incubate at 
room temperature for five minutes. Following incubation the well bottom was scratched 
vigorously with the tip of a micropipette and the lysate transferred to an AllPrep spin column 
after being pipetted up and down several times in order to further help lysis. The homogenate 
was spun through the column at 8,500g (Heraeus Pico21 centrifuge). For the first 24 samples, 
protein extraction was performed first, however for all subsequent samples RNA extraction 
was performed first. 
For protein extraction, the Protein Cleanup spin column was vortexed briefly and, after the 
cap was loosened slightly and the bottom snapped off, centrifuged for 3 minutes at 700g 
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(Heraeaus Pico21 centrifuge). PBS (500μl; Life Technologies, cat# 10010-023) was added to 
the spin column and then the column was centrifuged at 700g for 3 minutes. Protein-
containing flow through was kept on ice prior to addition to the columns. The flow through 
from the AllPrep column was pipetted dropwise slowly onto the gel and then the sample was 
centrifuged at 200g for 3 minutes. The resultant flow through, which contained total protein, 
was stored at -80°C until use. 
Note: Analysis of intracellular N-cadherin protein was not possible due to readings being 
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2.10.2. ELISA protocol 
Pro-collagen 1-α DuoSet ELISAs (R&D Systems, cat# DY6220-05) were performed 
according to the manufacturer’s instructions. Briefly, a standard curve was produced by 
diluting the provided standard protein 1:30 in PBS and then creating a series of dilutions (1:2) 
down to 39pg/ml. The detection antibody was diluted 1:10 to a concentration of 100ng/μl.  
A 96-well plate was coated with capture antibody (4μg/ml, 100μl) overnight at room 
temperature. Wells were washed three times with wash buffer before the wells were protein-
blocked by adding reagent diluent (300μl) to the wells for 1 hour at room temperature. Wells 
were washed three times with wash buffer. 
Cell culture supernatant (collected as described in 2.10.1.1) or standard was added to the 
wells and incubated for 2 hours at room temperature. Wells were washed three times with 
wash buffer. Detection antibody (100μl) was applied to the wells for 2 hours at room 
temperature, after which the wells were washed three times with wash buffer. Streptavidin-
HRP (100μl) was added to each well and incubated in the dark for 20 minutes at room 
temperature. Wells were washed three times with wash buffer. 
Substrate solution (100μl) was applied to each well and incubated in the dark for 20 minutes, 
before stop solution (50μl) was added to each well. Plates were read using a Spectramax M2 
(Molecular Devices) at 450nm (for quantification of sample) and 540nm and 570nm (for 
wavelength correction). All results were corrected using the average value obtained by the 
540nm and 570nm readings.  
,  Analysis of the data consisted of a two-way ANOVA applied to the three pHBEC groups 
treated with drugs, and all other data were analysed with one-way ANOVAs.  
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2.11. Statistical analyses 
All mathematical calculations were performed in Microsoft Excel 2013 and statistical 
analysis was performed in Graphpad Prism (v 7.03) and all data were represented as the mean 
value with error bars showing standard error of the mean (SEM). Analysis of the multi-group 
data usually consisted of a two-way ANOVA applied, while all other data were analysed with 
one-way ANOVAs. For subsequent comparisons of two potential groups of difference, 
Welch’s t-tests were performed for paired data, however where values were missing in paired 
data sets an unpaired t-test was performed instead. For the analysis of binomial data such as 
survival, Fisher’ exact test was used.   
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2.12. Reagent and buffer composition appendix 
2.12.1. Tris-HCl (0.5M) pH 7.6 with TWEEN20 
Used in: 2.7.2 and 2.9.1 
Ingredients 
60.56g trishydroxy-methyl-amino-methane (Merck; cat# 1083822500) 
90g NaCl 
HCl (approx. 42ml) 
5ml TWEEN20 (Sigma-Aldrich, cat# P-7949) 
Method 
1. Dissolve trishydroxy-methyl-amino-methane in 800ml de-ionised water. 
2. Add NaCl and dissolve. 
3. Adjust pH to 7.6 using HCl (and NaOH if needed). 
4. Add TWEEN20 and make up to 1L in volumetric flask. 
5. Check pH and adjust back to 7.6. 
6. Make up to 10L with deionised water.  
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2.12.2. Primary antibody information 
Used in: 2.7.2 and 2.9.1 
All primary antibodies used were anti-human. 
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Table 2.12-1 Antibody information for biopsy staining. Information for the primary antibodies used in section 2.7.2 for the staining of FFPE biopsies obtained from 
volunteers with and without COPD. 
 
KEY: * indicates that appropriate animal complete serum was used as the isotype control for the indicated antibody. 
Antibody target Animal IgG Clonality IgG type Supplier Catalogue number Dilution factor 
E-cadherin Mouse Monoclonal 1 Dako M3612 1:100 
N-cadherin Mouse Monoclonal 2a Invitrogen X18-0224 1:100 
Pan-cytokeratin ae/3 Mouse Monoclonal 1 Dako M3515 1:100 
Vimentin Mouse Monoclonal 1 Dako M7020 1:2,000 
S100A4 Rabbit Polyclonal * Dako A5114 1:3,000 
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Table 2.12-2: Antibody information for cell staining. Information for the primary antibodies used in section 













E-cadherin Mouse Monoclonal 1 Dako M3612 1:200 




Mouse Monoclonal 1 Dako M3515 1:200 
Vimentin Mouse Monoclonal 1 Dako M7020 1:1,000 




ICAM-1 Mouse Monoclonal 1 Chemicon mab2130 1:200 
TWIST Mouse Monoclonal 1 Abcam ab175430 1:200 
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3. Comparative growth of primary bronchial epithelial 
cells cultured from volunteers with and without COPD 
and the effects of cryopreservation on primary cells 
3.1. Introduction 
Primary cell cultures are taken directly from the tissue of animals, patients or plants and 
cultured with the aim of maintaining their in vivo phenotype as much as possible. Primary 
cells are widely considered to provide a more accurate representation of in vivo disease 
phenotypes and mechanisms, especially considering that they can be isolated from patients 
with diseases. WhileWhile healthy cells can be induced to model the phenotype, since 
induction often only involves one or a few pathways whereas a disease cannot always be 
accurately artificially replicated in vitro as the condition is often the result of a myriad of 
interconnected signals and mechanisms which work together to contribute to the condition. 
This makes primary cells from diseased patients especially valuable as models.  
However, cells taken from non-cancerous tissues have a finite lifespan, as they experience 
senescence and a decline in growth and proliferation [218, 219]. This is in comparison to 
cells lines and cells derived from cancer, which are ‘immortalised’ either through mutation or 
via transformation with a virus such as the SV40 adenovirus. Primary cells’ limited lifespan 
is due to the fact that they can divide only a limited number of times before undergoing 
senescence; this limit is called the ‘Hayflick limit’ after the author who first described it, and 
is one of the major issues associated with culturing primary cells [222].  
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The Hayflick limit is not the only consideration when culturing primary cells. Simply 
isolating the desired cell type and maintaining it as a pure culture can be difficult. Since 
primary cells are sourced directly from the organ of interest, which is typically not formed of 
a single homogenous cell type, often the desired primary cells can be overtaken by more 
readily proliferating cells which are inadvertently collected alongside the target cells. In 
epithelial cultures, fibroblasts are particularly well known for overtaking cultures [223]. Even 
if attempts are made to physically isolate or dissect out the area of collection or to remove 
cells from a specific area, unwanted cells can still be collected and proliferate significantly 
before being noticed [221].  
Contamination with other cell types from the tissue of origin is not the only source of cellular 
contamination primary cultures are exposed to. There are reports of cell cultures being 
overtaken by hardy, immortalised cells which are cultured in the same space, often entering 
cultures through shared media, and which can completely subsume a less proliferative 
primary culture [222-227]. Cross-contamination can occur even when the culture of the 
different cell types is separated in time [229], or even between cultures of different species 
[225].  
An additional concern when collecting primary lung cells from people with diseases like 
COPD who often have in vivo chronic bacterial colonisation and carry a high overt burden of 
infection [48], is that pathogens may be collected along with the desired cells. Fungi and 
bacteria are common cell culture contaminants, and can be extremely resistant to attempts to 
deter their growth, particularly if they are innoculated directly into the cultures during 
collection. Additionally, diseased cells may be more susceptible to invading pathogens than 
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healthy cells, and therefore an important facet of the study may be irrevocably impaired if an 
infection manages to begin spreading among samples. Steps can be taken to reduce the risk of 
these contaminants, including refusing to sample patients who have had recent infections, 
however healthy lungs and airways are naturally colonised by bacteria [228-230], which may 
potentially contaminate cultures.  
Finally, once primary cells have been successfully isolated and cultured, they are 
typicallyused immediately, without cryopreservation [33, 103, 111, 192, 194, 231-236]. 
Previous work has been done in isolating and culturing primary bronchial epithelial cells 
(pHBECs) from healthy and COPD-affected airways, however none have looked at 
cryopreservation of these valuable cells. Generally, primary bronchial epithelial cells have 
been obtained in a number of ways, ranging from the ex vivo culture of airway biopsies [33, 
103, 231] to extraction from biopsied tissue via enzymatic isolation [111, 232, 235, 236], 
purchase from a commercial cell bank [194, 233, 234] or removal of the cells from the airway 
wall via brushing during bronchoscopy [192]. These cells were used directly following 
collection with only minimal culture time, although some cultures were passaged as high as 
passage 6 before use [189]. However, they are not cryopreserved as is common in 
immortalised cell lines. While immediate usage avoids the Hayflick limit and changes 
brought on by continual passaging, it presents some challenges. When cells are collected 
regularly, however do not proliferate rapidly enough to be used in experiments before more 
cells are collected the backlog of growing cells can quickly fill all available culture space. 
New samples may have to be refused due to lack of space and resources to culture them, 
which is undesirable when collecting such a limited resource as primary cells. 
Cryopreservation is commonly used to avoid such space-related issues in immortalised cells 
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and cancer-derived cell lines, as it allows cells to be frozen and stored until needed. This 
allows samples to be brought up in controlled amounts and used when needed. It also allows 
back-up cells to be kept safe against possible loss or experimental failure or for future 
experiments. However, this technique is not applied to primary bronchial epithelial cells, 
possibly due to concerns about the cells being too fragile to survive freezing.  
There are significant advantages to utilising primary cells for modelling disease and other 
conditions, however it is important to keep the issues inherent in using primary cells in mind 
when culturing these cells. The process of cryopreserving these valuable cells and thus 
having more control over how and when they are used, as well as opening up the possibility 
of banking these cells for later study, is an important consideration, and the effects of the 
process of pHBECs is currently unknown. The current chapter of this thesis will explore the 
growth of primary epithelial cells isolated from the airways of non-smokers, smokers with 
normal lung function and people with airflow limitation who are either current or ex-smokers, 
via bronchial brushing. Of particular interest was whether the primary cells suffered 
deleterious effects from cryopreservation, such as retarded growth or reduced viability, ifif 
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3.1.1. Chapter aims 
The aims of this chapter were as follows:  
• To establish stable, pure and proliferative epithelial cell cultures obtained via 
bronchial brushings from healthy non-smokers, smokers with normal lung function, 
smokers with airlflow limitation and ex-smokers with airflow limitation.  
• To characterise these cells’ growth and determine whether growth is affected by 
disease or smoking status. 
• To examine the effect of cryopreservation upon the primary cells’ growth and identify 
any potential differences due to smoking or disease status.  
 
Hypothesis: Smoking and airflow limitation, both with and without smoking, will have a 
negative effect on primary bronchial epithelial cells’ ability to survive and proliferate in a 
culture situation and will negatively affect the cells’ ability to survive cryopreservation and to 
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3.2.1. Phenotypic examination of primary bronchial epithelial cells in culture 
Ofthe 50 volunteer samples collected, all volunteers which produced viable cultures produced 
at least one culture of epithelial cells; of 204 successful cultures, only three were overrun 
with fibroblasts. Primary cells were considered to be epithelial if they appeared to 
consistently exhibit standard epithelial ‘cobblestone’ morphology based on visual evaluation 
of morphology during culture. Cells taken from non-smokers typically showed a normal 
epithelial cobblestone morphology when sufficiently confluent (Figure 3.2-1 - top left). Some 
mildly fibroblastic cells were noted in cultures from smokers with normal lung function 
(Figure 3.2-1 - top right) and people with airflow limitation (Figure 3.2-1 - bottom left), 
however these did not match the elongated spindle-shape and organised growth pattern of 
cells seen in fibroblast overrun cultures (Figure 3.2-1 - bottom right). Despite these abnormal 
cells in cultures from smokers with normal lung function and people with airflow limitation, 
the sporadic nature of these cells across the entire sample (estimated as <10% of cells at the 
most prolific) and the fact that the majority of cells exhibited normal epithelial morphology 
meant that these cultures were deemed pure epithelial cultures.  
Although no further investigation of epithelial characteristics was undertaken at this point in 
the study, later studies (see following chapters) observed the cells’ expression of epithelial 
and mesenchymal markers and confirmed that these cells expressed epithelial markers such 
as E-cadherin and tight junction protein-1. Overall, bronchial epithelial cells were 
successfully isolated and cultured from volunteers both with and without airflow limitation, 
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and from people with different smoking statuses, with only minor contamination of 







Figure 3.2-1: Morphology of 
primary epithelial cell cultures VS 
fibroblasts. pHBECs were grown in 
submerged culture in BEGM 
following collection from volunteers, 
as described in the Methods and 
Materials section. Images were 
taken immediately prior to the first 
passage following collection using 
phase contrast microscopy at 4x 
objective magnification. Images 
presented here were representative 
of the entire culture.  
 
Please note: image brightness and 
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3.2.2. Rates of growth and survival of cells by smoking status after isolation  
During the initial stages of culture, following removal of the cells from the airways until 
initial passaging, the survival rates between the four investigative groups was similar. 
Approximately 80% of all flasks reaching 80-90% confluence, allowing them to be passaged 
(Figure 3.2-2). Cells from current smokers with airflow limitation (COPD-CS on the graph) 
trended towards decreased survival, however this was not significantly different from the 
other groups (Fisher’s exact test NNS versus COPD-CS p = 0.32, NLFS versus COPD-CS p 
= 0.81, COPD-CS versus COPD-ES p = 0.35). The survival data do not have error bars as the 
data are binary. Every flask which reached sufficient confluence to be passaged was classed 
as surviving; all other flasks were designated as not surviving.  
Around 5-10% of flasks were discarded due to fungal infection, however this was a single 
infection that spread between samples at an isolated time. The infection was identified as 
fungus both by microscopic examination and by the large, attached ‘fuzzy’ islands of fungal 
growth that floated in the cultures. The origin of the fungus was likely improperly processed 
water placed into the incubator’s humidifying tray, rather than contamination originating 
from a sample, as multiple samples exhibited superficially identical fungal growth at the 
same time. The fungus persisted and proliferated despite anti-fungal compounds in the 
culture media, but was eradicated following a move of all non-affected flasks into a different 
incubator and disposal of infected flasks. The incubator was subsequently sterilised and 
infection did not recur. Aside from cultures which became infected with fungus, no volunteer 
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The average time taken for the first flask within a given volunteer sample to reach confluence 
was approximately 15-20 days (Figure 3.2-3) although there was a large degree of variability 
between patient samples, and even within a single sample there could be up to five days of 
difference between the first and last flask passaged.   
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Figure 3.2-2: Survival rates for primary cells  following collection. Each volunteer provided 
four individual brushings from the airways, each one producing a separate culture. Additionally, 
the four brushes together provided an additional culture, meaning each volunteer produced 5 
flasks in total. Cells were grown in submerged culture in BEGM until 80-90% confluent and 
were then passaged. Failed samples did not reach confluence, either due to lack of proliferation, 
death of cells or infection.  
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current 
smokers with COPD; COPD-ES = ex-smokers with COPD.  
n = NNS: 78; NLFS: 46; COPD-CS: 32; COPD-ES: 45 
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Figure 3.2-3: Time between collection and first passage for primary bronchial epithelial cells. 
Each volunteer provided four individual brushings from the airways, each one producing a 
separate culture. Additionally, the four brushes together provided an additional culture, 
meaning each volunteer produced 5 flasks in total. However, only the first culture to reach 
confluency for each volunteer was included here. Cultures from a single volunteer usually 
reached confluence within 3 days of the first culture. Cells were grown in submerged culture in 
BEGM until 80-90% confluent and were then passaged. Failed samples did not reach 
confluence, either due to lack of proliferation, death of cells or infection.  
 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current 
smokers with COPD; COPD-ES = ex-smokers with COPD. 
 
n = NNS: 17; NLFS: 11; COPD-CS: 5; COPD-ES: 10.  
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3.2.3. Rates of growth and survival of cells by smoking status following first subculture  
Following the initial passage, samples from smokers with normal lung function exhibited a 
decrease in survival, from nearly 80% to 60% (Figure 3.2-4), which was significantly lower 
than the survival rates for non-smokers and ex-smokers with airflow limitation (Fisher’s 
exact test NNS versus NLFS p = 0.0058, NLFS versus COPD-ES p = 0.0052). However, it 
was not statistically significantly different from the survival rates of samples for volunteers 
with airflow limitation who were current smokers (Fisher’s exact test p = 0.14). A single 
volunteer sample was lost to fungal infection during this period of growth. The infection was 
caused by spread of a single fungal infection (see section 3.2.1), contaminating flasks which 
were passaged during the fungal infection period, with all flasks within that sample being 
contaminated during passaging.  
During passage 1 cells took an average of 13-19 days to reach sufficient confluence to be 
passaged (Figure 3.2-5). p  
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Figure 3.2-4: Survival rate of cells following initial passage. Each culture which successfully 
reached confluence after the initial subculture was enzymatically dissociated and cryopreserved, 
stored in vapour phase liquid nitrogen. Cells were grown in submerged culture in BEGM until 
80-90% confluent and were then cryopreserved. Failed samples did not reach confluence, either 
due to lack of proliferation, death of cells or infection.  
 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current 
smokers with COPD; COPD-ES = ex-smokers with COPD.  
n = NNS: 107; NLFS: 53; COPD-CS: 32; COPD-ES: 67 
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Figure 3.2-5: Time between first passage and cryopreservation for primary bronchial epithelial 
cells. Each culture which successfully reached confluence after the initial subculture was 
enzymatically dissociated and cryopreserved, stored in vapour phase liquid nitrogen. Cells were 
grown in submerged culture in BEGM until 80-90% confluent and were then cryopreserved. 
However, only the first culture to reach confluency for each volunteer was included here. Cultures 
from a single volunteer usually reached confluence within 3 days of the first culture. Failed 
samples did not reach confluence, either due to lack of proliferation, death of cells or infection.  
 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current 
smokers with COPD; COPD-ES = ex-smokers with COPD; p0 = passage zero; p1 = passage 
one. 
 
n = NNS: 17; NLFS: 9; COPD-CS: 4; COPD-ES: 8. 
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3.2.4. Rates of growth and survival of cells by smoking status after cryopreservation  
Bronchial epithelial cells from both non-smokers and ex-smokers with airflow limitation had 
a survival rate of almost 60% when brought up from frozen stocks (Figure 3.2-6). In 
comparison, cells from current smokers with airflow limitation trended towards decreased 
survival, with only 40% of samples surviving. The trend was even more pronounced in cells 
from smokers without airflow limitation survived only 27% of the time, although due to 
small sample sizes the trends were not statistically significant. Previously three vials of cells 
had been harvested and cryopreserved from a single confluent T-755 flask at passage 1, and 
initially a single vial was used to seed a single T-75 flask at low seeding density. However, 
the low seeding density caused low survival rates and poor proliferation, which prompted 
changes in methodology; with cells being seeded at high density and used after seven days. 
Only cells seeded at the low density were included in the data, as the highly-seeded cells 
were used regardless of growth.  
In the time taken for cells to proliferate sufficiently to be used in experiments following 
cryopreservation and thawing, there was no difference between cells taken from non-smokers 
and ex-smokers with airflow limitation (Figure 3.2-7). Commentcould not be made on 
smokers with normal lung function (n=1) or current smokers with airflow limitation (n=2), 
other than to say that anecdotally, they grew more consistently close to the average for ex-
smokers with airflow limitation than the non-smokers. However, this should not be taken as a 
serious consideration, given the large variation seen in the non-smokers’ time of growth. 
There waswas no statistically significant difference between the times of growth for non-
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smokers and ex-smokers with airflow limitation, although the latter demonstrated a more 
precise spread with considerably lower variation than the non-smokers.  
It is important to note that Figure 3.2-6 and Figure 3.2-7 contain combined data from myself 
and Kaitlyn Scoyler, who also worked with these cells.  
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Figure 3.2-6: Survival rates for primary cells brought up from cryopreservation.  Flask 
survival following cryopreservation dropped to approximately 60% for non-smokers (NNS) 
and ex-smokers with COPD (COPD-ES). Each culture which successfully reached confluence 
after the initial subculture was enzymatically dissociated and cryopreserved, stored in vapour 
phase liquid nitrogen. Cells were grown in submerged culture in BEGM until 80-90% 
confluent and were then cryopreserved. Failed samples did not reach confluence, either due to 
lack of proliferation, death of cells or infection. 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = 
current smokers with COPD; COPD-ES = ex-smokers with COPD.  
n = NNS: 11; NLFS: 15; COPD-CS: 7; COPD-ES: 9. 
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Figure 3.2-7:  Time taken for samples revived from cryopreservation to reach levels of growth 
which were sufficient for samples to be collected. Each culture which successfully reached 
confluence after the initial subculture was enzymatically dissociated and cryopreserved, stored in 
vapour phase liquid nitrogen. Cells were grown in submerged culture in BEGM until 80-90% 
confluent and were then cryopreserved. However, only the first culture to reach confluency for 
each volunteer was included here. Cultures from a single volunteer usually reached confluence 
within 3 days of the first culture. Failed samples did not reach confluence, either due to lack of 
proliferation, death of cells or infection. 
 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current 
smokers with COPD; COPD-ES = ex-smokers with COPD; p2 = passage two; p3 = passage 
three. 
 
n = NNS: 5, NLFS: 1; COPD-CS: 2; COPD-ES: 5. 
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3.2.5. Effect passaging and cryopreservation on primary cells by smoking status 
Comparing the survival rates within each group and considered across all passages, trends 
occur (Figure 3.2-8). Non-smokers did not appear to be affected by passaging alone, and 
while there was a 15% decrease in survival rate following cryopreservation, it did not reach 
statistical significance. However, given the apparent effect of cryopreservation on all the 
groups and based on the effects of passaging alone, it seemed likely that cryopreservation 
itself had a deleterious effect on cell survival. Passaging generally appeared to negatively 
affect the survival of cells taken from smokers with normal lung function. Although the 
changes only reached statistical significance following cryopreservation (Fisher’s exact test 
p0-p2 p = 0.0054; p1-p2 p = 0.0067), there appeared to be a downwards trend at p1 which 
was intermediate between survival at p0 and survival following cryopreservation, but which 
did not reach statistical significance. Survial of cells from bothb current and ex-smokers with 
airflow limitation declined following cryopreservation, with current smokers’ decreased 
survival reaching statistical significance, dropping by nearly 30% (Fisher’s exact test p = 
0.0399), suggesting a likely smoking effect. 
Despite the changes in survival rates, smokers with normal lung function and current and ex-
smokers with airflow limitation exhibited no change in their rate of growth as passaging 
progressed, averaging around 15-17 days to reach confluency (Figure 3.2-9). Only non-
smokers showed any change in their growth rate, increasing from 15 days at passage 1 to 35 
days following cryopreservation (ANOVA p0-p2 p = 0.022; p1-p2 p = 0.036).  
Tracking a select few samples individually across passages in an attempt to discern the 
effects of cell density on the rate of growth following collection and the effect of 
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cryopreservation at an individual level rather than as a whole sample group (data not shown) 
revealed that cultures which took fewer than thirty days to reach confluence following 
collection generally took approximately the same amount of time to reach confluence 
following passaging, whereas those that took more than thirty days may have taken so long 
due to low cell seeding density, as passaging appeared to lower the time taken to reach 
confluence to levels comparable to the other samples. The only exception is in current 
smokers with airflow limitation, where the firstfirst passage appeared to cause a uniform, 
albeit slight, increase in time taken to reach confluence. Cryopreservation typically appeared 
to increase the time taken for cells to reach confluence.   
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Figure 3.2-8 Comparison of survival rates in the phenotypical groups following subdivision 
and cryopreservation. Cells were grown in submerged culture in BEGM until 80-90% confluent 
and were then sub-divided following p0 or cryopreserved following p1. Cells in the ‘cryo’ group 
were brought up from frozen. Failed samples did not reach confluence, either due to lack of 
proliferation, death of cells or infection. 
 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current 
smokers with COPD; COPD-ES = ex-smokers with COPD; p1 = passage one; cryo = post-
cryopreservation.  
n = NNS: 11-107; NLFS: 15-53; COPD-CS: 7-32; COPD-ES: 9-67  
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Figure 3.2-9: Changes in the length of time taken for samples in the four phenotypical groups to grow to 
confluence following subdivision and cryopreservation. Cells were grown in submerged culture in BEGM until 
80-90% confluent and were then sub-divided following p0 or cryopreserved following p1. Cells in the ‘cryo’ group 
were brought up from frozen. However, only the first culture to reach confluency for each volunteer was included 
here. Cultures from a single volunteer usually reached confluence within 3 days of the first culture. Failed samples 
did not reach confluence, either due to lack of proliferation, death of cells or infection. 
 
KEY: NNS = non-smokers; NLFS = smokers with normal lung function; COPD-CS = current smokers with 
COPD; COPD-ES = ex-smokers with COPD; p1 = passage one; cryo = post-cryopreservation.  
n = NNS: 5-17; NLFS: 1-11; COPD-CS: 2-5; COPD-ES: 5-10. 
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3.4. Chapter discussion 
Primary bronchial epithelial cells were successfully cultured from airway brushings taken 
from non-smokers, smokers with normal lung function and people with chronic airflow 
limitation, whichwhich has been referred to as ‘COPD’ within figures in this thesis. These 
epithelial cells were successfully cryopreserved and brought back from frozen stock, however 
cells from current smokers, regardless of airflow limitation, exhibited decreased viability 
following cryopreservation.  
This study collected cells via bronchial brushings partly due to agreement with hospital staff 
and partly due to the relative non-invasiveness compared to biopsy sampling, which is an 
established technique [192]. It was also thought that using brushings would reduce the 
possibility of the epithelial cultures becoming overrun with invasive fibroblasts from the 
airway wall and parenchymal, which is a risk when isolating primary cells, and fibroblast 
contamination affected only 3 out of 204 cultures in total.   
Cells from smokers and people with airflow obstruction exhibited star-shaped, fibroblast-like 
morphology more frequently than cells from non-smokers and were often observed to 
‘clump’ and form multi-cell layered clusters more frequently than the neatly cobblestone-like 
non-smokers’ cells. Despite this, they did not take on the narrow, spindle-like shape of true 
fibroblasts, nor exhibit the organised flowing patterns of growth seen in the overrun flasks 
(Figure 3.2-1) and were determined to be merely slightly abnormal epithelial cells.  
Primary cell lines are often not passaged extensively, due primarily to their known finite 
lifespans and fragility [222] as well as due to fear that excessive passaging may lead to a loss 
of their useful in vivo phenotype. Primary cells in research are often used without any 
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cryopreservation, although they may be passaged up to six times [33, 103, 111, 192, 194, 
231-236]. Cryopreservation of cells is a well-established and common technique in 
immortalised cell lines. It is very useful, as it allows cells to be stored with no upkeep and 
using minimal space (a single liquid nitrogen storage container can hold many thousands of 
vials) and they can be stored for many years without the changes associated with long-term 
culture.  
Passaging alone did not appear to have any significant effect on the growth rate of the 
samples. Non-smokers, which took an average of 20 days to reach confluence following 
collection, dropped to the same levels as the other groups, and all four groups averaged 
around 16 days to reach confluence following the initial passage (Figure 3.2-5). At no point 
prior to cryopreservation did the different groups show a significant difference in growth 
rates.  
Although the growth rate of the pHBECs was unaffected by passaging, the same could not be 
said for their survival. Even at baseline, immediately following collection, cells from current 
smokers with airflow limitation were 10% less likely to survive than cells from the other 
groups, although the difference did not reach statistical significance (Figure 3.2-2). Passaging 
had a marked effect on the survival of the cells, with only 60% of current smokers with 
normal lung function’s flasks surviving, compared to 80% for the other groups (Figure 3.2-4). 
The decline was not statistically significant when compared to the cells’ survival at passage 
0. The fact that there was no significant difference between the survival rate of the smokers 
with normal lung function and that of current smokers with airflow limitation suggested that 
this decline was probably a smoking-related issue.  
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Interestingly, there did not appear to be an airflow limitation-related effect at the initial stages 
of culture following collection, since neither current nor ex-smokers with airflow limitation 
showed significant changes in their survival compared to non-smokers, despite the literature 
suggesting that cells taken from people with COPD are more likely to die than those from 
non-smokers [30]. However, the difference between the literature and the observed results at 
this point may simply be due to the early stage of disease, and if cultures from people with 
clinically diagnosed COPD were taken, the results may have been closer to what was seen in 
the literature.  
It was not until cryopreservation following passage 1 that there were any significant changes 
to the growth rates of the cells. Due to insufficient numbers, objective comment could not be 
made on the cells from smokers with current lung function, nor on current smokers with 
airway obstruction. However cells from non-smokers took 38 days to reach confluence 
following cryopreservation, significantly longer than following collection or the initial 
passage (Figure 3.2-9). This demonstrated that although passaging has the potential to affect 
the growth of cells, cryopreservation of primary cells has a more immediate effect on the 
cells’ ability to proliferate. In particular, pHBECs taken from healthy non-smokers were 
susceptible to the deleterious effects of cryopreservation, possibly because they were not 
normally subjected to harsh environmental stimuli (ie. cigarette smoke) and were thus less 
able to adapt rapidly to changing circumstances.  
Cryopreservation significantly impacted the survival of cells taken from current smokers. 
Non-smokers’ cells and cells from ex-smokers with airflow limitation survival dropped to 
around 60%, down 20% from previous levels. However, current smokers with airflow 
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limitation survived only 40% of the time and cells from smokers with normal lung function 
had a survival rate of only 26% (Figure 3.2-6). Despite the large differences in survival rates 
between the four groups, there was no statistical significance between groups, likely due to 
type 2 error caused by small sample sizes. However, looking within each group and tracking 
survival, the difference between cells from smokers with normal lung function before and 
after cryopreservation was significant, both when comparing post-collection and post-
cryopreservation and passage 1 and post-cryopreservation survival rates (Figure 3.2-8). Cells 
from current smokers with airflow limitation also demonstrated a significant decline in 
survival following cryopreservation. Cryopreservation in general caused noticeable but non-
statistically significant drop in survival across all groups, but cells taken from current 
smokers were less likely to survive than cells from any other group, whether considering the 
effect of passaging or cryopreservation. This study was not designed or equipped to 
investigate this interesting result, however it may be of importance in understanding the more 
acute effects of smoking, and quitting, on the airway epithelium. It is possible that the Nrf-2 
and DAMP signalling pathways may be involved, as they have been implicated in cigarette 
smoke induced apoptosis and cell death in the airway epithelium in a number of studies [240-
242]. It would be interesting to examine their interaction and any association between these 
pathways and the cells’ survival following cryopreservation. Additionally, inhibition of the 
Nrf-2/DAMP pathways or blocking of pathway inhibitors might increase cell survival 
following cryopreservation, allowing more work to be performed on this valuable sample 
group.   
Based on these results, while it is tempting to suggest that cryopreservation is not 
recommended for primary cells, the time which these cells were stored for (around two years) 
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likely played a role in the decline in survival noted here. It has previously been shown that 
the longer cells are stored, the fewer cells survive thawing [243], so while it is important to 
know that cells from smokers with normal lung function suffer more from freezing than other 
cells, if cryopreservation was used for short-term storage, it may alleviate some of the effect. 
The cells may also have been suffering from the effects of the Hayflick limit, as the cells 
were encouraged to proliferate greatly before storage (See Materials and Methods 2.4.1 for 
more details).  
Overall, passaging and cryopreservation were detrimental to pHBECs’ survival, however 
they affect cells differently depending on the cells’ source. Although the effects of passaging 
vs cryopreservation cannot be fully untangled within this study, the fact that in the literature 
primary cells can survive for more than three passages suggests the effects seen here may be 
primarily attributed to cryopreservation, possibly with some interference from the Hayflick 
limit. This may be due to insufficient levels of cryoprotectant (DMSO), the cells may require 
additional supplementation with serum in their media immediately following thawing, or it 
may simply be an unavoidable side-effect of freezing primary cells. However, a major factor 
is the fact that the cells were stored for two years prior to use, as prolonged storage is known 
to affect the viability of cells [243]. Further work, with samples collected both before and 
after cryopreservation for molecular study, as well as samples which were passaged without 
freezing paired with frozen samples would help to understand the effects of the 
cryopreservation process on these valuable cells.  Additional work to reduce the impact of 
multi-year storage would also be valuable, and when working with cells taken from current 
smokers with normal lung function, special care is required to ensure their survival. 
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3.5. Chapter conclusions 
At early stages it appeared that neither passaging nor cell seeding density at collection had 
any significant effect on the rate of growth of primary cells taken from non-smokers, smokers 
with normal lung function or people with airflow limitation, regardless of current smoking or 
disease status. However, cryopreservation negatively affected cells from non-smokers, nearly 
halving their growth rates, yet had no effect on ex-smokers with airflow limitation.  
Smoking appeared to negatively affect the survival rate of cells, with cells from current 
smokers surviving less often than those from non- or ex-smokers. Although initially cells 
from all groups survived about 80% of the time, after only one passage, cells taken from 
smokers with normal lung function had a lowered survival rate compared to the other groups, 
falling to around 60%. Cryopreservation severely impacted these cells’ survival – although 
the non-smoking groups suffered from a 10% decrease in survival after cryopreservation, 
cultures from smokers with airflow limitation showed a 30% decreased survival rate 
compared to earlier passages, with only 40% of cultures surviving. Likewise, current smokers 
with normal lung function exhibited decreased viability after cryopreservation, with a 
survival rate after cryopreservation of only 26%, a drop of nearly 60% from initial survival 
and 30% from passage 1. These results demonstrated that while cryopreservation is possible 
for pHBECs, it affects different groups of cells in different ways, and that cells from current 
smokers may be particularly sensitive to cryopreservation. It is advisable to attempt further 
optimisation of the process to reduce the deleterious effects of cryopreservation, possibly by 
altering levels of cryoprotectant or increasing cell density when bringing up frozen cells.  
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4. Modelling bronchial epithelial cells in vitro using 
primary cells and an immortalised cell line 
4.1.  Introduction 
4.1.1. Changes in the epithelium in the large airways during COPD 
The pseudostratified epithelial layer in the healthy, normal large airways provides both a 
barrier to foreign particles and bacteria, but also plays a key role in clearing particulates and 
debris from the lungs [19, 238]. The epithelial cells in the large airways possess cilia on their 
apical surface, which beat in time in order to move mucus and particles up the airways and 
out into the trachea, where they can be swallowed or otherwise expelled from the body [19]. 
In order to facilitate this, and to trap pathogens and unwanted substances, the epithelial layer 
has numerous goblet cells and sub-mucosal glands, and the mucus these cells and glands 
produce encapsulates pathogens and particulates, allowing them to move easily along the 
airway. Typically there is a minimal immune presence in both the airway walls and the 
lumen, as the airway epithelium is considered to be a site of ‘immune privilege’, similar to 
the testes [245].  However, in COPD, the epithelial layer is dysregulated and is the site of a 
number of pathological changes.  
Squamous metaplasia, the thickening of the airway epithelium, is among the easiest COPD-
realted change to spot, as is the proliferation and hyperactivity of mucus producing goblet 
cells and sub-mucosal glands [20-23]. There is also a decrease in cilia length and a 
corresponding reduction in airway clearance [24, 25]. Many of the more characteristic 
changes of the airway, however, such as immune cell activation and airway wall thickening, 
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occur in either the lumen or beneath the epithelial layer. It was not until 2010 that Sohal and 
colleagues proposed that the airway epithelium may be playing a different, more active role 
in COPD pathology, via the process of EMT [31]. Since 2010, it hass been demonstrated that 
the airway epithelium, particularly the basal cell layer, is highly dysregulated [26-30], 
expressing a number of mesenchymal markers such as S100A4, vimentin and α-smooth 
muscle actin [31-34], in addition to being highly activated via pathways such as the TGF-β 
related Smad pathway [207, 240, 241] and the Wnt signalling pathway [242]. Furthermore, 
the epithelial layer overexpresses viral and bacterial adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) and platelet activating factor receptors (PAFr) [243-252]. Not 
only is the epithelium dysregulated in vivo, but it has also been demonstrated that epithelial 
cells taken from people with airflow limitation exhibit sustained pathological differences 
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4.1.2. Differences between epithelial cells isolated from non-smokers and people with 
airflow limitation in vitro 
In vitro, epithelial cells taken from the airways of people with COPD do not proliferate as 
rapidly as those taken from non-smokers, nor do they survive and differentiate as well as cells 
from non-smokers when grown at an air-liquid interface (ALI) [26]. In 2010 Milara and 
colleagues were able to show that primary epithelial cells taken from the bronchi of people 
with COPD exhibited a sustained EMT phenotype in culture [33]. Fibroblasts taken from the 
airways of people with COPD have also shown that they secrete currently unknown factors 
into the surrounding environment which can cause epithelial cells to undergo EMT [34]. This 
suggests that bronchial epithelial cells taken from COPD airways exhibit a changed 
phenotype which endures in culture, potentially making them a valuable resource for 
identifying pathways and mechanisms.  
In vitro cell models need to mimic the in vivo disease as closely as possible, and ALI cultures 
are considered good for examining the airway epithelium since they allow differentiation of 
the cells into a full epithelial layer with secretory and ciliated cells [26]. However, there is 
evidence that epithelial cell dysregulation in COPD begins and stems primarily from issues 
with the basal progenitor cells in the epithelium, which are not terminally differentiated and 
comprise about 50% of the epithelial cell population in a pseduostratified layer [253]. 
TraditionalT submerged culture does not allow a differentiated epithelium to form, instead 
causing proliferation of undifferentiated basal cells, making it potentially more useful for 
studying airway epithelial dysregulation in the sub-population of cells it affectsa most than 
ALI culture. In light of this, it is important to not dismiss submerged culture, even though it 
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does not produce a differentiated airway epithelium. However, it is crucial to check, if 
possible, that a culture model accurately reflects both the disease and the non-pathogenic 
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4.1.3. Biopsies and cell culture: how do they complement each other in research? 
Biopsies and other ex-vivo fixed tissue samples such as whole organ excisions are a valuable 
resource in the understanding of normal organ function, and the pathological changes which 
occur in disease. They provide snapshots of a certain time and location in the disease, and 
provided they are stored correctly can be analysed many years in the future. They also allow 
researchers to look at the tissue as a whole, rather than as isolated cell types, revealing 
changes in structural relationships between different cell layers and structures.  Unlike cell 
culture, these samples do not have the same risk of changes over time; they are not 
continuously growing and they are an accurate representation of the tissue at the time of 
collection. However, biopsies and other fixed samples can be negatively affected by the 
fixation process, which can produce artefacts, destroy or alter certain markers or types of 
molecule and, depending on the method chosen, render the tissue unsuitable for certain 
analyses. For example, the commonly used fixation solution paraformaldehyde forms strong 
cross-links between proteins in the cell which then require reversal using antigen retrieval 
[260], and even then some proteins are too altered or damaged to be stained. In addition to 
molecular level changes, structural changes are also a product of collection and fixation; for 
example, lumen may collapse following collection, and this makes studying structures such 
as airways and alveoli challenging. Finally, although they do not change over time in the 
same way that cells do, prolonged storage may degrade antigen epitopes and other biopsy 
features. Despite these challenges, biopsies provide key insights into disease, and can often 
provide a starting point for identifying interesting processes and molecular changes which 
can direct and be further elucidated by cell culture studies.  
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Compared to biopsies, cell culture is extremely versatile, but at the cost of sacrificing a 
certain amount of in vivo accuracy. As previously mentioned (section 3.1) cells undergo 
changes during prolonged culture, which can reduce their relevance to the disease in 
question. They also are isolated from the intercellular milieu of the body, and therefore may 
not accurately represent the full spectrum of disease, nor is it possible to ascertain if there are 
any knock-on effects in other important functional areas from seemingly minor changes in 
protein expression without complicated co-cultures.  
However, the continual growth and proliferation of cell culture is also a boon – because they 
are still alive, the cells can be treated with drugs, cytokines or other molecules or compounds 
of interest, such as cigarette smoke, and their reactions observed. It is possible to treat cells 
with chemical substances it would be extremely difficult to administer to, or even get ethical 
approval to use on, humans. Cigarette smoke, and its effect on non-smokers’ cells, is a prime 
example, and the effects of drugs can be tested without concern for potential systemic side-
effects.  
Together, biopsies and cell culture can complement each other well, with biopsies 
providingproviding information on the gross physiological disease state, and cell culture 
providing theoretically free-rein on manipulation of micro-conditions and detailed 
investigation and manipulation of pathways. It is very important to keep both sides in mind 
when researching processes such as EMT, and the comparison of culture with biopsy can 
potentially reveal if the cells truly represent the condition naturally seen in the organ of 
interest. In this vein, the main focus of this chapter is the question of how well primary cells 
taken from the airway epithelium maintain their phenotype in culture, and if the 
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commercially available BEAS-2B cell line is truly an accurate representation of healthy 
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4.1.4. Chapter aims 
The aims of this chapter were as follows:  
• To establish the baseline differences between the epithelium in biopsies taken from 
non-smokers, smokers with normal lung function and people with airflow limitation 
with regards to markers of epithelial-mesenchymal transition (EMT). 
• To confirm that cultured cells taken from non-smokers, smokers with normal lung 
function and people with airflow limitation maintain their disease phenotype in 
culture by comparing their pattern of expression to the biopsies with regards to 
markers of epithelial-mesenchymal transition (EMT).  
• To further compare cells taken from non-smokers, smokers with normal lung function 
and people with airflow limitationlimitation, looking at the expression of additional 
EMT markers, two signalling molecules and two extracellular matrix remodelling 
factors.  
• To evaluate the suitability of the commercially available, immortalised BEAS-2B cell 
line as a model for healthy bronchial epithelial cells with regards to markers of EMT, 
two signalling molecules and two extracellular matrix remodelling factors. 
 
Hypothesis: Airflow limitation will be marked by increased EMT signals and increased 
expression of signalling molecules and extracellular matrix remodelling proteins compared to 
bronchial epithelial cells from non-smokers. Bronchial epithelial, while cells from smokers 
with normal lung function will exhibit an intermediate level of EMT, although and all 
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cultured cells will exhibit a slightly decreased intensity of EMT signals following culture and 
cryopreservation compared to the biopsies. BEAS-2B cells will express similar levels of 
EMT-related markers as primary bronchial epithelial cells isolated from non-smokers.   
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4.2.  Results 
4.2.1. Epithelial markers 
The expression of E-cadherin in cultured primary cells matched the pattern of expression 
seen in the epithelium of the biopsies taken from non-smokers, smokers with normal lung 
function and people with airflow limitation, with no differences in expression being observed 
between groups (Figure 4.2-1). thisThe immortalised BEAS-2B cell line demonstrated a trend 
towards lower levels of E-cadherin expression than primary cells from non-smokers, although 
this was not statistically significant.  
SimilarSimilar to E-cadherin, while the overall pattern of expression of cytokeratin between 
the three groups of primary cells matched the pattern observed in biopsies, there was no 
difference between the three primary cells groups, nor between primary non-smokers’ cells 
and BEAS-2B cells (Figure 4.2-2). 
While tight junction protein-1 (TJP1) expression was not measured in biopsies, its level of 
expression across all three groups of primary cells matched that seen in the other two 
epithelial markers, all three groups expressing the same level of TJP1 (Figure 4.2-3). 
However, unlike the other epithelial markers, BEAS-2B cells expressed 7.1-fold more TJP1 
than primary cells from non-smokers (unpaired t-test, p = 0.0374).  
Overall the primary cells mimicked the pattern of expression seen in the biopsies, however 
contrary contray to expectations the different groups of primary cells did not differentially 
express any of the epithelial markers measured. The.T BEAS-2B cell line did not appear to 
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match the expression levels of the primary cells, and expressed significantly higher levels of 






Figure 4.2-1: Expression of E-cadherin in biopsies and primary cell cultures from non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD)people with airflow limitation (COPD) and the BEAS-2B cell line as measured by immunocytochemistry 
and qPCR. Data are represented as mean with SEM. Immuno: Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single volunteer or 
experimental sample. qPCR: Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in non-smokers’ cells. The dashed line indicates the expression of the non-smokers’ cells. ΔΔCT shows the fold-change in expression, 
with ‘1’ being no change from baseline or the control.  
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Figure 4.2-2: Expression of cytokeratin in biopsies and primary cell cultures from non-smokers (NNS), smokers with normal lung function (NLFS) and people with 
COPD (COPD) and the BEAS-2B cell line as measured by immunocytochemistry. Data are represented as mean with SEM. Each sample measured had five non-
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Figure 4.2-3: Expression of tight junction protein-1 (TJP1) in biopsies and primary cell cultures 
from non-smokers (NNS), smokers with normal lung function (NLFS) and people with COPD 
(COPD) and the BEAS-2B cell line as measured by qPCR. Data are represented as mean with 
SEM. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in non-smokers’ cells. The dashed line indicates the 
expression of the non-smokers’ cells.   
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4.2.2. Mesenchymal markers 
At the protein and mRNA levels the cultured primary cells from non-smokers, smokers with 
normal lung function and people with airflow limitation agreed with the pattern of equal 
levels of N-cadherin seen in the biopsies (Figure 4.2-4). However, two of the cultured 
samples demonstrated levels of N-cadherin protein which appeared elevated when compared 
to the other samples. BEAS-2B cells, despite a single replicate which an expressed increased 
level of N-cadherin compared to the other samples, expressed similar levels of N-cadherin as 
cells from non-smokers, although at the mRNA level they expressed 16.8-fold higher levels 
of N-cadherin than non-smokers’ cells (unpaired t-test p<0.0001). 
Expression of vimentin in both biopsies and cultured primary cells appeared consistent 
between non-smokers, smokers with normal lung function and people with airflowairflow 
limitation, although as seen with N-cadherin a number of cell samples from smokers with 
normal lung function exhibited high levels of vimentin (Figure 4.2-5). BEAS-2B cells 
expressed levels of vimentin protein similar to primary cells from non-smokers, however at 
the mRNA level expressed 6464-fold higher levels of vimentin (one-way ANOVA p = 
0.0421).  
Expression of S100A4 mRNA in the primary cells was consistent across the three groups, as 
was the expression of the protein in biospies. Once again, BEAS-2B cells expressed 22.9-
timestimes higher levels of S100A4 than primary cells from non-smokers (one-way ANOVA 
p = 0.0050). Overall, the primary cells were a reasonably accurate representations of the 
epithelial layer in the large airways, mimicking patterns of expression well. BEAS-2B cells 
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matched the primary cells at the protein level, however demonstrated increased mesenchymal 






Figure 4.2-4: Expression of N-cadherin in biopsies and primary cell cultures from non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and the BEAS-2B cell line as measured by immunocytochemistry and qPCR. Data are represented as 
mean with SEM. Immuno: Each sample measured had five non-overlapping fields of view measured individually, and the results were averaged to 
get a single final value for each sample.  Each point on the graphs represents a single volunteer. qPCR: Gene expression was normalised to β-actin 
as the housekeeping gene, and further normalised to the average expression in non-smokers’ cells. The dashed line indicates the expression of the 
non-smokers’ cells.   







Figure 4.2-5: Expression of vimentin in biopsies and primary cell cultures from non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and the BEAS-2B cell line as measured by immunocytochemistry and qPCR. Data are represented as 
mean with SEM. Immuno: Each sample measured had five non-overlapping fields of view measured individually, and the results were averaged to 
get a single final value for each sample.  Each point on the graphs represents a single volunteer. qPCR: Gene expression was normalised to β-actin 
as the housekeeping gene, and further normalised to the average expression in non-smokers’ cells. The dashed line indicates the expression of the 
non-smokers’ cells.   









Figure 4.2-6: S100A4 protein and mRNA expression in biopsies taken from non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and the BEAS-2B cell line as measured by immunohistochemistry and qPCR. Data are represented 
as mean with SEM. Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
non-smokers’ cells. The dashed line indicates the expression of the non-smokers’ cells.   
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4.2.3. Signalling molecules and extracellular matrix remodelling 
Expression of TWISTappeared consistent across all three primary cells groups at both protein 
and mRNA levels (Figure 4.2-7). BEAS-2B cells expressed levels of TWIST protein equal to 
those seen in non-smokers’ cells, however at the mRNA level there was adecrease in 
expression, although this did not reach statistical significancesignificance.  
In primary cells taken from non-smokers, smokers with normal lung function and people with 
airflow limitation there nono significant change in Smad6 between non-smokers and the other 
two groups, despite despitea slight downwards trend in expression (Figure 4.2-8). BEAS-2B 
cells with minimal variation between samples likewise trended towards decreased expression 
of Smad6 compared tonon-smokers. 
Levels of the extracellular matrix remodelling markers MMP2 and collagen 1-α were similar 
across all groups of primary cells whether measured at the mRNA level (MMP2 and collagen 
1-α) or using the levels of precursor protein secreted into the cell culture supernatant (pro-
collagen 1-α) (Figure 4.2-9). However, once again BEAS-2B cells trended towards higher 
levels of MMP2 and collagen 1-α at the mRNA level than primary cells from non-smokers, 
although the increase was not translated into increased levels of pro-collagen 1-αalthough.  
Overall at the molecular level BEAS-2B cells appeared to vary in expression of both 
signalling molecules and proteins involved in extracellular matrix formation when compared 
to primary bronchial epithelial cells from non-smokers. Primary cells expressed these 
markers consistently across cells taken from non-smokers, smokers with normal lung 
function and people with airflowairflow limitation.   
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Figure 4.2-7: Expression of TWIST in primary cell cultures from non-smokers (NNS), smokers with normal 
lung function (NLFS) and people with COPD (COPD) and the BEAS-2B cell line as measured by 
immunocytochemistry and qPCR. Data are represented as mean with SEM. qPCR: Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in non-
smokers’ cells. The dashed line indicates the expression of the non-smokers’ cells.  
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Figure 4.2-8: Smad6 expression primary bronchial epithelial cells taken from non-smokers 
(NNS), and the BEAS-2B cell line as measured by qPCR. Data are represented as mean with 
SEM. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in non-smokers’ cells. The dashed line indicates the 
expression of the non-smokers’ cells.   
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Figure 4.2-9: Expression of MMP2 and collagen 1-α in primary cell cultures from non-smokers 
(NNS), smokers with normal lung function (NLFS) and people with COPD (COPD) and the 
BEAS-2B cell line as measured by ELISA of cell culture supernatant and qPCR. Data are 
represented as mean with SEM. qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in non-smokers’ cells. The 
dashed line indicates the expression of the non-smokers’ cells.   
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Primary cells taken from non-smokers, smokers with normal lung function and people with 
airflow obstruction appeared to accurately model the expression of epithelial-mesenchymal 
transition (EMT) markers, at least with regards to the patterns of expression seen between the 
three groups in biopsies. Levels of epithelial, mesenchymal and extracellular matrix markers 
remained consistent across all groups, indicating that primary bronchial epithelial cells can be 
used as an in vitro model of in vivo expression in the bronchial epithelium. 
Although this study was underpowered to detect statistically significant changes in the 
expression of EMT markers, the results suggested that the BEAS-2B cell line is likely to be 
an inaccurate representation of healthy primary human bronchial epithelial cells, especially 
when observing molecular changes at the mRNA level. The BEAS-2B cell line appeared to 
be less epithelial than primary cells from non-smokers, in addition to expressing increased 
levels of mesenchymal markers and extra-cellular matrix remodelling mRNA, although these 
changes did not often correspond to differences in protein expression. The increase in 
mesenchymal markers vimentin and N-cadherin were statistically significant, and the BEAS-
2B cells also trended towards increased expression of MMP2 and procollagen 1-α compared 
to primary cells from non-smokers.. This was likely due to a combination of the small sample 
size and the fact that the cells were not synchronised in their cell cycle stage, which is likely 
responsible for the large inter-sample variation seen in the BEASBEAs-2B cells. When 
attempting to confirm these changes, it is recommended that the cells be synchronised by 
serum starvation or application of a treatment such as a DNA synthesis inhibitor or a mitotic 
inhibitor such as nocodazole, depending on the phase of the cell cycle desired. Serum 
starvation, which synchronises cells in the G0/G1 phase, would be recommended for these 
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particular studies. Since BEGM media is naturally serum free, in this case ‘serum starvation’ 
is technically not the correct term – in order to starve the cells, the basal media without any 
growth factors (BEBM) would be used instead of the fully supplemented BEGM.  Despite 
these limitations, it was clear thatthe the BEAS-2B cells differeddiffer markedly in their 
EMT-related profile compared to primary cells from non-smokers, at least at the mRNA 
level.  
This raised the question that, if these differences between immortalised and primary cell lines 
were only measurable at the mRNA level then perhaps there were differences between the 
primary cells and in vivo tissue which were likewise only apparent at the molecular level. 
Indeed, perhaps the BEAS-2B cell line more accurately represents the mRNA expression 
profile of bronchial epithelium in vivo than the primary cells? Attempts were made during the 
study to apply RNAScope to biopsies matched to those taken for protein analysis (section 
2.7.3) in order to quantify mRNA expression in the tissue itself. However, despite several 
attempts at optimisation the RNAScope platform failed to stain the sections for the 
housekeeping gene Peptidylprolyl Isomerase B (PPIB). This was considered likely due to the 
fact that the sections were collected and preserved prior to the release of the RNAScope 
recommended guidelines for treatment of samples during collection. DrBased on out lab’s 
previous experience with in-situ hybridisation of tissue samples, the tissue was treated as 
described in the Methods and Materials, however the fixation times were far longer than 
recommended for the RNAScope kit. The original samples remain in storage and in future a 
technique such as formalin-fixed paraffin-embedded (FFPE) RNA extraction and analysis 
could be performed to examine differences in molecular level expression of markers, 
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although the epithelial layer would need to be isolated prior to extraction, possibly by laser-
dissection, in order to get a useful answer.  
Further study to confirm if the differences between BEAS-2B cells and primary cells seen in 
this study are real is required, however it would appear likely that even if the BEAS-2B cell 
line differs from healthy primary bronchial epithelial cells at the molecular level, if the 
changes do not extend to protein expression then the differences are unlikelyunlikely to be of 
functional significance. In this case, it would be prudent to preferentially examine protein-
level changes when utilising the BEAS-2B cell line as a model for healthy primary bronchial 
epithelial cells, as the molecular-level characteristics appeared to not be an accurate 
representation of expression.  
While this studywas primarily interested in the viability of primary and immortalised cell 
culture systems as models for in vivo bronchial epithelium, the results obtained from the 
biopsy tissue raised some mild concerns. Previously, the literature has demonstrated that 
EMT is active in COPD [31-33, 39, 40, 207], with increased expression of mesenchymal 
markers and decreased levels of epithelial markers. The results seen here do not match these 
data, however this is likely due to the fact that the volunteers recruited in this study did not 
have full, clinical COPD. While they did exhibit airflow limitation, it is possible that EMT 
may not be fully active at such an early stage of disease development. This means that, 
although BEAS-2B cells appeared to be unsuitable models of healthy airway epithelium, it is 
possible that they may still be useful for studying COPD-related disease, as they may share 
characterisitics with cells taken from established disease. Further work using cells taken from 
people with established, clinical COPD is recommended.  
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
 
158 
Additionally, the biopsies in the current study were not randomly selected – instead, biopsies 
which were paired to cell cultures which grew and survived well and produced a high number 
of cells for use were used, in order to produce paired data. Although this sort of selection bias 
is difficult to avoid in cell culture, it may have inadvertently caused biopsies from individuals 
with ‘healthier’ epithelium to have been selected for among the cohort with airflow 
limitation. This may have obscured any EMT signal produced by the airflow limitation, as the 
cells which grew well would, theoretically, approximate ‘normal’ cells in terms of their 
phenotype, and thus the biopsies’ epithelium would appear closer to healthy than diseased.  
Secondly, in the literature [31, 32, 40, 255] only cells within 10μm of the reticular basement 
membrane were counted (personal correspondence, Sukwinder Sohal 02/Feb/2017), and were 
referred to as ‘basal cells’. While in the case of stains such as E-cadherin or cytokeratin, 
which appeared to stain the entire epithelial layer with reasonable uniformity, this distinction 
is likely unimportant, N-cadherin and S100A4 demonstrated more discrete, point staining 
and, at least in the case of N-cadherin, appeared to localise in proximity to the basement 
membrane. Thus, it is possible that the difference in counting methodology contributed to the 
differences between the data in this study and the literature, although this is effect may be 
overshadowed by the fact that the cells used in this study did notdi dnot come from people 
with clinical COPD.  
In this regard, it is also worthwhile to note that the cell culture data obtained in this study did 
not agree with the results previously seen in the literature [33], which indicate a maintenance 
of an EMT phenotype in culture. However, as previously mentioned, the cells in this study 
were obtained from volunteers with pre-COPD, rather than established disease, which 
potentially explains the discrepancy. As the cells in this study agreed with their paired 
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biopsies with regards to the lack of presence of an EMT phenotype, this issue does not have a 
great impact on the results of this study.   
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4.4. Chapter conclusions 
Primary cells taken from non-smokers, smokers with normal lung function and people with 
airflow limitation appeared to exhibit a phenotype in culture which matched that seen in the 
epithelium of biopsies from similar subjects, despite undergoing two passages and 
cryopreservation. This suggests that they are, as is generally accepted, a reliable model of 
human bronchial epithelial cells in vivo. However, the BEAS-2B cell line, which is 
commonly used as a stand-in for healthy primary bronchial epithelial cells, appeared to 
exhibit an altered, mesenchymal-like, phenotype at the molecular level when compared to 
primary cells taken from non-smokers. This altered phenotype did not translate into changes 
at the protein level, suggesting that BEAS-2B cells may still be applicable for functional 
studies where non-smoker primary cells are unavailable, however analysis should focus on 
protein level changes rather than relying on mRNA wherever possible. While this study 
suggests that BEAS-2B cells may be an unreliable model of healthy bronchial epithelium, if 
they react in the same way to stimulus as the pHBECs then they may still prove to be a useful 
model, despite differences in their baseline phenotype.  
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5. Artificial induction of EMT in healthy bronchial 
epithelial cells and its relevance to EMT in COPD 
5.1. Introduction 
From the literature, EMT is known to occur in COPD airways [31-34], and epithelial cells 
cultured from people with COPD exhibit abnormal growth and differentiation, in addition to 
an EMT phenotype [26, 27, 33, 103, 235, 256]. This makes bronchial epithelial cells taken 
from COPD airways, which exhibit a changed phenotype that endures in culture a valuable 
resource for identifying pathways and mechanisms. However, they are challenging to obtain 
and difficult to work with. SinceS EMT can be induced in both primary and immortalised 
bronchial epithelial cells lines, is it possible to replicate the EMT phenotype seen in COPD in 
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5.1.1. The CSE-TGF-β-EMT pathway 
Exposure to cigarette smoke has been shown to induce EMT in both pHBECs and 
immortalised bronchial epithelial cells [33], as well as in alveoli-derived epithelial cells 
[203]. There have been a number of pathways implicated in cigarette smoke extract (CSE) 
induced EMT, including the Rac1 pathway [203], ERK1/2 phosphorylation, modulation of 
cyclic monophosphate and TGF-β signalling via Smad3 [33].  
Although TGF-β may not be the only factor modulating EMT in response to CSE, it is well 
known to be a reliable inducer of EMT on its own [33, 165, 257-260], as well as being 
involved in a number of diseases which involve epithelial-mesenchymal transition (EMT), 
including hepatic fibrosis [65, 80], kidney fibrosis [58, 79, 81] and non-COPD-related 
pulmonary fibrosis [58, 82].  Furthermore, TGF-β has been shown to have increased receptor 
expression in the acinar mucus glands in COPD airways [261], and has also been shown to be 
increased in the airway epithelium, where it is speculated to play a role in the recruitment of 
macrophages [85]. Cigarette smoke, potentially via TGF-β, is thought to drive EMT in 
COPD, likely through either the Smad signalling pathway [88, 89], or the Smad-independent 
MAPK pathway [90]. As both TGF-β and CSE are known to induce EMT in bronchial 
epithelial cells in culture, it is interesting to know whether CSE induced EMT is the same as 
EMT induced by TGF-β alone.  This study aimeded to examine the similarities and 
differences between CSE induced EMT and TGF-β induced EMT, with an eye to determining 
whether TGF-β signalling via the Smad pathway is the key factor in the CSE-TGF-β-EMT 
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5.1.2. Chapter aimsa 
The aims of this were as follows: 
• To determine if primary bronchial epithelial cells taken from non-smokers react to 
transforming growth factor-β1 in the same manner as the commercially available 
immortalised BEAS-2B cell line with regards to epithelial-mesenchymal transition 
(EMT) markers, two signalling pathways and expression of two extracellular 
remodelling factors.  
• To determine if primary bronchial epithelial cells taken from non-smokers react to 
cigarette smoke extract in the same manner as the commercially available 
immortalised BEAS-2B cell line with regards to EMT markers, two signalling 
pathways and expression of two extracellular remodelling factors.  
 
Hypothesis: BEAS-2B cells and primary bronchial epithelial cells taken from non-smokers 
will exhibit changes of similar magnitude in EMT-related markers in response to 
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5.2.1.1. Epithelial markers 
E-cadherin demonstrated no change in expression following exposure to cigarette smoke 
extract (CSE) in either primary or BEAS-2B cells (Figure 5.2-1). SimilarlySimilarly, 
cytokeratin (Figure 5.2-2) and tight junction protein-1 (Figure 5.2-3) did not change in 
response to CSE. Overall, CSE appeared to have no effect on epithelial marker expression.  
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Figure 5.2-1: Expression of E-cadherin in primary bronchial epithelial cells from non-smokers (NNS) and 
the immortalised BEAS-2B cell line following exposure to cigarette smoke extract (CSE) for 4 hours as 
measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are NNS pHBECs, open shapes are BEAS-2B cells. 
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
 
166 
Figure 5.2-2: Expression of cytokeratin in primary bronchial epithelial cells from non-smokers 
(NNS) and the immortalised BEAS-2B cell line following exposure to cigarette smoke extract 
(CSE) for 4 hours as measured by immunocytochemistry. Data are represented as mean with SEM. 
In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view 
measured individually, and the results were averaged to get a single final value for each sample.  
Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B).  
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Figure 5.2-3: Expression of tight junction protein-1 (TJP1) in primary bronchial epithelial cells 
from non-smokers (NNS) and the immortalised BEAS-2B cell line following exposure to cigarette 
smoke extract (CSE) for 4 hours as measured by qPCR. Data are represented as mean with SEM.  
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the 
average expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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5.2.1.2. Mesenchymal markers 
Exposure to cigarette smoke extract (CSE) increased N-cadherin protein expression by 405.3 
times in primary cells (Welch’s t-test p = 0.0363), however had no effect on protein 
expression in BEAS-2B cells (Figure 5.2-4). At the mRNA level, CSE had no effect on N-
cadherin expression in primary cells, although BEAS-2B cells exhibited an 87.3-fold 
decrease in expression (Welch’s t-test p = 0.0459) following exposure. 
Protein and mRNA levels of vimentin expression were unchanged in both cell types 
following CSE exposure (Figure 5.2-5). Levels of S100A4 mRNA were unchanged by CSE 
(Figure 5.2-6). Overall, CSE increased expression of mesenchymal markers in primary cells 
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Figure 5.2-4: Expression of N-cadherin in primary bronchial epithelial cells from non-smokers (NNS) and 
the immortalised BEAS-2B cell line following exposure to cigarette smoke extract (CSE) for 4 hours as 
measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-5: Expression of vimentin in primary bronchial epithelial cells from non-smokers (NNS) and the 
immortalised BEAS-2B cell line following exposure to cigarette smoke extract (CSE) for 4 hours as 
measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-6: Expression of S100A4 in primary bronchial epithelial cells from non-smokers (NNS) 
and the immortalised BEAS-2B cell line following exposure to cigarette smoke extract (CSE) for 4 
hours as measured by qPCR. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
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5.2.1.3. Signalling molecules 
TWIST expression at the protein level was unaffected by exposure to cigarette smoke extract 
(CSE) in both primary and BEAS-2B cells (Figure 5.2-7). Smad6 expression was unaffected 
by CSE in primary cells (Figure 5.2-8). Overall, the TWIST and Smad pathways were 
unaffected by CSE., despite suggestions of mild non-significant changes in expression at the 
mRNA level.   
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Figure 5.2-7: Expression of TWIST in primary bronchial epithelial cells from non-smokers (NNS) and the 
immortalised BEAS-2B cell line following exposure to cigarette smoke extract (CSE) for 4 hours as 
measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-8: Expression of Smad6 in primary bronchial epithelial cells from non-smokers (NNS) 
and the immortalised BEAS-2B cell line following exposure to cigarette smoke extract (CSE) for 4 
hours as measured by qPCR. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
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5.2.1.4. Extracellular remodelling 
MMP2 expression in the primary cells remained broadly unchanged by cigarette smoke 
extract (CSE) exposure, although a single sample did demonstrate a large increase in 
response to the treatment (Figure 5.2-9). In contrast, expression of MMP2 in the BEAS-2B 
decreased by 856.2-fold, although the changeit did not reach statistical sginificance.  
Both primary and BEAS-2B cells demonstrated a decrease in expression of collagen 1-α 
mRNA following CSE exposure, and while this change did not reach statistical significance 
there was a statistically significant decrease in the level of pro-collagen 1-α protein in the cell 
culture supernatant, it being too low to be detected in both primary and BEAS-2B cells 
following exposure ([primary] Welch’s t-test p = 0.0328; [BEAS-2B] Wlech’s t-test p<0.001) 
(Figure 5.2-9). Expression of extracellular matrix remodelling proteins appeared to be 
downregulated in both BEAS-2B and primary cells in response to CSE.   
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Figure 5.2-9: Expression of MMP2 and collagen 1-α in primary bronchial epithelial cells from 
non-smokers (NNS) and the immortalised BEAS-2B cell line following exposure to cigarette 
smoke extract (CSE) for 4 hours as measured by ELISA of cell culture supernatant and qPCR. 
Data are represented as mean with SEM.  qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The 
dashed line indicates the expression of the untreated cells.   
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5.2.2.1. Epithelial markers 
Exposure to transforming growth factor-β1 (TGF-β) had no effect on E-cadherin expression 
in either primary or BEAS-2B cells (Figure 5.2-10). Likewise, both cytokeratin (Figure 
5.2-11) and tight junction protein-1 expression (Figure 5.2-12) werewere unaffected in both 
cell types. Overall, TGF-β had no effect on epithelial marker expression.  
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Figure 5.2-10: Expression of E-cadherin in primary bronchial epithelial cells from non-smokers (NNS) and 
the immortalised BEAS-2B cell line following exposure to transforming growth factor-β1 (TGF-β) for 72 
hours as measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: 
In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-11: Expression of cytokeratin in primary bronchial epithelial cells from non-smokers 
(NNS) and the immortalised BEAS-2B cell line following exposure to transforming growth factor-
β1 (TGF-β) for 72 hours as measured by immunocytochemistry. Data are represented as mean with 
SEM. In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) 
were stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of 
view measured individually, and the results were averaged to get a single final value for each 
sample.  Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-
2B).  
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Figure 5.2-12: Expression of tight junction protein-1 (TJP1) in primary bronchial epithelial cells 
from non-smokers (NNS) and the immortalised BEAS-2B cell line following exposure to 
transforming growth factor-β1 (TGF-β) for 72 hours as measured by qPCR. Data are represented as 
mean with SEM. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. The dashed line indicates the expression of 
the untreated cells.   
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5.2.2.2. Mesenchymal markers 
Primary cells treated with TGF-β, despite showing a 19.1-fold decrease (one-way ANOVA p 
= 0.0461) in N-cadherin at the mRNA level showedshowed no change in N-cadherin 
expression at the protein level in response to TGF-β (Figure 5.2-13). Similarly, although 
BEAS-2B cells showed a 63.5-fold decrease (one-way ANOVA p<0.0001) in mRNA 
expression of N-cadherin, the protein level remained unchanged following TGF-β exposure. 
A downwards trend in vimentin mRNA expression was observed in both primary and 
BEAS2-2B cells, however this did not reach statistical significance and therethere was no 
change in protein level expression (Figure 5.2-14). S100A4 remained unaffected by TGF-β in 
both primary and BEASS-2B cells (Figure 5.2-15).  
Overall, while TGF-β appeared to have a suppressive effect on mRNA levels of 
mesenchymal markers in both primary and BEAS-2B cells, this did not result in changed 
protein level expression.   
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Figure 5.2-13: Expression of N-cadherin in primary bronchial epithelial cells from non-smokers (NNS) and 
the immortalised BEAS-2B cell line following exposure to transforming growth factor-β1 (TGF-β) for 72 
hours as measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: 
In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-14: Expression of vimentin in primary bronchial epithelial cells from non-smokers (NNS) and the 
immortalised BEAS-2B cell line following exposure to transforming growth factor-β1 (TGF-β) for 72 hours 
as measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-15: Expression of S100A4 in primary bronchial epithelial cells from non-smokers (NNS) 
and the immortalised BEAS-2B cell line following exposure to transforming growth factor-β1 
(TGF-β) for 72 hours as measured by qPCR. Data are represented as mean with SEM. Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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5.2.2.3. Signalling molecules 
TWIST expression in primary and BEAS-2B cells was unaffected by TGF-β at both the 
protein and mRNA level (Figure 5.2-16). , athlough it did not reach statistical 
significanceSimilarly, Smad6 was unaffected by TGF-β in both primaryand BEAS-2B cells 
(Figure 5.2-17). respondTGF-β appeared to have no effect on TWIST or Smad signalling in 
either primary or BEAS-2B cells.   
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Figure 5.2-16: Expression of TWIST in primary bronchial epithelial cells from non-smokers (NNS) and the 
immortalised BEAS-2B cell line following exposure to transforming growth factor-β1 (TGF-β) for 72 hours 
as measured by immunocytochemistry and qPCR. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  Each point on the graphs represents a 
single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as 
the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line 
indicates the expression of the untreated cells.   
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Figure 5.2-17: Expression of Smad6 in primary bronchial epithelial cells from non-smokers (NNS) 
and the immortalised BEAS-2B cell line following exposure to transforming growth factor-β1 
(TGF-β) for 72 hours as measured by qPCR. Data are represented as mean with SEM. Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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5.2.2.4. Extracellular remodelling 
Both primary cells and BEAS-2B cells demonstrated no change in MMP2 expression in 
response to TGF-β treatment (Figure 5.2-18), nornor did the expression of collagen 1-α 
change in response to the exposure. P proteinexpression in the primary cells also remaineded 
unchanged, however the BEAS-2B cells produced 15.1 times more protein following 
exposure (Welch’s t-test p = 0.0158). Overall, TGF-β had littlelittle effect on extra-cellular 
matrix remodelling protein expression however, not unexpectedly, it produced an increase in 
pro-collagen 1-α expression, although only in the BEAS-2B cell line, while the primary cells 
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Figure 5.2-18: Expression of MMP2 and collagen 1-α in primary bronchial epithelial cells from 
non-smokers (NNS) and the immortalised BEAS-2B cell line following exposure to 
transforming growth factor-β1 (TGF-β) for 72 hours as measured by ELISA of cell culture 
supernatant and qPCR. Data are represented as mean with SEM.  qPCR: Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression 
in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are NNS pHBECs, open shapes are BEAS-2B cells. 
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
 
190 
5.3. Chapter discussion 
5.3.1. CSE discussion 
Cigarette smoke extract (CSE) is an interesting substance to work with. Although it has clear 
biological relevance to smoking-related diseases such as chronic obstructive pulmonary 
disease (COPD), utilising it in vitro presents a unique challenge. Smokers vary in the 
frequency and depth of their puffs when smoking [268], and the chemical and particulate 
content of cigarette smoke varies between brands [263, 264]. These facts make it challenging 
to standardise the application of cigarette, although if a study focusses on a specific 
component such as nicotine they can standardise the content of that component [199]. In this 
study, the CSE used was kindly donated by others who had used the same extract in prior 
published work [209], and our colleague Jessica Kregor had previously performed dose 
response work in the author’s group to find a concentration which was not lethal to BEAS-2B 
cells. 
Primary cells reacted differently than BEAS-2B cells following exposure to cigarette smoke, 
with CSE exertingexerting a mixed effect on epithelial-mesenchymal transition (EMT) 
markers and pathway signalling molecules.. While CSE increasedincrease the mesenchymal 
profile of primary cells, it had no effect on epithelial markers, and actually decreased 
expression of the affected mesenchymal markers in BEAS-2B cells. theThis suggests that the 
BEAS-2B cell line is not ideal as a model of smoking-related changes in bronchial epithelial 
cells, and when possible primary cells should be employed instead.  
With regards to the induction of EMT by CSE, the results were somewhat mixed, but 
generally suggested that CSE did not induce complete EMT in the cells. Epithelial markers 
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appeared unaffected, both in primary and BEAS-2B cells, however primary cells exhibited a 
significant increase in N-cadherin expression, although all other mesenchymal markers 
remained unchanged. While both primary and BEAS-2B cells exhibited a significant decrease 
in the level of pro-collagen 1-α in the culture supernatant, with levels too low to be detected, 
this may be due to the fact that the CSE-containing supernatant was only applied to the cells 
for 4 hours and therefore conained lower levels of secreted factors than the control 
supernatant, which was exposed to the cells for 24 hours. It would appear that CSE acts 
through neither the TWIST nor the Smad pathway, which disagrees with the literature [33], at 
least with regards to Smad. However, there are two possible explanations for this discrepancy 
– differences in the model system and differences in the markers measured.  
Firstly, Milara and colleagues utilised a differentiated epithelium grown at an air-liquid 
interface, as compared to the submerged culture system used in the current study. This likely 
affected the responses of the cells to stimulation and may account in part for the observed 
difference.  
The other fact is that Milara and colleagues measured activation of Smad3 expression, 
whereas the present study looked at Smad6 expression. Smad3 is part of the excitatory 
pathway in TGF-β signalling, being activated via phosphorylation and forming an active 
complex with Smad2, while Smad6 is an inhibitory Smad [87]. Smad6 is known to be 
upregulated in an auto-inhibitory feedback loop in response to TGF-β [87], which is 
upregulated in the airways of smokers [86, 240] and the expression of which is induced by 
CSE exposure in epithelial cells [33, 265], which makes it a good target for analysis via 
qPCR as compared to an activating Smad like Smad4, which is constitutively expressed [87]. 
However, it is possible that CSE, which contains many compounds and the composition of 
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which varies depending on the source, may act via an unknown mechanism to inhibit the 
production of inhibitory Smads, which would allow for the fact that Smad3 activation 
increased in the Milara paper while Smad6 expression remained unchanged in the current 
study. Another possibility is that CSE activates more strongly pathways such as the NF-κB 
pathway, which selectively upregulates the inhibitory Smad7 without Smad6 activation [87], 
although this theory does not account for the known activation of Smad3 seen in cells 
exposed to CSE [33].  
Future study should look at both Smad6 expression and Smad3 phosphorylation in these 
cells, to attempt to disentangle the reason behind the conflicting results between this study 
and the literature. Analysis of the non-Smad associated MAPK pathway is also advisible, on 
the basis that TGF-β can also act via that mechanism [90]. Further, as with all chapters in this 
study, increased sample sizes are highly recommended to increase the power to detect 
changes in the level of expression of the markers.  
Within the limitations of the current results, it is reasonable to conclude that the BEAS-2B 
cell line reacts differently to CSE than primary bronchial epithelial cells at the molecular 
level, although generally the protein-level responses appear similar. Thus, when the BEAS-
2B cell line is used in place of primary cells, focus should be placed on protein analysis over 
molecular changes, as noted in previous chapters. Additionally, while CSE appeared to 
induce a partial EMT phenotype in the primary cells it did not appear to be a potent inducer 
of EMT in the BEAS-2B cells, even being slightly suppressive, and thus primary cells should 
be preferred when examining the effects of CSE on bronchial epithelial cells in culture, 
particularly when examining mRNA level changes.   
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5.3.2. TGF-β discussion 
In this study, exposure to transforming growth factor-β1 (TGF-β) failed to induce signs of 
epithelial-mesenchymal transition in primary cells taken from non-smokers or in BEAS-2B 
cells, although it did trigger increased expression of collagen 1-α in BEAS-2B cells. While 
the fact that the primary and BEAS-2B demonstrated similar responses to TGF-β suggests 
that BEAS-2B cells may be a useful model of healthy bronchial epithelial cells’ reactions to 
cytokines, the fact that TGF-β exposure failed to induce EMT in either cell type is a 
noticeable issue.  
The literature demonstrates, in epithelial cells taken from multiple different origins, that 
TGF- β is a reliable inductor of EMT [33, 63, 92, 93, 165, 200, 257-259, 266], which raisedd 
the question of why it failed to produce an EMT phenotype in the current study. Previous 
work, during the author’s Honours work and by others within the group with TGF-β in the 
BEAS-2B cell line has generated data consistent with the literature, making this non-result a 
curiosity. This reduced activity is worth noting, however the TGF-β still retained some 
activity, as evidenced by the increase in pro-collagen 1-α expression in the BEAS-2B cells 
the cytokine had not lost all activity, and thus may still yield some useful data in future 
experiments.  
Repetition of these experiments with fresh cytokine would be recommended in order to either 
validate the unresponsiveness of the cells to TGF-β or, more likely, to properly examine the 
differences in response of the primary cells and the BEAS-2B cells to TGF-β. Furthermore, 
prior to experimentation it is recommended to test the activity of the TGF-β cytokine, which 
can be done utilising the MBF-11 or TMLC cell line-based bioassayslines [267, 268].  
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With the current results, it is possible to speculate that the primary cells and BEAS-2B cells 
may respond differentially to TGF-β along the TWIST and Smad pathways, and that the 
BEAS-2B cell line may have a more extreme pro-fibrotic response to the cytokine than the 
primary cells. This data suggests that while the BEAS-2B cells may be useful substitutes for 
primary cells with regards to EMT markers, they are unreliable models of pathway 
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5.4. Chapter conclusions 
As in previous chapters, primary and BEAS-2B cells differed in their molecular level 
expression of markers and other factors, in this case following exposure to transforming 
growth factor-β1 (TGF-β) or cigarette smoke extract (CSE). Although they generally agreed 
at the protein level of expression, it would appear preferable to avoid using the BEAS-2B cell 
line to represent healthy bronchial epithelial cells whenever possible, and if it cannot be 
avoided then protein-level data should be preferred over mRNA expression.  
In this study, despite the literature, neither TGF-β nor CSE appeared to successfully induce a 
full EMT phenotype in either primary or BEAS-2B cells. Further study with fresh cytokine 
and, if possible, a larger number of samples to confirm or deny possible changes observed in 
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6. Effect of current COPD therapeutic drugs on EMT in 
vitro 
6.1. Chapter aims 
The aims of this chapter were as follows: 
• To examine the effects of the chronic obstructive pulmonary disease drugs salmeterol 
xinafoate, tiotropium bromidebormide monohydrate and fluticasone proprionate, both 
alone and in combination on epithelial-mesenchymal transition (EMT) in epithelial cells 
taken from non-smokers, smokers with normal lung function and people with airflow 
obstruction, as well as in the immortalised BEAS-2B cell line. 
o Hypothesis: Salmeterol xinafoate will suppress EMT markers, possibly by 
interaction with TWIST. Tiotropium bromide monohydrate will suppress EMT 
related markers via suppression of the TGF-β signalling pathway, potentially via 
Smad signalling. Fluticasone proprionate will decrease EMT related markers, 
although the potential mechanisms behind this are unclear.  
• To examine the effects of the three drugs alone and in combination on EMT in both 
normal primary epithelial cells taken from non-smokers and in the immortalised BEAS-
2B cell line following application of either transforming growth factor-β1 or cigarette 
smoke extract.  
 
o Hypothesis: Salmeterol xinafoate will suppress EMT changes by interaction 
with TWIST, with best effect on those changes induced by cigarette smoke 
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extract. Tiotropium bromide monohydrate will suppress EMT related changes 
via the , especially those induced by transforming growth factor-β1 signalling 
pathway.. Fluticasone proprionate will decrease EMT related changes and will 
be effective on EMT induced by either transforming growth factor-β or cigarette 
smoke extract.  
The aims of this section were as follows:  
• To examine the effects of combined salmeterol, tiotropium and fluticasone on EMT 
markers, two signalling pathway markers and two extracellular matrix remodelling 
factors in primary bronchial epithelial cells taken from non-smokers, smokers with 
normal lung function and people with COPD, as well as in the commercially available 
immortalised BEAS-2B cell line.  
o Hypothesis: The combination of the three drugs will exert a synergistic EMT-
suppressing effect on both primary and immortalised bronchial epithelial 
cells.cells. The drugs will also suppress both the TWIST and Smad signalling 
pathways. 
• To examine the effects of either transforming growth factor-β1 or cigarette smoke 
extract combined with salmeterol, tiotropium and fluticasone on EMT markers, two 
signalling pathway markers and two extracellular matrix remodelling factors in primary 
bronchial epithelial cells taken from non-smokers and the commercially available 
immortalised BEAS-2B cell line.  
o Hypothesis: The combination of the three drugs will suppress EMT-related 
changes caused by exposure to either transforming growth factor-β1 or cigarette 
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6.2. Salmeterol xinafoate 
6.2.1. Introduction 
Salmeterol is a long-acting beta-2 adrenoreceptor-agonist (LABA) used in the treatment of 
asthma and COPD [269]. It is lipophilic and accumulates in the cell membrane, which allows it 
to act over a longer period of time than short-acting bronchodilators (SABAs) [270]. However, 
because it is a partial agonist, compared to a full agonist like formoterol, it has greatly reduced 
functionality in inflamed tissue, and unlike formoterol the concurrent application of a 
corticosteroid does not improve this reduced effect. Despite this, salmeterol a common 
apharmacological therapyy used to treat COPD [208].  
Salmeterol and other LABAs reduce inflammation in the airways[270] as well as reducing 
airway remodelling and slowing the decline in lung function which results from COPD [271, 
272].  They are commonly prescribed in COPD, and have been shown to be effective at 
increasing quality of life, as well as reducing the number of exacerbations [271, 273, 274]. 
LABAs like salmeterol act via binding to β2-adrenergic receptors, which are known to be 
present on airway epithelial cells [111, 173, 233, 234, 272, 275, 276], and cause upregulation of 
cAMP and the MAPK pathways in order to reduce inflammation [173, 234, 275].  There are a 
number of long-term effects which come from prolonged use of LABAs, including 
desensitisation, increased inflammatory responses and mucin (mucous proteins) production 
[234, 275], however LABAs, along with long acting muscarinic antagonists (LAMAs) are 
among the few non-surgical therapies which are known to slow the progression of COPD [271].  
Of specific interest to this study, LABAs are known to reduce epithelial cells’ motility and 
impair wound healing [272], which suggests that it may be having an effect on the process of 
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EMT. It is therefore possible that some of salmeterol’s effects in COPD may be due not only to 
its effects on the inflammatory lung environment, but also changes it is capable of producing in 
epithelial cells. Examining the effect of salmeterol on EMT, which is thought to cause airway 
remodelling, may shed further light on salmeterol’s actions in COPD and elucidate the pathway 
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6.2.2.1. Effects of salmeterol on EMT markers in primary and BEAS-2B cells 
6.2.2.1.1. Epithelial markers 
Salmeterol had no effect on E-cadherin expression at the protein level or mRNA in primary 
cells (Figure 6.2-1). BEAS-2B cells’ expression of E-cadherin waslikewise unaffected by 
application of salmeterol. None of the three primary cell groups exhibited any change in 
cytokeratin protein expression in response to salmeterol, however BEAS-2B cells increased 
protein expression by 1.9 times (one-way ANOVA p = 0.0278) following exposure to 
salmeterol (Figure 6.2-2). NeitherNeither primary cells nor BEAS-2B cells exhibited any 
change in tight junction-1 (TJP1) mRNA expression in response to salmeterol (Figure 6.2-3). 
Overall, salmeterol had nono effect on epithelial junction expression, however increased 
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Figure 6.2-1: Expression of E-cadherin in non-smokers (NNS), smokers with normal lung function (NLFS) 
and people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and 
qPCR with and without exposure to salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: 
In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-2: Expression of cytokeratin in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by 
immunocytochemistry with and without exposure to salmeterol for 24 hours. Data are represented 
as mean with SEM.  In immunocytochemical images cellular protein (brown) was stained with DAB. 
Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured had five non-
overlapping fields of view measured individually, and the results were averaged to get a single final 
value for each sample.  Each point on the graphs represents a single volunteer (NNS) or biological 
replicate (BEAS-2B).  
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-3: Expression of tight junction protein-1 (TJP1)  in non-smokers (NNS), smokers with 
normal lung function (NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to salmeterol for 24 hours. Data are represented as 
mean with SEM.  Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. The dashed line indicates the expression of 
the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.2.2.1.2. Mesenchymal markers 
At the protein level, salmeterol reduced variatbilityreduce variation in N-cadherin protein 
expression in cells from smokers with normal lung function, although this change couldn’t be 
analysed statistically, however N-cadherin expression in the other primary groups was 
unchanged (Figure 6.2-4). At the mRNA level there was no change in N-cadherin expression in 
any of the three primary cell groups, and at both the protein and mRNA level N-cadherin 
expression in the BEAS-2B cells appeared unchangedunchanged.  
Vimentin expression appeared broadly unchanged by salmeterol treatment in both primary and 
BEAS-2B cells, although primary cells taken from smokers with normal lung function 
exhibited reduced variation in protein expression following treatment, which again could not be 
quantified statistically (Figure 6.2-5). Likewisewith the exception of a couple of samples in the 
COPD-affected group which increased expression of S100A4 mRNA, salmeterol had no effect 
on either primary or BEAS-2B cells’ expression of S100A4 (Figure 6.2-6). 
Overall, while salmeterol appeared to reduce variation in mesenchymal marker expression in 
smokers with normal lung function, the drug had no other effect on mesenchymal marker 
expression in either primary or BEAS-2B cells.   
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Figure 6.2-4: Expression of N-cadherin in non-smokers (NNS), smokers with normal lung function (NLFS) 
and people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and 
qPCR with and without exposure to salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: 
In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-5: Expression of vimentin in non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and qPCR 
with and without exposure to salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-6: Expression of S100A4 in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by qPCR 
with and without exposure to salmeterol for 24 hours. Data are represented as mean with SEM. Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.2.2.1.3. Signalling molecules 
Exposure to salmeterol appeared to havehave no effect on TWIST mRNA expression in both 
primary and BEAS-2B cells (Figure 4.2-7). Smad6 expression waswas likewise unaffected by 
exposure to salmeterol (Figure 6.2-8). Overall, salmeterol hadhave no effect on either TWIST 
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Figure 6.2-7: Expression of TWIST in non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD)people with airflow limitation (COPD) and immortalised BEAS-2B cells as 
measured by immunocytochemistry and qPCR with and without exposure to salmeterol for 24 hours. Data are 
represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) was stained 
with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured had five non-
overlapping fields of view measured individually, and the results were averaged to get a single final value for each 
sample.  Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells. ΔΔCT shows the fold-
change in expression, with ‘1’ being no change from baseline or the control.  
 
Key: Filled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-8: Expression of Smad6 in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by qPCR 
with and without exposure to salmeterol for 24 hours. Data are represented as mean with SEM. Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.2.2.1.4. Extracellular matrix remodelling 
Across all three groups, primary cells were unaffected by exposure to salmeterol with regards to 
both MMP2 and collagen 1-α expression, a result which waswas mirrored by the BEAS-2B 
cells (Figure 6.2-9).   
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Figure 6.2-9: Expression of MMP2 and collagen 1-α  in non-smokers (NNS), smokers with 
normal lung function (NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells 
as measured by ELISA of cell culture supernatant and qPCR with and without exposure to 
salmeterol for 24 hours. Data are represented as mean with SEM.  qPCR: Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression 
in untreated cells. The dashed line indicates the expression of the untreated cells.  
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
 
215 
6.2.2.2. TGF-β and CSE-induced EMT 
6.2.2.2.1. Epithelial markers 
In both primary and BEAS-2B cells treated with transforming growth factor-β1 (TGF-β), 
salmeterol had no effect overall on E-cadherin expression at either the protein or mRNA level 
(Figure 6.2-10). CSE appeared to increase variability with the primary cell grousp, although 
this could not be tested statisitcally and the cells’ average mRNA levels remained unaffected.  
The combination of TGF-β and salmeterol had no effect on cytokeratin protein expression in 
primary cells, however increased protein expression 3.7-fold (one-way ANOVA p = 0.0090) in 
BEAS-2B cells (Figure 6.2-11). The combination of salmeterol with CSE had no effect on 
cytokeratin expression in either primary or BEAS-2B cells.  
Tight junction protein-1 (TJP1) expression in primary and BEAS-2B cells was unaffected 
following treatment with TGF-β and salmeterol (Figure 6.2-12). However, in both primary and 
BEAS-2B cells the combination of TGF-β and salmeterolcalmeterol did reduceappear to reduce 
expression of TJP1 in cells which initially expressed high levelsit more highly initially, 
although this cannot be statistically confirmed.  
Overall, the combination of TGF-β and salmeterol had no effect on epithelial markers in 
primary cells, although the combination increased cytokeratin expression compared to TGF-β 
treated cells in the BEAS-2B cell line. CSE and salmeterol appeared to suppress expression of 
TJP1TJP1 in previously highly expressing samples, however this was not confirmed via 
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Figure 6.2-10: Expression of E-cadherin in non-smokers (NNS) and immortalised BEAS-2B cells as measured 
by immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) 
combined with salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-11: Expression of cytokeratin in non-smokers (NNS) and immortalised BEAS-2B cells 
as measured by immunocytochemistry with and without exposure to TGF-β (72 hours) or CSE (4 
hours) combined with salmeterol for 24 hours. Data are represented as mean with SEM. In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view 
measured individually, and the results were averaged to get a single final value for each sample.  
Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B).   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-12: Expression of tight junction protein-1 (TJP1)  in non-smokers (NNS) and 
immortalised BEAS-2B cells as measured by qPCR with and without exposure to TGF-β (72 hours) 
or CSE (4 hours) combined with salmeterol for 24 hours. Data are represented as mean with SEM. 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the 
average expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.2.2.2.2. Mesenchymal markers 
Salmeterol applied to cells treated with transforming growth factor-β1 (TGF-β) did notaffect N-
cadherin expression in primary cells or BEAS-2B cells at either the protein or mRNA level in 
BEAS-2 cells (Figure 6.2-13).While salmeterol appeared to rescuedid technically ‘rescue’ the 
change in N-cadherin mRNA expression in primary cells caused by CSE, based on the 
statistical analysis, the salmeterol-treated cells were not significantly different in expression 
compared to the cells treated with CSE alone and the change is likely due to increased 
variability between samples rather than being a true change.. In primary cells, cigarette smoke 
extract (CSE) and salmeterol in combination had no effect on N-cadherin protein or mRNA 
expression compared to CSE alone. CSE and salmeterol had no effect on protein level 
expression of E-cadherin compared to CSE alone in BEAS-2B cells, although only a single 
datum point was available for mRNA work, which meantt no conclusions could be drawn on 
that front. 
Salmeterol hadto no effect on changes in vimentin expression caused by TGF-β in either 
primary or BEAS-2B cells when looking at the protein and mRNA expression (Figure 6.2-14).  
Similarly, salmeterol and TGF-β combined hadhave no effect on primary or BEAS-2B cells 
(Figure 6.2-15). In both primary and BEAS-2B cells treated with CSE, the addition of 
salmeterol di dnothad no effect on S100A4 expression.  
Overall, salmeterol had no effect on TGF-β induced changes in mesenchymal markers in either 
primary cells or the BEAS-2B cell line. , possibly decreasing,   
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Figure 6.2-13: Expression of N-cadherin in non-smokers (NNS) and immortalised BEAS-2B cells as measured 
by immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) 
combined with salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
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Figure 6.2-14: Expression of vimentin in non-smokers (NNS) and immortalised BEAS-2B cells as measured by 
immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: In immunocytochemical images 
cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each 
sample measured had five non-overlapping fields of view measured individually, and the results were averaged to 
get a single final value for each sample.  Each point on the graphs represents a single volunteer (NNS) or 
biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the housekeeping gene, and 
further normalised to the average expression in untreated cells. The dashed line indicates the expression of the 
untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.2-15: Expression of S100A4 in non-smokers (NNS) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view 
measured individually, and the results were averaged to get a single final value for each sample.  
Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B). 
qPCR: Gene expression was normalised to β-actin as the housekeeping gene, and further normalised 
to the average expression in untreated cells. The dashed line indicates the expression of the untreated 
cells.   
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6.2.2.2.3. Signalling molecules 
At the protein level in both primary and BEAS-2B cells, the combination of salmeterol and 
transforming growth factor-β1 (TGF-β) or salmeterol and CSE had no effect on the expression 
of TWIST in either primary or BEAS-2B cells (Figure 6.2-16). However, CSE and salmeterol 
in combination increased expression of TWIST in BEAS-2B cells 3.2-fold (one-way ANOVA p 
= 0.0323) at the mRNA level, while in the primary cells it was unchanged, although there 
waswith a non-statisitcally significant trend towards reduced expressionsuggestion of a possible 
decrease in expression.  
Smad6 mRNA expression was unaffected by the combination of salmeterol and either TGF-β or 
CSE in both primary cells and BEAS-2B cells (Figure 6.2-17).Overall, salmeterol appeared to 
effect BEAS-2B cells and primary cells treated with CSE differently when looking at thethe 
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Figure 6.2-16: Expression of TWIST in non-smokers (NNS) and immortalised BEAS-2B cells as measured by 
immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with salmeterol for 24 hours. Data are represented as mean with SEM.  Immuno: In immunocytochemical images 
cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each 
sample measured had five non-overlapping fields of view measured individually, and the results were averaged to 
get a single final value for each sample.  Each point on the graphs represents a single volunteer (NNS) or 
biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the housekeeping gene, and 
further normalised to the average expression in untreated cells. The dashed line indicates the expression of the 
untreated cells.   
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Figure 6.2-17: Expression of Smad6 in non-smokers (NNS) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with salmeterol for 24 hours. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.2.2.2.4. Extracellular matrix remodelling  
Salmeterol had no effect on TGF-β induced changes in either MMP2 or collagen-1α expression 
in primary or BEAS-2B cells, nor did it affect pro-collagen 1-α expression in either cell group 
when the cells were treated with either TGF-β or CSE (Figure 6.2-18). Likewise, salmeterol 
hadappeared to have no effect on MMP2 or collagen 1-α expression in primary or BEAS-2B 
cells treated with CSE. appeared to possibly haveisOverall, salmeterol had no effect on fibrotic 
changes caused by either TGF-β or CSE.   
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Figure 6.2-18: Expression of collagen 1-α and MMP2 in non-smokers (NNS) and immortalised 
BEAS-2B cells as measured by ELISA of cell culture supernatant and qPCR with and without 
exposure to TGF-β (72 hours) or CSE (4 hours) combined with salmeterol for 24 hours. At both 
the protein and mRNA levels, treatment with salmeterol fails to rescue the effects of either TGF-
β or CSE on collagen 1-α expression in primary cells and has no effect on MMP2 expression in 
the same. Data are represented as mean with SEM. qPCR: Gene expression was normalised to β-
actin as the housekeeping gene, and further normalised to the average expression in untreated 
cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.2.3. Discussion of the effects of salmeterol 
Primary cells and BEAS-2B cells in this study reacted differently to salmeterol, indicating that 
BEAS-2B cells may not be a reliable model of healthy bronchial epithelial cells from non-
smokers. These differences were most apparent at the mRNA level, and once again support the 
suggestion that when utilising BEAS-2B cells as a model of healthy primary epithelial cells, 
focus should be placed on protein-level data as opposed to mRNA level data in order to get 
more accurate representation of what occurs in primary cells.  
In terms of its effects, salmeterol , increased expression of cytokeratin in BEAS-2B 
cellsS100A4, while exerting no effect on other epithelial markers, extracellular matrix proteins 
or mesenchymal markers in either cell type.. In both primary cells and BEAS-2B cells treated 
with transforming growth factor-β (TGF-β) salmeterol appeared to exert no additional effect on 
EMT-related markers, however in BEAS-2B cells exposed to cigarette smoke extract (CSE) 
there a trend towards a suppressive effect of salmeterol, although it did not reach statistical 
significance. appeared The lack of statistical significance may in part be attributable to large 
variation between samples within the groups, and if these experiments are repeated then it 
would be recommended to synchronise the cell cycle of the samples via serum starvation to 
reduce this variation. Samples were synchronised by apparent confluence for this study, 
however extra steps should be taken in future to further reduce variation.  
Salmeterol alonealone did not affect TWIST signalling, which was unexpected given that 
salmeterol acts via upregulating cAMP levels [173, 234, 275], and TWIST is regulated at least 
in part by cAMP [277]. However, in BEAS-2B cells treated with salmeterol and CSE together, 
there was a significant increase in TWIST signalling compared to controls. Since TWIST 
upregulation is also associated with EMT and depletion of E-cadherin in epithelial cells [277, 
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278], thisthis would suggest that salmeterol may not be a good treatment for current smokers, as 
cigarette smoke promoted TWIST signalling when combined with salmeterol. This study was, 
as noted in previous chapters, limited by the small sample sizes, which restricts the conclusions 
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6.2.4. Conclusions on the effects of salmeterol 
Within the limitations of this study, the only firm conclusion which could be drawn from the 
data was that BEAS-2B cells do not accurately represent healthy primary bronchial epithelial 
cells with regards to their responses to the long acting β-agonist salmeterol. The differences 
appeared most pronounced at the mRNA level, suggesting that if using the BEAS-2B cells line 
as a model protein level examination of effects is recommended over mRNA changes.  
Salmeterol, despite activating cAMP and thereby potentially activating TWIST signalling, 
appeared to be pro-epithelial in unstimulated cells, but otherwise had no effect on EMT-related 
changes..   
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6.3. Tiotropium bromide monohydrate 
6.3.1. Introduction 
Tiotropium bromide (tiotropium) is a quaternary ammonium compound which acts as a long-
acting muscarinic antagonist (LAMA) commonly used as a dry powder inhalation for treating 
asthma and COPD. It is functionally selective for M3 receptors due to a slow dissociation rate 
compared to the rate of dissociation from M2 receptors [279, 280]. Dysregulation of muscarinic 
receptors in airway smooth muscle has been linked to airway hyperresponsiveness in asthma 
and application of muscarinic antagonists such as tiotropium reduces bronchomotor tone and 
promotes airway widening in COPD; it is for this reason that tiotropium is applied as a 
bronchodilator [287]. In vitro, tiotropium has been shown to affect airway smooth muscle cell 
migration, which may contribute to its bronchodilatory effects in diseases with airway 
remodelling such as COPD [282]. 
Treatment with tiotropium decreases the number of exacerbations experienced by people with 
COPD, increases the time before first exacerbation and improves forced expiratory volume in 
one second (FEV1) and quality of life in patients over four years [283, 284]. In terms of 
improvement inin exacerbation rates, tiotropium is more effective than both indactarol and 
glycopyrronium [285, 286] and despite better outcomes in the first four hours of treatment with 
glycopyrronium compared to tiotropium, both drugs give similar results at 28 days [285]. 
Additionally the SPARK trial, based on relative risk assessment, showed that tiotropium is 
more cost effective than glycopyyronium in the UK, Spain, Canada, and Sweden [287], making 
it a preferable treatment option for COPD, although there is minor evidence that it may have a 
mild effect on mucous clearance [288] 
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While the precise action of tiotropium in COPD remains unclear, a number of potential avenues 
of action have been demonstrated. Cigarette smoke iss known to trigger increased expression of 
M3 muscarinic receptors in airway epithelial cells, in addition to increasing expression of 
acetylcholine which then triggers (studied via application of the agonist carbachol) an 
inflammatory response via TGF-β and IL-8 [282]. This inflammatory response is blocked by 
tiotropium. Carbachol has been demonstrated to induce EMT in alveolar epithelial cells via the 
Smad/ERK pathways [289], and TGF-β is known to induce EMT in airway epithelial cells 
[165, 207, 257]. Both TGF-β and carbcahol-induced EMT can be blocked by the application of 
an M3 antagonist, such as tiotropium [289] which suggests that tiotropium may not only be 
acting on the inflammatory aspect of COPD but may also contribute to blocking pathological 
changes in the epithelium. This effect on the epithelial layer is of special interest to this thesis, 
and the focus of this study.   
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6.3.2.1. Effects of tiotropium on EMT markers in primary and BEAS-2B cells 
6.3.2.1.1. Epithelial markers 
Tiotropium did not affect expression of E-cadherin at the protein level in primary or BEAS-2B 
cells, although in both cell types it reduced expression in samples which initially expressed high 
levels (Figure 6.3-1). At the mRNA level, BEAS-2B cells were unaffected by tiotropium, 
except for a single expressing sample which initially expressed high levels of E-cadherin and 
decreased expression to become consistent with the other samples following treatment, while 
all primary cell groups werewere unaffected.  
In both primary and BEAS-2B cells, cytokeratin expression was unaffected by tiotropium 
exposure (Figure 6.3-2). Likewise, primary cells treated with tiotropium exhibited no change in 
tight junction protein (TJP1) mRNA expression (Figure 6.3-3). Overall, epithelial markers were 
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Figure 6.3-1: Expression of E-cadherin in non-smokers (NNS), smokers with normal lung function (NLFS) 
and people with COPD (COPD)people with airflow limitation (COPD) and immortalised BEAS-2B cells as 
measured by immunocytochemistry and qPCR with and without exposure to tiotropium for 24 hours. Data are 
represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) was stained 
with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured had five non-
overlapping fields of view measured individually, and the results were averaged to get a single final value for each 
sample.  Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells. ΔΔCT shows the fold-
change in expression, with ‘1’ being no change from baseline or the control.  
 
Key: Filled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-2: Expression of cytokeratin in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by 
immunocytochemistry with and without exposure to tiotropium for 24 hours. Data are represented 
as mean with SEM.  Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for each sample.  Each point on 
the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B).  
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-3: Expression of tight junction protein-1 (TJP1) in non-smokers (NNS), smokers with 
normal lung function (NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to tiotropium for 24 hours. Data are represented as 
mean with SEM. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. The dashed line indicates the expression of 
the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.3.2.1.2. Mesenchymal markers 
Treatment with tiotropium reducede variability between samplessamples in cells from smokers 
with normal lung function and people with airflow obstruction (Figure 6.3-4). At the mRNA 
level the trend in primary cells was the same, with primaryprimary cells in all three groups 
being generally unaffected, and ini BEAS-2B cells tiotropium had no effect on N-cadherin 
expression at either the protein or mRNA level.  
Tiotropium did not affect protein level expression of vimentin in either primary or BEAS-2B 
cells, nor did it affect mRNA expression in BEAS-2B cells (Figure 6.3-5). However, at the 
mRNA level in pHBECs tiotropium increased vimentin expression 15-fold in non-smokers’ 
cells, and if the untreated samples from all three groups were combined into a single ‘baseline’ 
group then the increase in non-smokers’ cells following treatment reached statistical 
significance (unpaired t-test p<0.0001).  
S100A4 expression increasedappeared to increase in aa subset of non-smokers’ samples 
following tiotropium exposure, however these changes could not be confirmed statistically and 
most primary cells and the BEAS-2B cells’ expression of S100A4 were unaffected by the drug 
(Figure 6.3-6).  
Overall, tiotropium hadhave limited effect on mesenchymal markers in primary cells from non-
smokers,with other primary cells and BEAS-2B cells being unaffected.   
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Figure 6.3-4: Expression of N-cadherin in non-smokers (NNS), smokers with normal lung function (NLFS) 
and people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and 
qPCR with and without exposure to tiotropium for 24 hours. Data are represented as mean with SEM.  Immuno: 
In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-5: Expression of vimentin  in non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and qPCR 
with and without exposure to tiotropium for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-6: Expression of S100A4  in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by qPCR 
with and without exposure to tiotropium for 24 hours. Data are represented as mean with SEM. 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the 
average expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.3.2.1.3. Signalling molecules 
Exposure to tiotropium had no effect on any of the three primary cell groups’ expression of 
TWIST at the mRNA level, nor did it affect expression in BEAS-2B cells (Figure 6.3-7). 
SimilarlySimilarly, in both primary cells and BEAS-2B cells, tiotropium hadhave no effect on 
Smad6 expression (Figure 6.3-8). Overall, tiotropium hadhave no effect on either TWIST or 
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Figure 6.3-7: Expression of TWIST  in non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and qPCR 
with and without exposure to tiotropium for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-8: Expression of Smad6  in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by qPCR 
with and without exposure to tiotropium for 24 hours. Data are represented as mean with SEM.  
Immuno: In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei 
(blue) were stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping 
fields of view measured individually, and the results were averaged to get a single final value for each 
sample.  Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-
2B). qPCR: Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. The dashed line indicates the expression of 
the untreated cells.   
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6.3.2.1.4. Extracellular matrix remodelling  
Application of tiotropium hadhad no effect on expression of MMP2 in either primary cells or 
BEAS-2B cells (Figure 6.3-9).  
Collagen 1-α expression, both at the protein and mRNA level was unaffected in BEAS-2B 
cells, as well as in the majority of primary cells taken from people with airflowairflow 
limitation, although a single sample exhibited a sharp increase in expression in response to the 
drug. In cells taken from non-smokers and smokers with normal lung function, tiotropium had 
no effect on either collagen 1-α or MMP2. 
Overall, tiotropium possibly ahad no effect on extracellular remodelling proteins in either 
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Figure 6.3-9: Expression of MMP2 and collagen 1-α  in non-smokers (NNS), smokers with 
normal lung function (NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells 
as measured by ELISA of cell culture supernatant and qPCR with and without exposure to 
tiotropium for 24 hours. Data are represented as mean with SEM. qPCR: Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression 
in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.3.2.2. TGF-β and CSE-induced EMT 
6.3.2.2.1. Epithelial markers 
Tiotropium had no effect on E-cadherin expression in either primary cells or BEAS-2B cells 
treated with transforming growth factor-β1 (TGF-β) or cigarette smoke extract (CSE) (Figure 
6.3-10).  
Tiotropium had no effect on cytokeratin expression in primary cells treated with either TGF-β 
or CSE, nor did it affect expression in BEAS-2B cells treated with TGF-β (Figure 6.3-11). 
However, BEAS-2B cells treated with TGF-β and tiotropium exhibited a 1.7 times increase 
(one-way ANOVA p = 0.0127) in cytokeratin expression following exposure compared to cells 
treated with only TGF-β. raise the expression to nearExpression of tight junction protein-1 
(TJP1) in cells treated with TGF-β and tiotropium exhibited no change in expression in either 
primary cells or BEAS-2B cells (Figure 6.3-12).  
Overall, the combination of TGF-β and tiotropium did not affect epithelial marker expression in 
the primary cells, except in primary cells treated with CSE.  
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Figure 6.3-10: Expression of E-cadherin in non-smokers (NNS) and immortalised BEAS-2B cells as measured 
by immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) 
combined with tiotropium for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-11: Expression of cytokeratin in non-smokers (NNS) and immortalised BEAS-2B cells 
as measured by immunocytochemistry with and without exposure to TGF-β (72 hours) or CSE (4 
hours) combined with tiotropium for 24 hours. Data are represented as mean with SEM.  Each 
sample measured had five non-overlapping fields of view measured individually, and the results were 
averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B).  
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Figure 6.3-12: Expression of tight junction protein-1 (TJP1) in non-smokers (NNS) and 
immortalised BEAS-2B cells as measured by immunocytochemistry and qPCR with and without 
exposure to TGF-β (72 hours) or CSE (4 hours) combined with tiotropium for 24 hours. Data are 
represented as mean with SEM.  Gene expression was normalised to β-actin as the housekeeping gene, 
and further normalised to the average expression in untreated cells. The dashed line indicates the 
expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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6.3.2.2.2. Mesenchymal markers 
In primary and BEAS-2B cells exposed to either transforming growth factor-β1 (TGF-β) or 
cigarette smoke extract (CSE) tiotropium appeared to have no effect on the expression of N-
cadherin (Figure 6.3-13). While the expression of N-cadherin in primary cells treated with 
tiotropium in combination with TGF-β or CSE appeared statistically to return to baseline 
expression at the protein (TGF-β treated cells) and mRNA (CSE treated cells) level, it is clear 
thatthe this change is likelyprobably due to changes in variabilityvariation between samples 
rather than a true effect.  
Expression of vimentin in both primary and BEAS-2B cells exposed to TGF-β was not affected 
by the application of tiotropium (Figure 6.3-14). At the protein and mRNA level, cells exposed 
to CSE and tiotropium likewise exhibited no change in vimentin expression.S100A4 expression 
was unaffected by tiotropium in either primary or BEAS-2B cells exposed to TGF-β or CSE 
(Figure 6.3-15).  
Overall, tiotropium had no effect on the expression of mesenchymal markers in either primary 
or BEAS-2B cells exposed toto TGF-β or CSE.   
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Figure 6.3-13: Expression of N-cadherin in non-smokers (NNS) and immortalised BEAS-2B cells as measured 
by immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) 
combined with tiotropium for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
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Figure 6.3-14: Expression of vimentin  in non-smokers (NNS) and immortalised BEAS-2B cells as measured by 
immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with tiotropium for 24 hours. Exposure to TGF-β and tiotropium caused no change in vimentin expression as 
compared to TGF-β alone in either primary or BEAS-2B cells. Data are represented as mean with SEM.  
Immuno: In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for each sample.  Each point on the graphs 
represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to 
β-actin as the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed 
line indicates the expression of the untreated cells.   
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Figure 6.3-15: Expression of S100A4  in non-smokers (NNS) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with tiotropium for 24 hours. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.3.2.2.3. Signalling molecules 
The combination of transforming growth factor-β1 (TGF-β) and tiotropium had no effect on 
TWIST expression in either primary or BEAS-2B cells (Figure 6.3-16). Likewise, the 
combination of cigarette smoke extract (CSE) and tiotropium had no effect on TWIST 
expression in either primary or BEAS-2B cells. Tiotropium had no effect on Smad6 expression 
in primary or BEAS-2B cells exposed to TGF-β or CSE (Figure 6.3-17).  
Overall, neither primary nor BEAS-2B cells exhibited any response in the TWIST or Smad6 
signalling molecules following treatment with tiotropium and exposure to either TGF-β or CSE.   
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Figure 6.3-16: Expression of TWIST  in non-smokers (NNS) and immortalised BEAS-2B cells as measured by 
immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with tiotropium for 24 hours. In primary cells treated with TGF-β tiotropium had no effect on TWIST 
expression at either the protein or mRNA level. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.3-17: Expression of Smad6 in non-smokers (NNS) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with tiotropium for 24 hours. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.3.2.2.4. Extracellular matrix remodelling  
 Both primary and BEAS-2B cells exposed to transforming growth factor-β1 (TGF-β) and 
tiotropium exhibited no change in the expression of MMP2 compared to cells exposed to TGF-
β alone, nornor did tiotropium affect MMP2 expression in cells treated the cigarette smoke 
extract (CSE) (Figure 6.3-18). Tiotropium hadhad no effect on the expression of collagen 1-
α and pro-collagen 1-α in primary and BEAS-2B cells exposed to TGF-β or CSE. ,although di 
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Figure 6.3-18: Expression of MMP2 and collagen 1-α in non-smokers (NNS) and immortalised 
BEAS-2B cells as measured by ELISA of cell culture supernatant and qPCR with and without 
exposure to TGF-β (72 hours) or CSE (4 hours) combined with tiotropium for 24 hours. Data 
are represented as mean with SEM. qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The 
dashed line indicates the expression of the untreated cells.   
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6.3.3. Discussion of the effects of tiotropium 
In this study, primary bronchial epithelial cells taken from non-smokers appeared to 
demonstrate similar reactions to cells taken from people with airflow limitation when treated 
with tiotropium. Specifically, there was no change in epithelial or mesenchymal marker 
expression in response to tiotropium. Tiotropium had no effect on  expression of fibrotic 
extracellular matrix protein collagen 1-α or MMP2. Tiotropium overall appeared to have no 
effect on EMT in untreated cells, nor in primary or BEAS-2B cells treated with either 
transforming growth factor-β1 (TGF-β) or cigarette smoke extract (CSE). The only exception to 
this is cells from non-smokers, which demonstrated an increase in vimentinin response to 
tiotropium, suggesting limited pro-EMT activity. 
Despite the fact that tiotropium is known to inhibit TGF-β-induced EMT [289] it appeared to 
have no effect on Smad6 levels in this study. The reason for this is unclear, however it is 
possible that although carbachol induces EMT via the Smad pathway, tiotropium acts via a 
different mechanism to reduce EMT. There may also be variation between the action of 
tiotropium in alveolar epithelial cells, used in Yang and colleagues’ study [289], and epithelial 
cells taken from the airways, utilised in this study. It is likely that the lack of effect seen in this 
study is due to the failure to induce an active EMT phenotype in the cells, resulting in 
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6.3.4. Conclusions on the effect of tiotropium 
BEAS-2B cells appeared to be a reasonably accurate representation of primary bronchial 
epithelial cells’ responsescells to the long acting muscarinic antagonist tiotropium, however, 
there was a significant difference in the cells’ responses to tiotropium when observing the 
mesenchymal marker vimentin.. Tiotropium may be detreimental to healthy non-smokers, 
inducing a mildly mesenchymal phenotype, however since tiotropium is used to treat 
established disease this result, while interesting, is not of clinical relevance.. Tiotropium 
appeared to have no effect on induced EMT in primary cells, although this was likely due to 
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6.4. Fluticasone propionate 
6.4.1. Introduction 
Fluticasone is a glucocorticoid used to treat COPD [290]. It is known that COPD is generally 
resistant to inhaled corticosteroid (ICS) treatment, however co-treatment with a long-acting β-
agonist (LABA) has been shown to rescue the corticosteroid resistant phenotype induced in 
bronchial epithelial cells by inflammatory mediators [291]. As an additional note, the 
phosphodiesterase-4 inhibitor roflumilast reverses corticosteroid resistance in neutrophils in 
COPD [56], once again emphasising that this is a complex disease with a number of inter-
linked aspects underlying its pathology.   
The global initiative for chronic obstructive lung disease (GOLD) recommendations for the 
management of stable COPD do not recommend ICS monotherapy, although they do not 
condemn it [208]. This may be due to the fact that corticosteroid treatment increases the risk of 
lower respiratory tract infections, septicaemia [298] and both contracting pneumonia [299] and 
experiencing recurring pneumonia infections [294].  However GOLD does note that dual or 
triple therapy in combination with one or more bronchodilators, particularly LABAs, is of 
benefit in moderate to severe COPD [208].  
While corticosteroids are often considered to act on inflammation in COPD, targeting the 
immune cells, there is evidence that they can act directly on the epithelial cells [295-298].  Of 
particular relevance to this study is the fact that corticosteroid exposure, specifically 
dexamethasone, has been shown to reduce the ability of epithelial cells to repair wounds, a 
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6.4.2.1. Effects of fluticasone on EMT markers in primary and BEAS-2B cells 
6.4.2.1.1. Epithelial markers 
Fluticasone have no effect on the expression of E-cadherin in the three primary cell groups, not 
in BEAS-2B cells (Figure 6.4-1).  
Exposure to fluticasone also had no effect on the expression of cytokeratin in the primary  or 
BEAS-2B cells(Figure 6.4-2) nornor did it affect tight junction protein-1 (TJP1) expression in 
any of the primary groups, although one individualividu in the non-smoker group did greatly 
increase expression following treatment (Figure 6.4-3).  
Overall, fluticasone hadhave no effect on the expression of epithelial markers in either primary 
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Figure 6.4-1: Expression of E-cadherin in non-smokers (NNS), smokers with normal lung function (NLFS) 
and people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and 
qPCR with and without exposure to fluticasone for 24 hours. Data are represented as mean with SEM.  
Immuno: In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for each sample.  Each point on the graphs 
represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to 
β-actin as the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed 
line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.4-2: Expression of cytokeratin in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by 
immunocytochemistry with and without exposure to fluticasone for 24 hours. Data are represented 
as mean with SEM. Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for each sample.  Each point on 
the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B).  
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Figure 6.4-3: Expression of tight junction protein-1 (TJP1) in non-smokers (NNS), smokers with 
normal lung function (NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as 
measured by and qPCR with and without exposure to fluticasone for 24 hours. Data are represented 
as mean with SEM. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. The dashed line indicates the expression of 
the untreated cells.   
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6.4.2.1.2. Mesenchymal markers 
Primary cells taken from non-smokers and people with airflow obstruction did not show 
alteredexpression of N-cadherin in response to fluticasone, although cells from smokers which 
initially expressed higher levels of N-cadherin protein reduced expression to the same level as 
the other groups following treatment (Figure 6.4-4). Similarly, BEAS-2B samples expressing 
initially high levels of N-cadherin protein appeared to decrease expression following exposure 
to fluticasone. Primary and BEAS-2B cells generally exhibited no change in expression of N-
cadherin mRNA in response to fluticasone, although two primary samples from non-smokers 
appeared to greatly increase expression in response to the drug. 
Vimentin expression in response to fluticasone followed a similar pattern to N-cadherin 
expression, with primary cells which initially expressed high levels of vimentin protein 
decreasing expression, and a subset of non-smoker samples increasing mRNA level expression 
following exposure (Figure 6.4-5). Once again, the BEAS-2B cells’ expression of vimentin 
protein remained unchanged after exposure. BothBoth primary and BEAS-2B cells’ expression 
of S100A4 mRNA was unchanged following treatment with fluticasone, with the exception of a 
sample from a smoker with normal lung function which initially expressed high levels of 
S100A4 and decreased expression following treatment.  
Overall, it would appear that primary cells expressing low levels of mesenchymal markers were 
unaffected by fluticasone, although those which expressed high levels decreased in in response 
to the drug. However,, however broadly speaking fluticasone did not have any significant effect 
on mesenchymal markers in either primary or immortalised cells.   
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Figure 6.4-4: Expression of N-cadherin in non-smokers (NNS), smokers with normal lung function (NLFS) 
and people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and 
qPCR with and without exposure to fluticasone for 24 hours. Data are represented as mean with SEM.  
Immuno: In immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for each sample.  Each point on the graphs 
represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to 
β-actin as the housekeeping gene, and further normalised to the average expression in untreated cells. The dashed 
line indicates the expression of the untreated cells.   
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Figure 6.4-5: Expression of vimentin in non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and qPCR 
with and without exposure to fluticasone for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
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Figure 6.4-6: Expression of S100A4 in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by qPCR 
with and without exposure to fluticasone for 24 hours. Data are represented as mean with SEM. 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the 
average expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.4.2.1.3. Signalling molecules 
Both primary cells and BEAS-2B cells demonstrated no change in the expression of TWIST at 
either the protein or mRNA level (Figure 6.4-7) following treatment with fluticasone. Smad6 
expression in primary cells taken from non-smokers and people with airflow limitation 
remained unchanged following treatment, although some samples taken from smokers with 
normal lung function appeared to increase expression following treatment, while some BEAS-
2B cell samples exhibited a sharp decrease in expression which was offset by one sample which 
remained unchanged (Figure 6.4-8). Overall, fluticasone had no significant effect on the 
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Figure 6.4-7: Expression of TWIST in non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD) and immortalised BEAS-2B cells as measured by immunocytochemistry and qPCR 
with and without exposure to fluticasone for 24 hours. Data are represented as mean with SEM.  Immuno: In 
immunocytochemical images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. Each sample measured had five non-overlapping fields of view measured individually, and 
the results were averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The dashed line indicates 
the expression of the untreated cells.   
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Figure 6.4-8: Expression of Smad6 in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells as measured by qPCR 
with and without exposure to fluticasone for 24 hours. Data are represented as mean with SEM. 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the 
average expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.4.2.1.4. Extracellular matrix remodelling  
MMP2 expression was unaffected by fluticasone across all three groups of primary cells, 
although the more highly expressing BEAS-2B samples which initially expressed higher 
levelssample demonstrated adecrease in expression in response to treatment with fluticasone 
(Figure 6.4-9). Fluticasone had no effect on expression of collagen 1-α, either at the mRNA 
level or at the level of pro-collagen 1-α secreted into the cell culture supernatant in primary 
cells from non-smokers and smokers with normal lung function, as well as in BEAS-2B cells. 
However, aa subset of samples from people with airflow limitation appeared to demonstrate an 
increase in collagen 1-α expression following exposure to fluticasone. Fluticasone had no effect 
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Figure 6.4-9: Expression of MMP2 and collagen 1-α in non-smokers (NNS), smokers with 
normal lung function (NLFS) and people with COPD (COPD) and immortalised BEAS-2B cells 
as measured by ELISA of cell culture supernatant and qPCR with and without exposure to 
fluticasone for 24 hours. Data are represented as mean with SEM. qPCR: Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression 
in untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.4.2.2. TGF-β and CSE-induced EMT 
6.4.2.2.1. Epithelial markers 
The application of fluticasone to primary and BEAS-2B cells exposed to transforming growth 
factor-β1 (TGF-β) had no effect on expression of E-cadherin at either the protein or mRNA 
level (Figure 6.4-10). AA similar lack of effect was seen in both primary and BEAS-2B cells 
exposed to fluticasone and cigarette smoke extract (CSE).  
Fluticasone appeared to have no effect on expression of cytokeratin in primary or BEAS-2B 
cells treated with either TGF-β or CSE (Figure 6.4-11), nor did it affect the expression of tight 
junction protein-1 (TJP1) in cells exposed to TGF-β or CSE (Figure 6.4-12). Overall, 
fluticasone had no effect on epithelial markers in primary possibly of BEAS-2B cells following 
exposure to TGF-β or CSE.  
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Figure 6.4-10: Expression of E-cadherin in non-smokers (NNS) and immortalised BEAS-2B cells as measured 
by immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) 
combined with fluticasone for 24 hours. Neither primary cells nor BEAS-2B cells treated with TGF-β exhibited 
a change in E-cadherin expression following exposure to fluticasone at either the protein or mRNA level. Data 
are represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) was 
stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured had five non-
overlapping fields of view measured individually, and the results were averaged to get a single final value for each 
sample.  Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are pHBECs, open shapes are BEAS-2B cells. 
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Figure 6.4-11: Expression of cytokeratin in non-smokers (NNS) and immortalised BEAS-2B cells 
as measured by immunocytochemistry with and without exposure to TGF-β (72 hours) or CSE (4 
hours) combined with fluticasone for 24 hours. Data are represented as mean with SEM. Each 
sample measured had five non-overlapping fields of view measured individually, and the results were 
averaged to get a single final value for each sample.  Each point on the graphs represents a single 
volunteer (NNS) or biological replicate (BEAS-2B).  
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Figure 6.4-12: Expression of tight junction protein-1 (TJP1) in non-smokers (NNS) and 
immortalised BEAS-2B cells as measured by qPCR with and without exposure to TGF-β (72 hours) 
or CSE (4 hours) combined with fluticasone for 24 hours. Data are represented as mean with SEM. 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the 
average expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.4.2.2.2. Mesenchymal markers 
In primary cells treated with either transforming growth factor-β1 (TGF-β) or cigarette smoke 
extract (CSE) fluticasone had no effect on the expression of N-cadherin at either the protein or 
mRNA level (Figure 6.4-13). At the protein and mRNA levels, BEAS-2B cells treated with 
TGF-β and fluticasone likewise appeared to have no change in expression of N-
cadherin.potential expression,the change did not Similarlychanges 
Fluticasone treatment had no effect on vimentin expression in either primary or BEAS-2B cells 
exposed to TGF-β (Figure 6.4-14). BEAS-2B cells treated with fluticasone and CSE likewise 
exhibited no change in their vimentin expression, however at both the protein and mRNA level 
primary cells exposed to CSE and fluticasone expressed increased levels of vimentin, with 3.9-
fold higher levels of vimentin mRNA compared to untreated controls (one-way ANOVA p = 
0.0411) and a trend towards increased expressioncompared to cells treated with CSE alone. 
Primary and BEAS-2B cells treated with fluticasone following exposure to either TGF-β or 
CSE exhibited no change in expression of S100A4 (Figure 6.4-15).  
Overall, primary cells and BEAS-2B cells exhibited no response to fluticasone at baseline, 
however primary cells exposed to a combination of fluticasone and CSE increased expression 
of vimentin. BEAS-2B cells exposed to CSE were unaffected by CSE.   
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Figure 6.4-13: Expression of N-cadherin in non-smokers (NNS) and immortalised BEAS-2B cells as measured 
by immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) 
combined with fluticasone for 24 hours. Primary cells exposed to either TGF-β or CSE demonstrated no change 
in N-cadherin expression following exposure to fluticasone at either the mRNA or protein level. Data are 
represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) was stained 
with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured had five non-
overlapping fields of view measured individually, and the results were averaged to get a single final value for each 
sample.  Each point on the graphs represents a single volunteer (NNS) or biological replicate (BEAS-2B). qPCR: 
Gene expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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Figure 6.4-14: Expression of vimentin in non-smokers (NNS) and immortalised BEAS-2B cells as measured by 
immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with fluticasone for 24 hours. Data are represented as mean with SEM.  Immuno: In immunocytochemical 
images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. 
Each sample measured had five non-overlapping fields of view measured individually, and the results were 
averaged to get a single final value for each sample.  Each point on the graphs represents a single volunteer 
(NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the housekeeping 
gene, and further normalised to the average expression in untreated cells. The dashed line indicates the expression 
of the untreated cells.   
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Figure 6.4-15: Expression of S100A4 in non-smokers (NNS) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with fluticasone for 24 hours. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.4.2.2.3. Signalling molecules 
Expression of TWIST at both the protein and mRNA levels in primary cells was unaffected by 
the combination of fluticasone and either transforming growth factor-β1 (TGF-β) or cigarette 
smoke extract (CSE) (Figure 6.4-16). While BEAS-2B cells did not exhibit changes in TWIST 
expression at the protein level following exposure to fluticasone and either TGF-β or CSE, at 
the mRNA level TWIST expression was increased5.0-fold by fluticasone when compared to 
cells exposed to TGF-β alone (one-way ANOVA p = 0.0360). BEAS-2B cells treated with 
fluticasone and CSE also trended towards increased expression of TWIST mRNA compared to 
cells treated with CSE alone, although this change did not reach statistical significance. 
Primary and BEAS-2B cells treated with fluticasone following exposure to TGF-β 
demonstrateddemonstrated no change in expression of Smad6 (Figure 6.4-17). Overall, primary 
cells appeared to be insensitive to fluticasone with regards to the TWIST pathway, while 
BEAS-2B cells appeared to be activated at the mRNA level, even if these changes did not 
translate into protein-level changes. Smad6 was unaffected in both cell types by fluticasone 
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Figure 6.4-16: Expression of TWIST in non-smokers (NNS) and immortalised BEAS-2B cells as measured by 
immunocytochemistry and qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with fluticasone for 24 hours. Data are represented as mean with SEM.  Immuno: In immunocytochemical 
images cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. 
Each sample measured had five non-overlapping fields of view measured individually, and the results were 
averaged to get a single final value for each sample.  Each point on the graphs represents a single volunteer 
(NNS) or biological replicate (BEAS-2B). qPCR: Gene expression was normalised to β-actin as the housekeeping 
gene, and further normalised to the average expression in untreated cells. The dashed line indicates the expression 
of the untreated cells.   
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Figure 6.4-17: Expression of Smad6 in non-smokers (NNS) and immortalised BEAS-2B cells as 
measured by qPCR with and without exposure to TGF-β (72 hours) or CSE (4 hours) combined 
with fluticasone for 24 hours. Data are represented as mean with SEM. Gene expression was 
normalised to β-actin as the housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.4.2.2.4. Extracellular matrix remodelling  
 Fluticasone had no effect on MMP2  or collagen 1-α expression in primary or BEAS-2B cells 
treated with either transforming growth factor-β1 (TGF-β) or cigarette smoke extract (CSE) 
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Figure 6.4-18: Expression of MMP2 and collagen 1-α in non-smokers (NNS) and immortalised 
BEAS-2B cells as measured by ELISA of cell culture supernatant and qPCR with and without 
exposure to TGF-β (72 hours) or CSE (4 hours) combined with fluticasone for 24 hours. Data 
are represented as mean with SEM.  qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The 
dashed line indicates the expression of the untreated cells.   
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6.4.3. Discussion of the effects of fluticasone 
Fluticasone had no effect on epithelial-mesenchymal transition (EMT) markers in unstimulated 
primary or BEAS-2B cells in this study. Fluticasone, in combination with cigarette smoke 
extract (CSE), appeared to promote a mesenchymal profile in both primary and BEAS-2B cells, 
although the change was only statistically significant in primary cells. Further work to confirm 
or deny the increased levels of N-cadherin in BEAS-2B cells is recommended, as the observed 
trend was not statistically significant, likely due to a lack of power and large variation between 
samples at baseline. InterestinglyInteresting, BEAS-2B cells appeared to express increased 
levels of N-cadherin in response to the combination of CSE and fluticasone, while primary cells 
expressed significantly increased levels of vimentin, once more demonstrating that BEAS-2B 
cells are likely an inaccurate model of EMT in normalnormal bronchial epithelial cells. 
Despite the known inhibitory effect of the corticosteroid dexamethasone on epithelial cell 
proliferation and migration [305], in this study fluticasone had no effect on EMT-related 
markers. There are a number of possible explanations for this, from the possibility that 
fluticasone acts differently in epithelial cells to dexamethasone, to the possibility that although 
corticosteroids may affect epithelial cell migration they act through a non-EMT related 
pathway. Certainly the lack of signal in the TWIST and Smad6 pathways is not unexpected, as 
dexamethasone acts through the MAPK/Erk signalling pathway [305], which is an alternative 
non-Smad-dependant pathway for TGF-β signalling [87]. Further study focussing on the 
MAPK pathway would be recommended when building upon these results, however was not 
feasible within the current studies.  
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As with the other two drugs, fluticasone may only be able to exert a noticeable, real effect on 
activated epithelial cells underoing EMT, and future work with samples confirmed to be fully 
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6.4.4. Conclusions on the effect of fluticasone 
BEAS-2B cells exposed to cigarette smoke extract (CSE) appeared to respond differently to 
fluticasone than primary cells taken from non-smokers, although further work is required to 
confirm this. The differences in response makes BEAS-2B cells undesirable as models for 
bronchial epithelial cells’ responses to corticosteroids in activated bronchial epithelial cells, 
although they appeared to accurately represent untreated primary cells’ responses. Fluticasone 
hadhad no significant effect on EMT-related marker expression in unstimulated cells, however 
the combination of fluticasone and CSE promoted an increasedpromote a mesenchymal 
phenotype, which suggests that fluticasone may not be an ideal treatment for COPD in cases 
where the patient does not cease smoking.   
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6.5. Combination therapy 
6.5.1. Introduction 
Due to the complicated nature of diseases such as COPD, it can be beneficial to give patients 
multiple drugs concurrently, and thus target a number of different contributing pathways. In 
addition, some drug combinations produce synergistic effects, which is to say that in 
combination they produce a more marked effect than would be expected by combining their 
individual effects. For example, the effect of tiotropium is enhanced when combined with a 
corticosteroid such as formoterol [306]. In the GOLD guidelines for the treatment and 
management of COPD, triple therapy is noted as a step up from dual therapy with a long-acting 
β-agonist (LABA) and either an inhaled corticosteroid or long-acting muscarinic antagonist 
(LAMA) [208]. There are a variety of triple-powder inhalers available, and the combination of 
tiotropium bromide, fluticasone and salmeterol has been examined in a number of trials.  
The EAGLE study demonstrates that tiotropium (a LAMA) combined with salmeterol (a 
LABA) and fluticasone (a corticosteroid) provides an increase in airway conductance and an 
improvement in both FEV1 and residual volume compared to fluticasone and salmeterol 
without tiotropium [301]. The combination of salmeterol, tiotropium and fluticasone has been 
shown to improve lung function indices such as forced expiratory volume in one second (FEV1) 
and bronchodilation, as well as reducing dyspnoea and reducing the need for rescue mediation 
[302, 303]. Similar results hold true for other combinations of LAMA/LABA/corticosteroid 
triple therapy [304]. As discussed in previous sections in this chapter, salmeterol, tiotropium 
and fluticasone all have confirmed or likely actions in the bronchial epithelium (sections 6.2.1, 
6.3.1 and 6.4.1), therefore the action of the three drugs in combination on the epithelium is 
worth investigating.  
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6.5.2.1. Epithelial markers 
The combination of salmeterol, tiotropium and fluticasone had no effect on E-cadherin levels in 
any of the three primary cell groups at the protein level, however ithowever it did appear to 
reduce variability between samples, although  this could not be confirmed via statistical 
analysis (Figure 6.5-1).  Cytokeratin expression was unaffected by the combination of drugs 
(Figure 6.5-2), as was tight junction protein-1 expression (Figure 6.5-3). Overall, the drugs had 
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Figure 6.5-1: Expression of E-cadherin in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) cells as measured by immunocytochemistry and qPCR with 
and without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 hours. Data 
are represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) 
was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured 
had five non-overlapping fields of view measured individually, and the results were averaged to get a 
single final value for each sample.  Each point on the graphs represents a single volunteer. qPCR: Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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Figure 6.5-2: Expression of cytokeratin in non-smokers (NNS), smokers with normal lung 
function (NLFS) and people with COPD (COPD) cells as measured by immunocytochemistry 
with and without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 
hours. Data are represented as mean with SEM. Each sample measured had five non-overlapping 
fields of view measured individually, and the results were averaged to get a single final value for 
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Figure 6.5-3: Expression of tight junction protein-1 (TJP1) in non-smokers (NNS), 
smokers with normal lung function (NLFS) and people with COPD (COPD) cells as 
measured by qPCR with and without exposure to a combination of salmeterol, tiotropium 
and fluticasone for 24 hours. Data are represented as mean with SEM.  Gene expression 
was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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6.5.2.2. Mesenchymal markers 
Application of the combination of salmeterol, tiotropium and fluticasone to primary cells 
appeared to increaseincrease expression of N-cadherin in a subsetsubset of the samples taken 
from non-smokers while also reducing expression in the smokers with normal lung function 
cells which expressedexpressed high levels of N-cadherin protein at baseline (Figure 6.5-4). 
Despite these trendspossible changes, no overall effect on N-cadherin protein expression was 
observed in primary cells treated with the three drugs. The mRNA expression of N-cadherin 
remained unchanged following treatment in cells from non-smokers and smokers with normal 
lung function and the drugs hadhad no effect on the protein level expression of N-cadherin in 
cells from people with airflowairflow limitation. No comment can be made on the mRNA 
levels in cells from people with airflow limitation due to only having a single post-treatment 
datum point.  
Vimentin expression was unchanged by treatment at the protein level, except for reducing 
expression in a single current smokers’ sample which initially expressed high levels of vimentin 
(Figure 6.5-5). At the mRNA level, there appeared to be a subset of cells from both the smokers 
with normal lung function and people with airflow limitation which increased expression of 
vimentin in response to the drug combination, however others remained unchanged. Non-
smokers, however, appeared to increase expression of vimentin mRNA in response to the drugs 
and, if the three untreated groups are combined into a single ‘baseline’ group and compared to 
the treated non-smokers’ cells then the 16.3-fold increase reaches statistical significance 
(Welch’s t-test p = 0.0349). S100A4 expression remained unchanged in cells from smokers 
with normal lung function following treatment, however one individual from each the non-
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smoker and people with airflow limitation group exhibited a sharp increase in expression after 
exposure (Figure 6.5-6). 
Overall, the combination of salmeterol, tiotropium and fluticasone appeared, with the exception 
of the increased mRNA levels of vimentin in non-smokers’ cells, to have no effect on the 
expression of mesenchymal markers in primary cells.   
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 




Figure 6.5-4: Expression of N-cadherin in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) cells as measured by immunocytochemistry and qPCR with 
and without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 hours. Data 
are represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) 
was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured 
had five non-overlapping fields of view measured individually, and the results were averaged to get a 
single final value for each sample.  Each point on the graphs represents a single volunteer. qPCR: Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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Figure 6.5-5: Expression of vimentin in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) cells as measured by immunocytochemistry and qPCR with 
and without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 hours. Data 
are represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) 
was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured 
had five non-overlapping fields of view measured individually, and the results were averaged to get a 
single final value for each sample.  Each point on the graphs represents a single. qPCR: Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
expression in untreated cells. The dashed line indicates the expression of the untreated cells.   
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Figure 6.5-6: Expression of S100A4 in non-smokers (NNS), smokers with normal lung 
function (NLFS) and people with COPD (COPD) cells as measured by qPCR with and 
without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 hours. 
Data are represented as mean with SEM. Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The 
dashed line indicates the expression of the untreated cells.   
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6.5.2.3. Signalling molecules 
At both the protein and mRNA levels expression of TWIST was beunaffected by exposure to 
with the combination of salmeterol, tiotropium and fluticasone across all three groups of 
primary cells (Figure 6.5-7). In contrast, cells from  in non-smokers and smokers with normal 
lung function exhibited reduced appeared to cause a reduction in variability in Smad6of 
expression between samples following treatment, as well as potentially decreasing overall 
expression, although this change did not reach statistical significance (Figure 6.5-8).) Smad6 
expression in cells taken from people with airflow limitation were unaffected by the drug 
cocktail. Overall,the three drugs in combination did not appear to affect the expression of either 
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Figure 6.5-7: Expression of TWIST in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) cells as measured by immunocytochemistry and qPCR with 
and without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 hours. Data 
are represented as mean with SEM.  Immuno: In immunocytochemical images cellular protein (brown) 
was stained with DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. Each sample measured 
had five non-overlapping fields of view measured individually, and the results were averaged to get a 
single final value for each sample.  Each point on the graphs represents a single volunteer. qPCR: Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average 
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Figure 6.5-8: Expression of Smad6 in non-smokers (NNS), smokers with normal lung 
function (NLFS) and people with COPD (COPD) cells as measured by qPCR with and 
without exposure to a combination of salmeterol, tiotropium and fluticasone for 24 hours. 
Data are represented as mean with SEM. Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in untreated cells. The 
dashed line indicates the expression of the untreated cells.   
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6.5.2.4. Extracellular matrix remodelling  
Exposure to the increased MMP2 expressiona subset of samples across the three primary cell 
groups, although there was no significant overall change in MMP2 expression (Figure 6.5-9). 
The drugs also appeared to have no effect on collagen 1-α, both at the mRNA level and as 
measured by quantification of pro-collagen 1-α in the culture supernatant, although it appeared 
to appeared to induce increased variability in samples taken from people with airflow 
limitation. Overall, the combination of salmeterol, tiotropium and fluticasone havehave no 
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Figure 6.5-9: Expression of MMP2 and collagen 1-α in non-smokers 
(NNS), smokers with normal lung function (NLFS) and people with 
COPD (COPD) cells as measured by ELISA of cell culture supernatant 
and  qPCR with and without exposure to a combination of salmeterol, 
tiotropium and fluticasone for 24 hours. Data are represented as mean 
with SEM.  qPCR: Gene expression was normalised to β-actin as the 
housekeeping gene, and further normalised to the average expression in 
untreated cells. The dashed line indicates the expression of the untreated 
cells.   
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6.5.3. Discussion of the effects of combined drug therapy 
The combination of salmeterol, tiotropium and fluticasone appeared to have no effect on 
markers of epithelial-mesenchymal transition (EMT) in primary cells, with the exception of 
vimentin, which was increased at the mRNA level in non-smokers’ cells only. However, the 
changes observed in vimentin were almost identical to the effects of tiotropium alone (6.3.2), 
suggesting that the combination of the three drugs had no additive or synergistic effect on the 
cells with regards to EMT related markers. The drug cocktail also had no effect on the 
expression of the extracellular matrix remodelling markers MMP2 or collagen 1-α. 
DespiteDespite the presence of salmeterol in the mixture, the TWIST pathway appeared to be 
unaffected, which was unexpected [173, 234, 275] however appeared consistent within the 
results of this thesis. It was unclear why TWIST was not upregulated in this study, and while 
the combination of sample sample sizes and large variation between samples may have 
contributed, the activity of the drugs should be confirmed prior to use in  future studies.   
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6.5.4. Conclusions on the effects of combined drug therapy 
The combination of salmeterol, tiotropium and fluticasone had no additive or synergistic effects 
on the primary cells compared to the individual application of the drugs. Thechanges observed 
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7. PAFr expression in chronic airflow limitation 
7.1. Introduction 
7.1.1. Bacterial infection and PAFr in COPD 
People with COPD experience higher rates of chronic and acute bacterial infections than those 
without COPD [42, 44], and bacterial infections are commonly seen in acute exacerbations 
[45]. The most commonly seen bacteria in COPD airways are Haemophilius influenzae, 
Staphylococcus aureus, Streptococcus pneumoniae or Pseudomonas aeruigonsa [42, 47, 48], 
with H. influenzae being the most predominant and occurring in 20-30% of exacerbations [44]. 
The reasons these bacteria are able to colonise the airways so effectively in COPD and the 
mechanisms by which they persist are currently unclear, although recent work has shed light on 
the role of attachment molecules such as platelet-activating factor receptor (PAFr). Attachment 
to the airway epithelium has been known for some time to be a key step in the establishment 
and persistence of bacterial infection [51], and the mechanism behind how these bacterial 
species attach outside of COPD has been studied. It is thought that upregulation and 
overexpression of adhesion molecules, such as PAFr, may be an additional feature of an 
activated or irritated epithelial layer, in addition to processes like epithelial-mesenchymal 
transition. 
H. influenzae, Streptococcus pneumonia and P. aeruginosa express phosphorylcholine, 
abbreviated as ChoP, which they utilise as a host-attachment molecule [49, 50, 52]. ChoP is an 
oligosaccharide which, among many other functions, is one of the major active groups of 
platelet-activating factor (PAF) [107]. Bacteria which express ChoP are capable of using this 
similarity to attach to cells via PAFr [49, 50, 52]. This of course raises the question of whether 
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this mechanism is important in the airways; previous work has demonstrated that the airway 
epithelium expresses PAFr, albeit at low levels in healthy non-smokers’ airways [199, 245, 
246]. Importantly, PAFr expression is increased in the airways of people with COPD and in 
smokers [199, 245, 246] which suggests that it, and CHoP, may play a role in the increased 
prevalence of bacterial infection in COPD.  Looking at the functional aspects of the relationship 
between PAFr and CHoP, previous work with normal, immortalised bronchial epithelial cells 
has shown that they express low levels of PAFr when grown in culture [177, 199]. However, if 
bronchial epithelial cells are stimulated with cigarette smoke, then the expression of PAFR is 
increased and H. influenzae are able to attach more readily to these activated cells [49, 50, 199]. 
This suggests a potentially key role for PAFr in the pathology of COPD and makes it attractive 
for further examination. Insofar this study examinedxamined PAFr, itwas as an additional 
marker for epithelial activation rather than as a bacterial adhesion molecule, since the 
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7.1.2. Viral infection and ICAM-1 in COPD 
Viral infections, similarly to bacterial infections, are known to be associated with 23-39% of 
acute exacerbations of COPD, although there is a suggestion they may precede as many as 64% 
of exacerbations and are thought to promote the likelihood and severity of the events [305]. 
While the precise pathways and mechanisms behind how they trigger exacerbations are largely 
unknown, their increased prevalence in COPD is of some concern, given this association.  The 
most common viral pathogen seen in COPD and acute exacerbations is Rhinovirus, which is 
responsible for the common cold, and occurs in 20-58% of virus-associated exacerbations [44, 
305]. Rhinovirus are known to adhere to cells and gain entry via a transmembrane glycoprotein 
called intercellular adhesion molecule-1 (ICAM-1) [306], and the expression of ICAM-1 is 
known to be upregulated in COPD airways [243, 247, 248, 251, 252]. As with PAFr, the scope 
of this study did not allow examination of the functional aspects of ICAM-1 with regards to 
viral adhesion, but instead looked at it as a marker of dysregulated epithelial function in people 
with airflowairflow limitation.  
Looking at both PAFr and ICAM-1, the question arises whether upregulation of these 
molecules in occurs in primary bronchial epithelial cells activated by stimulus such as 
transforming growth factor-β1 and cigarette smoke extract. Additionally, examination of the 
degree of change and a comparison of primary cells to immortalised cells could reveal if 
immortalised cell culture models should be utilised to test the effects of potential therapies, and 
the answer could help ascertain the validity of the BEAS-2B immortalised cell line as a model 
for airway epithelial cells. 
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7.1.3. Chapter aims 
The aims of this chapter were as follows:  
• To determine the baseline level of expression of PAFr and ICAM-1 in primary 
bronchial epithelial cellsisolated from non-smokers, smokers with normal lung function 
and people with airflow limitation and to compare levels of PAFr and ICAM-1 
expression between these three groups.  
• To compare the expression of PAFr in primary bronchial epithelial cells to the 
expression of PAFr in the commercially available, immortalised bronchial epithelial 
BEAS-2B cell line. 
• To examine the effect transforming growth factor β1 on the expression of PAFr in 
primary epithelial cells and immortalised bronchial epithelial cells. 
• To examine the effect of cigarette smoke extract on the expression of PAFr in primary 
and immortalised bronchial epithelial cells.  
• To examine the effects of a long-acting β-agonist (salmeterol), a long-acting muscarinic 
antagonist (tiotropium) and a corticosteroid (fluticasone) on primary and immortalised 
bronchial epithelial cells at baseline with regards to PAFr expression and, in primary 
epithelial cells only, ICAM-1 expression. 
To examine the effects of a combination of a long-acting β-agonist (salmeterol), a long-
acting muscarinic antagonist (tiotropium) and a corticosteroid (fluticasone) on PAFR 
expression in primary bronchial epithelial cells following exposure to TGF-β or CSE.  
o Hypothesis: The three drugs will decrease expression of PAFr and ICAM-1, 
with salmeterol being effective in cells exposed to cigarette smoke extract and 
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tiotropium bormide monohydrate being more effective in transforming growth 
factor-β1 exposed cells. 
 
Hypothesis: Bronchial epithelial cellsCells isolated from people with airflow limitation and 
BEAS-2B cells will exhibit increased levels of the microbial adhesion molecules PAFr and 
ICAM-1 compared to bronchial epithelial cells from non-smokers. Smokers’ cells will exhibit 
intermediate levels of PAFr and ICAM-1. Transforming growth factor-β1 and cigarette smoke 
extract will increase expression of PAFr in both primary cells isolated from non-smokers and in 
immortalised bronchial epithelial cells. The three drugs, salmeterol, tiotropium, and fluticasone 
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7.2.1.1. PAFr expression in pHBECs from non-smokers, smokers with normal lung function 
and people with airflow limitation and BEAS-2B cells 
At both the protein (Figure 7.2-1) and the mRNA level (Figure 7.2-2), there was no difference 
in the expression of PAFr between cells taken from non-smokers, smokers with normal lung 
function and people with airflow limitation. Salmeterol had no significant effect on either the 
protein or mRNA level expression of PAFr in the primary cells, nor did tiotropium or 
fluticasone (Figure 7.2-1 and Figure 7.2-2). However, there was a suggestion that the 
combination of salmeterol, tiotropium and fluticasone may increaseincrease expression of PAFr 
protein and mRNA in primary cells taken from non-smokers (Figure 7.2-1). Indeed, if the 
untreated samples from the non-smokers, smokers with normal lung function and people with 
airflow limitaion were combined into a single ‘baseline’ group then the 106-times increase 
caused by the combination of drugs reached statistical significance (one-way ANOVA p = 
0.0034). A smaller, non-significant 9-fold increase in PAFr expression was also seen at the 
mRNA level in non-smokers’ cells in response to all three drugs (Figure 7.2-2).  
BEAS-2B cells expressed 5.8 times more PAFr at the protein level than cells from non-smokers 
(Figure 7.2-3) and 93 times more PAFr at the mRNA level (Figure 7.2-4), although the number 
of samples was insufficient to allow formal statistical tests to detect a significant difference. 
Salmeterol, tiotropium or fluticasone had no effect on the expression of PAFr at the protein or 
mRNA level in BEAS-2B cells (Figure 7.2-5 and Figure 7.2-6). Overall, neitherneither 
smoking nor airflow limitation hadappeared to have an effect on PAFr expression, and 
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salmeterol, fluticasone or tiotropium alone had no effect on PAFr levels. A combination of all 
three drugs caused PAFr expression to increase, however only in non-smokers. BEAS-2B cells 
appeared to express higher levels of PAFr than cells from non-smokers, although like the 
primary cells they did not respond to any of the drugs.  
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Figure 7.2-1: Baseline PAFr protein expression in non-smokers (NNS), smokers with normal lung function 
(NLFS) and people with COPD (COPD) as measured by immunocytochemistry with and without exposure to 
drugs. Each sample measured had five non-overlapping fields of view measured individually, and the results were 
averaged to get a single final value for each sample.  Each point on the graphs represents a single volunteer.  
A: Immunocytochemical images of cells from non-smokers, smokers with normal lung function and people with 
airflow limitation (COPD). Cellular protein (brown) was stained with DAB. Nuclei (blue) were stained with 
Meyer’s haematoxylin. B: Graphical representation of the area stained by immunocytochemistry quantified in the 
three groups. Data are represented as mean with SEM.  
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 




Figure 7.2-2: Comparison of bacterial adhesion molecule platelet-activating factor receptor (PAFr) mRNA 
expression in pHBECs derived from non-smokers (NNS), smokers with normal lung function (NLFS) and 
people with COPD (COPD)people with airflow limitation (COPD) treated with a LABA (salmeterol), LAMA 
(tiotropium) or corticosteroid (fluticasone). Gene expression was normalised to β-actin as the housekeeping 
gene, and further normalised to the average expression in untreated non-smokers’ cells. Data are expressed as 
mean with SEM. The dashed line indicates the expression of the untreated non-smokers’ cells. ΔΔCT shows the 
fold-change in expression, with ‘1’ being no change from baseline or the control. Each point on the graphs 
represents a single volunteer. 
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Figure 7.2-3: PAFr protein expression in non-smokers (NNS) 
compared to BEAS-2B cells as measured by immunocytochemistry. 
Each sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for 
each sample.  Each point on the graphs represents a single volunteer 
(NNS) or biological replicate (BEAS-2B).  
A: Immunocytochemical images of non-smokers’ cells and BEAS-2B 
cells. Cellular protein (brown) was stained with DAB. Nuclei (blue) were 
stained with Meyer’s haematoxylin. B: Graphical representation of the 
area stained by immunocytochemistry. Data are represented as mean 
with SEM.  
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Figure 7.2-4. Comparison of bacterial adhesion molecule platelet-activating factor receptor (PAFr) mRNA 
expression in pHBECs derived from non-smokers (NNS) and the immortalised BEAS-2B cell line. Gene 
expression was normalised to β-actin as the housekeeping gene, and further normalised to the average expression 
in untreated BEAS-2B cells. Data are expressed as mean with SEM. The dashed line indicates the expression of the 
untreated BEAS-2B cells. ΔΔCT shows the fold-change in expression, with ‘1’ being no change from baseline or 
the control. Each point on the graphs represents a single volunteer or experimental sample. 
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Figure 7.2-4: Platelet activating factor receptor (PAFr) protein 
expression in BEAS-2B cells with and without exposure to salmeterol, 
tiotropium or fluticasone for 24 hours as measured by 
immunocytochemistry. Each sample measured had five non-overlapping 
fields of view measured individually, and the results were averaged to get 
a single final value for each sample.  Each point on the graphs represents 
a single biological replicate.  
A: Immunocytochemical images of BEAS-2B cells with and without drug 
treatment. Cellular protein (brown) was stained with DAB. Nuclei (blue) 
were stained with Meyer’s haematoxylin. B: Graphical representation of 
the area stained by immunocytochemistry. Data are represented as mean 
with SEM.  
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Figure 7.2-5: Comparison of bacterial adhesion molecule 
platelet-activating factor receptor (PAFr) mRNA expression in 
BEAS-2B cells following treatment with a LABA (salmeterol), 
LAMA (tiotropium) or corticosteroid (fluticasone). Gene 
expression was normalised to β-actin as the housekeeping gene, 
and further normalised to the average expression in untreated 
BEAS-2B cells. Data are expressed as mean with SEM. The dashed 
line indicates the expression of the untreated BEAS-2B cells.  
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7.2.1.2. PAFr expression in CSE exposed cells 
In primary cells taken from non-smokers, exposure to cigarette smoke extract (CSE) for 4 hours 
increased PAFr protein expression by 22.2 times, although this did not reach statistical 
significance (Figure 7.2-7). The addition of salmeterol or fluticasone to the CSE treated cells 
did not affect PAFr protein expression, however combining CSE and tiotropium resulted in a 
statistically significant 51.7 times increase in PAFr protein expression (one-way ANOVA p = 
0.0105). At the mRNA level, CSE exposure had no effect on PAFr expression (Figure 7.2-8), 
nor did any of the three drugs in combination with CSE affect PAFr mRNA expression.  
While the BEAS-2B cells were similar to the pHBECs in that CSE had no effect on the mRNA 
expression of PAFr (Figure 7.2-9), BEASS-2B cells exhibited a 7.7-fold decrease in PAFr 
when treated with salmeterol and CSE (one-way ANOVA p = 0.0133), a 6.8-fold decrease 
when treated with tiotropium and CSE (one-way ANOVA p = 0.0149) and a 7.3-fold decrease 
following treatment with fluticasone and CSE (one-way ANOVA p = 0.0265) when compared 
to BEAS-2B cells treated with CSE alone (Figure 7.2-9). At the protein level, BEAS-2B cells 
exposed to CSE for 4 hours exhibited a decrease in PAFr expression 4.6 times (one-way 
ANOVA p = 0.0295) (Figure 7.2-10). The addition of salmeterol or fluticasone for 24 hours in 
addition to the CSE did not rescue this effect, and although tiotropium treated cells did not 
show a statistically significantly difference from the untreated cells, they appeared to be more 
similar to CSE treated cells than the control cells.  
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Figure 7.2-6: Platelet activating factor receptor (PAFr) protein 
expression in primary cells following exposure to salmeterol, tiotropium 
or fluticasone for 24 hours and cigarette smoke extract (CSE) for 4 
hours, as measured by immunocytochemistry. Each sample measured 
had five non-overlapping fields of view measured individually, and the 
results were averaged to get a single final value for each sample.  Each 
point on the graphs represents a single volunteer.  
A: Immunocytochemical images of non-smokers’ cells treated with both 
CSE and the indicated drug. Cellular protein (brown) was stained with 
DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. B: 
Graphical representation of the area stained by immunocytochemistry. 
Data are represented as mean with SEM.  
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Figure 7.2-8. Comparison of bacterial adhesion molecule platelet-activating factor receptor (PAFr) mRNA expression in pHBECs derived from non-smokers (NNS) and 
the immortalised BEAS-2B cell line following treatment with CSEβ for 4 hours. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. Data are expressed as mean with SEM. The dashed line indicates the expression of the untreated cells. ΔΔCT shows 
the fold-change in expression, with ‘1’ being no change from baseline or the control. Each point on the graphs represents a single volunteer or experimental sample. 
 
  
Key: FilledFilled shapes are NNS pHBECs, open shapes are BEAS-2B cells. 
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Figure 7.2-7: Comparison of bacterial adhesion molecule platelet-activating factor receptor (PAFr) mRNA 
expression in pHBECs derived from non-smokers (NNS) and the immortalised BEAS-2B cell line following 
treatment with CSE for 4 hours and exposure to a LABA (salmeterol), LAMA (tiotropium) or corticosteroid 
(fluticasone) for 24 hours. Gene expression was normalised to β-actin as the housekeeping gene, and further 
normalised to the average expression in untreated cells. Data are expressed as mean with SEM. The dashed line 
indicates the expression of the untreated cells.   
 
Key: Coloured shapesFilled shapes are NNS pHBECs, open shapes are BEAS-2B cells. 
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Figure 7.2-8: Platelet activating factor receptor (PAFr) protein 
expression in BEAS-2B cells following exposure to salmeterol, 
tiotropium or fluticasone for 24 hours and cigarette smoke extract 
(CSE) for 4 hours, as measured by immunocytochemistry. Each sample 
measured had five non-overlapping fields of view measured individually, 
and the results were averaged to get a single final value for each sample.  
Each point on the graphs represents a single biological replicate.  
A: Immunocytochemical images of BEAS-2B cells treated with both CSE 
and the indicated drug. Cellular protein (brown) was stained with DAB. 
Nuclei (blue) were stained with Meyer’s haematoxylin. B: Graphical 
representation of the area stained by immunocytochemistry. Data are 
represented as mean with SEM.  
  
Useful abbreviations 
NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
 
326 
7.2.1.3. PAFr expression in TGF-β exposed cells 
Exposure of primary cells from non-smokers to transforming growth factor β1 (TGF-β) 
appeared to increase PAFr expression at the protein level by 22.9 times, however this did not 
reach statistical significance (Figure 7.2-11). Cells exposed to a combination of TGF-β with 
salmeterol, tiotropium or fluticasone were not significantly different from baseline nor cells 
treated with TGF-β alone, although they appeared to more closely resemble cells exposed to 
TGF-β than unstimulated cellscells.  
In BEAS-2B cells TGF-β, alone or in combination with salmeterol, tiotropium or fluticasone, 
had no effect on PAFr protein levels (Figure 7.2-12). At the mRNA level, TGF-β either with 
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Figure 7.2-9: Platelet activating factor receptor (PAFr) protein 
expression in primary cells following exposure to transforming growth 
factor β1 (TGF-β) for 72 hours and salmeterol, tiotropium or 
fluticasone for 24 hours as measured by immunocytochemistry. Each 
sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for 
each sample.  Each point on the graphs represents a single volunteer.  
A: Immunocytochemical images of non-smokers’ cells treated with both 
TGF-β and the indicated drug. Cellular protein (brown) was stained with 
DAB. Nuclei (blue) were stained with Meyer’s haematoxylin. B: 
Graphical representation of the area stained by immunocytochemistry. 
Data are represented as mean with SEM.  
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Figure 7.2-10: Platelet activating factor receptor (PAFr) protein 
expression in BEAS-2B cells following exposure to transforming 
growth factor β1 (TGF-β) for 72 hours and salmeterol, tiotropium or 
fluticasone for 24 hours as measured by immunocytochemistry. Each 
sample measured had five non-overlapping fields of view measured 
individually, and the results were averaged to get a single final value for 
each sample.  Each point on the graphs represents a single biological 
replicate.  
A: Immunocytochemical images of BEAS-2B cells treated with both TGF-
β and the indicated drug. Cellular protein (brown) was stained with DAB. 
Nuclei (blue) were stained with Meyer’s haematoxylin. B: Graphical 
representation of the area stained by immunocytochemistry. Data are 
represented as mean with SEM.  
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Figure 7.2-13. Comparison of bacterial adhesion molecule platelet-activating factor receptor (PAFr) mRNA 
expression in pHBECs derived from non-smokers (NNS) and the immortalised BEAS-2B cell line following 
treatment with TGF-β for 72 hours and exposure to a LABA (salmeterol), LAMA (tiotropium) or 
corticosteroid (fluticasone) for 24 hours. Gene expression was normalised to β-actin as the housekeeping gene, 
and further normalised to the average expression in untreated cells. Data are expressed as mean with SEM. The 
dashed line indicates the expression of the untreated cells. ΔΔCT shows the fold-change in expression, with ‘1’ 
being no change from baseline or the control. Each point on the graphs represents a single volunteer or 
experimental sample. 
Key: FilledFilled shapes are NNS pHBECs, open shapes are BEAS-2B cells.  
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7.2.2.1. ICAM-1 expression in non-smokers, smokers with normal lung function and people 
with airflow limitation 
There was no significant difference in ICAM-1 protein expression across cells taken from 
non-smokers, smokers with normal lung function and people with airflow limitation (Figure 
7.2-14), although there was a suggestion that smokers with normal lung function may have 
two distinct groups, one with low ICAM-1 expression and one with high ICAM-1 expression.  
There appeared to be no effect in any of the three groups on ICAM-1 expression at the 
protein level by exposure to salmeterol (Figure 7.2-14) , tiotropium (Figure 7.2-14) , 
fluticasone (Figure 7.2-14)  or all three drugs combined (Figure 7.2-14). ICAM-1 levels 
appeared unaffected by exposure to salmeterol, tiotropium or fluticasone and cells from 
smokers or people with airflow limitation did not express levels of ICAM-1 which differed 
from non-smokers, although there may be a sub-group of smokers with normal lung function 
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Figure 7.2-11: Baseline ICAM-1 protein expression in non-smokers (NNS), smokers with normal 
lung function (NLFS) and people with COPD (COPD) as measured by immunocytochemistry with 
and without exposure to drugs. Each sample measured had five non-overlapping fields of view 
measured individually, and the results were averaged to get a single final value for each sample.  Each 
point on the graphs represents a single volunteer.  
A: Immunocytochemical images of cells from non-smokers, smokers with normal lung function and 
people with airflow limitation (COPD). Cellular protein (brown) was stained with DAB. Nuclei (blue) 
were stained with Meyer’s haematoxylin. B: Graphical representation of the area stained by 
immunocytochemistry quantified in the three groups. Data are represented as mean with SEM.   
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7.3. Chapter discussion 
7.3.1. PAFr 
In this study, there did not appear to be any difference in expression of the bacterial adhesion 
factor PAFr between cells from non-smokers, smokers with normal lung function and people 
with airflow limitation. Salmeterol, tiotropium or fluticasone individually appeared to have 
no effects on PAFr expression, although the combination of the three drugs significantly 
increased PAFr expression in cells from non-smokers. Although interesting, this information 
does not have any real clinicalclinical significance, as healthy individuals would not be 
prescribed these drugs.  
This study agreed with the literature [177, 199], demonstrating a trend towards PAFr 
upregulation in primary cells following exposure to cigarette smoke extract (CSE). This study 
further demonstrated that this effect was exacerbated by exposure to tiotropium. This result 
suggests that tiotropium may not be a preferable method of treatment for airflow obstruction 
or COPD in people who continue to smoke, although it would likely be acceptable for ex-
smokers.  
TGF-β had no effect on PAFr expression in this study, although when combined with the 
three drugs there was a trend towards increased expression, suggesting that there may be 
some activity. Further work utilising fresh TGF-β is required to confirm this trend.  
BEAS-2B cells, in contrast to the primary cells and previous literature nono change in 
expression of PAFr following exposure to CSE, although it was interesting to note that 
BEAS-2B cells exposed to CSE and any of salmeterol, tiotropium or fluticasone exhibited a 
significant decrease in PAFr expression compared to cells exposed to CSE alone. 
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Furthermore, TGF-β exposure had no effect on PAFr expression, nor did any of the three 
drugs appear to affect PAFr expression when combined with TGF-β. These results once again 
demonstrated that the BEAS-2B cell line is an unreliable and generally inaccurate model of 
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This study demonstrated that ICAM-1 did not appear to be upregulated in the large airways 
of current smokers or people with airflow limitation compared to healthy non-smokers. 
Previous literature has shown that soluble ICAM-1 is elevated in COPD [243, 247-251], 
however the majority of work looking at ICAM-1 expression in COPD has been focussed on 
ICAM-1 expression in bronchoalveolar lavage fluid (BALF) or serum [243, 248-251] with 
only a limited number of examinations of the airway wall and epithelium [247]. This may 
have been partiallyresponsible for the differences in ICAM-1 expression observed in this 
study, however it is unlikely the whole story, since it is known to be upregulated in the 
epithelial layer [247].  
This study was limited by small sample sizes, however the most likely explanation for the 
lack of change in ICAM-1 expression in cells from people with airflow limitation is that 
increased ICAM-1 is present in more developed COPD, but not in early stages of airflow 
limitation. Within this study, there was no evidence that salmeterol, tiotropium or fluticasone 
had any effect on ICAM-1 expression, either alone or in combination. However, further study 
of the drug effects in either artificially activated epithelium or in epithelium derived from 
clinical COPD may show different results, and is highly recommended. Additionally, it 
would be advisable to compare cultured cells to biospies, in order to confirm that culture 
conditions have not adversely affected ICAM-1 expression, and perhaps erased changes in 
the diseased cells.   
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7.4. Chapter conclusions 
Neither PAFr nor ICAM-1 appeared to be upregulated in cells from people with chronic 
airflow limitation. Similarly, PAFr and ICAM-1 expression was not affected by salmeterol, 
tiotropium or fluticasone. While a combination of the three drugs did cause increased 
expression of PAFr, this effect was only present in cells taken from non-smokers and the drug 
cocktail had no effect on ICAM-1 expression in any group. The clinical relevance of this 
result is unlikely to be important, however it was also seen that tiotropium and cigarette 
smoke extract together significantly increased PAFr expression, suggesting that tiotropium 
may not be an ideal treatment choice for current smokers. As in previous sections of this 
study, the small number of samples limited the statistical analysis of these data, however the 
results were useful for indicating possible areas for further investigation.  
The BEAS-2B cell line, which is commonly utilised in research when primary human 
bronchial epithelial cells (pHBECs) are unavailable, is, as in previous chapters, bears only a 
slight relevance to true healthy pHBECs when observing PAFr expression. Although not 
sufficiently powered to detect statistical significance, it appeared that the BEAS-2B cells 
expressed higher levels of PAFr at baseline than primary cells from non-smokers. 
Furthermore, the BEAS-2B cells appeared to react differently to CSE than primary cells. 
Although the results did not reach statistical significance, there appeared to be upregulation 
of PAFr in primary cells exposed to CSE, while BEAS-2B cells exhibited a decrease in 
expression. It is essential that further study on this topic is undertaken, as it suggests that 
BEAS-2B cells are not only a less than ideal model for EMT but may have major flaws as a 
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8. General discussion 
This thesis aimed to determine whether epithelial mesenchymal transition (EMT), a process 
which is known to be active in chronic obstructive pulmonary disease (COPD) [31-34], is 
active at early stages of the disease. Primary cells were isolated from non-smokers, smokers 
with normal lung function and people with airflow obstruction which did not reach the cut-off 
for a clinical diagnosis of COPD [208]. In this study iti appeared that, although EMT is 
thought to play a role in established COPD [31-34], at very early stages of airflow obstruction 
EMT diddid not appearappeare to be active.    
There still remains the question of what triggers the process of EMT in COPD - cigarette 
smoke has been shown to induce EMT in bronchial epithelial cells from smokers, as well as 
in non-smokers with lung cancer [33, 238, 307, 308]. It has been demonstrated to act, at least 
partially, via the TGF-β signalling pathway [33, 233, 265], and TGF-β in vitro is known to be 
a potent inducer of EMT in epithelial cells derived from a variety of organs [58, 65, 79-82]. 
This CSE-TGF-β-EMT pathway has been demonstrated in primary bronchial epithelial cells 
(pHBECs) from non-smokers who have lung cancer [33], and TGF-β alone activates EMT in 
both pHBECs and the immortalised cell line BEAS-2B [165, 207, 257]. However, the 
response of healthy pHBECs to cigarette smoke required further investigation, in order to 
study what effects the initiation of smoking might have on a person’s airways.  
In this study, exposure to cigarette smoke extract (CSE) did not induce complete EMT in 
primary cells from non-smokers, despite the evidence of previous literature [33]. TheT 
mesenchymal marker N-cadherin was significantly increased in response to CSE, however 
CSE exposure significantly reduced expression of fibrotic protein collagen 1-α. It was likely, 
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however, that some, if not all, of this unexpected decrease in pro-collagen 1-α expression was 
due to the short amount of time the cells were exposed to the CSE-containing media, which 
would have resulted in less accumulation of secreted factors and proteins than the control 
media, which was applied to the cells for longer prior to collection. CSE also did not affect 
expression of Smad6, a molecule involved in the TGF-β pathway. Based on these data, it 
would appear that while acute exposure to CSE did affect healthy pHBECs, they wereare 
somewhat resistant to induction of complete EMT. Further, TGF-β did not appear to be 
involved in the induction of the EMT-like effect, at least not through the Smad pathway. It is 
possible that the MAPK/Erk pathway may have been involved, as it has been implicated in 
TGF-β induced EMT in the literature [92].  
The response of both primary and BEAS-2B cells to TGF-β in this study appeared to be 
lower than expected when compared with previous literature [165, 257], however it appeared 
to produceproduce some indications of a mild, EMT-like phenotype in the BEAS-2B cells, 
although it did not affect all markers studied. This would suggest that although the changes 
seen in this study were slight, they may be real effects partly obscured by a dulled response 
and are worth further investigation. Especially important is confirmation ofthe fact that the 
biological activity of TGF-β should ideally be confirmed before attempting work, possibly 
utilising the MBF-11 or TMLC cell line-based bioassayslines [267, 268]. 
All three drugs examined as part of this study (salmeterol, tiotropium and fluticasone) 
appeared havehave no effect on either TWIST or Smad6 signalling, which is unexpectedun 
given previous literature on salmeterol [277] and tiotropium [289].. All three drugs are 
known to have effects on the epithelial layer of the airways [172, 272, 282, 295, 296], 
however this is the first time their effect on EMT has been directly measured. Salmeterol has 
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previously been shown to reduce epithelial wound healing and repair [272], a process which 
is directly linked to EMT, however there has not been a molecular-level examination of EMT 
following exposure to the drug. In this study, salmeterol had no significant effect on EMT-
related markers.  
On the contrary, tiotropium exposure in cells from people without airway obstruction 
upregulated some markers of EMT, although most of this upregulation was limited to the 
mRNA level, without associated protein level changes. Of special interest was the fact that 
tiotropium, when combined with CSE, appeared to increase expression of the mesenchymal 
marker vimentin in primary and N-cadherin in BEAS-2B cells. This promotion of 
mesenchymal marker expression suggests that tiotropium may not be an ideal treatment for 
people with COPD who continue to smoke.  
In addition to the primary aims, this study also allowed collection of valuable technical 
information. It showed that pHBECs cells can be successfully stored using cryopreservation, 
although the current smoking status of the cells’ donor negatively affected the viability of the 
cells following storage. Airflow obstruction, however, appeared to have no effect on cell 
growth or viability during cryopreservation. This is a novel finding, as within the literature 
pHBECs are used without cryopreservation [33, 103, 111, 192, 194, 231-236]. It indicates 
that pHBECs can be stored for future use, although it would be recommended to attempt 
optimisation of the recovery process to aid survival of cells taken from current smokers.  
Furthermore, this study directly compared pHBECs from healthy non-smokers to the 
immortalised BEAS-2B cell line. The immortalised BEAS-2B cells, despite its prevalence as 
a model of healthy bronchial epithelial cells, were demonstrated to be substantially more 
mesenchymal when compared to pHBECs, as well as expressing higher levels of PAFr. 
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These differences were observable both at baseline and in the cells’ responses to stimulus and 
drug treatments. However, the differences appeared to be restricted primarily to the molecular 
level rather than the protein level expression. This suggests that if utilising the BEAS-2B cell 
line to model healthy bronchial epithelial cells, it is preferable to study protein-level changes 
as compared to mRNA level changes.  
This study comprised of a collection of primary cells from volunteers with well-phenotyped 
clinical airway characteristics. However, due to the logistics of collection and the effects of 
cryopreservation, not to mention the limited number of samples collected in the smoking and 
disease groups and limited available time for experimental procedures and analysis, the 
number of samples able to be utilised for this study was low.  
Due to the limited number of samples, this study focussed more on a broad preliminary 
approach, examining a number of markers of EMT and selected associated pathways. While 
it would have been better from a statistical standpoint to look at a larger number of samples, 
possibly sacrificing some markers, it was not feasible within this study. As such, the results 
of this study should be considered to suggest future areas requiring more in-depth study 
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8.1. Future directions 
Although the results of these studies did not, overall, yield any statistically significant novel 
findings, they did provide some potentially interesting insights into EMT in airflow 
limitation, as well as information pertinent to both primary and immortalised bronchial 
epithelial cell culture. These results provide a rationale for should be explored in future work 
directedin order to confirmingfirmly establish or deny the patterns observed inseen these 
studies, and can provide a basis for further study. 
The most potentially interesting, and concerning, result of these studies was the observation 
that primary bronchial epithelial cells from non-smokers and the immortal BEAS-2B cell line 
not only exhibited baseline differences in their expression of EMT-related markers but also 
appeared to respond differently to both inducers such as TGF-β and CSE as well as to the 
different drug therapies. As previously discussed (section (1.3.1.2), the BEAS-2B cell line is 
both known and expected to differ at baseline from primary cells in a number of ways, 
including its inability to differentiate when cultured at an air-liquid interface. However, for 
experimental purposessince it is widely considered to be representative of ‘normal’, healthy 
bronchial epithelium, and thus needsit would be expected to behave in a similar fashion to 
primary bronchial epithelialepithleial cells from healthy individualsindivduals when exposed 
to stimuli. The results of the studies undertaken within this thesis suggest that the BEAS-2B 
cell line may not, in fact, be an ideal model for normal bronchial epithelial cells and further 
work should be undertaken to either confirm or deny this, not only in BEAS-2B cells but 
perhaps also in other commercially available cells such as the 16HBE cell line.. A more 
detailed examination of signalling pathways, as well as an increased number of primary cell 
samples would be an excellent starting point, as would synchronising cell cycles prior to 
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extraction of mRNA and protein work in order to reduce variation between samples. Overall, 
the possibility that the BEAS-2B cell line has a more mesenchymal phenotype than normal 
bronchial epithelium at baseline means that these cells may not be ideal for studies of EMT, 
wound healing and cell migration, or other studies that rely on the cells exhibiting a healthy 
epithelial profile. 
In a similar vein, although the current studies showed no difference in EMT markers between 
cells taken from non-smokers and people with mild, non-COPD airflow limitation, the 
inclusion of cells taken from people with clinically-defined COPD, especially Stage II or III, 
would be of enormous benefit, since it could shed light on the role of EMT in not only mild 
airflow limitation but in established obstructive pulmonary disease. Furthermore, additional 
experimental techniques such as RNAScope in biopsy samples and Western blotting in 
cultured cell samples, as well as examining cells differentiated at an air-liquid interface could 
provide a more complete picture of the changes occurring in airflow obstruction, both pre-
clinically and in COPD. Although attempts were made to apply RNAScope to the current 
studies, the way the samples had been processed and stored proved incompatible with the 
available techniques, however future studies can ensure that sample collection and 
preservation are suited for these technologies.  
The need forFurther study of the effects of smoking on primary cell survival and growth were 
also highly suggested by the results of these studies. Smoking, more than airflow limitation, 
appeared to play a key role in determining cell survival, especially following 
cryopreservation. The current studies were not equipped to investigate this result in any 
depth, and further study of the mechanism behind this phenomenonphenomenom is 
warranted, possibly examining. This study was not designed or equipped to investigate this 
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interesting result, however it may be of importance in understanding the DAMP/more acute 
effects of smoking, and quitting, on the airway epithelium. It is possible that the Nrf-2 and 
DAMP signalling pathways may be involved, as they have been implicated in cigarette 
smoke induced apoptosis and cell death in the airway epithelium in a number of studies [309-
311]  
Overall, despite being underpowered to make strong statistically supported claims, the studies 
in this thesis have highlighted a number of potentially interesting areas where further research 
could dramatically enhance not only our understanding of EMT and airflow limitation, but 
also reveal potentially important and previously under-recognisedunderrecognised 
differences between immortalised cell lines and healthy cells.  
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9. General conclusions 
The results of this study indicated that while healthy bronchial epithelial cells are negatively 
affected by exposure to cigarette smoke, undergoing partial EMT and showing signs of a 
trend towards upregulation of bacterial adhesion site PAFr, the cigarette smoke extract-
transforming growth factor-β1-epithelial-mesenchymal transition (CSE-TGF-β-EMT) 
pathway may not be the initial mechanism behind the damage caused by cigarette smoke. 
This suggestion is further advanced by the fact that TGF-β induced EMT appeared to exhibit 
a different expression profile from that induced by CSE, although in this study the changes 
induced by TGF-β did not reach statistical significance.  
This study also demonstrated that in pre-clinical COPD, which is to say in people with 
airflow obstruction which does not reach the threshold for a clinical diagnosis of COPD, 
EMT did not appear to be active in the airway epithelium. This provides further corroboration 
for the conclusion that EMT is not continuously active in the epithelium until the disease is 
fully established. Furthermore, while the long-acting β-agonist salmeterol and the long-acting 
muscarinic antagonist may act to reduce EMT caused by cigarette smoke extract, they have 
no benefit when applied to cells which are not activated, nor do they appear to act by 
affecting TGF-β signalling. Tiotropium may even be mildly detrimental in people without 
airflow obstruction, and particularly when combined with cigarette smoke, suggesting that 
care should be taken when considering prescribing these drugs for treatment of early COPD.  
This study also demonstrated that the BEAS-2B cell line, which is commonly used as a 
model for healthy bronchial epithelial cells not only is more mesenchymal at baseline than 
cells taken from non-smokers but also responds differently to stimuli. This was especially 
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true at the mRNA level, and raises questions regarding the suitability of this cell line as a 
model for healthy tissue.  
However, the conclusions drawn from this study were hampered by a lack of power and were 
indicated by apparent trends rather than defined, clear signals. Further work is required to 
ascertain if these trends represented true and consistent signals. Despite this drawback, this 
study provided evidence that prolonged EMT activity not be an early, pre-COPD phenomena, 
and that late-stage therapies such as tiotropium may be detrimental if applied at early disease 
stages or in patients whom do not cease smoking.
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Appendix 1: FIJI and ImageJ Macros (Raw Code) 
Macro for automatically converting .vsi files into .tiff file format using FIJI 
The function of this macro was to iterate through a folder containing multiple files saved 
from the Olympus Virtual Slide Scanner VS120 and convert them into .tiff files using the 
BioFormats plugin. The macro was designed to go through every file within a folder.  
Functionality was built in to allow the user to alter which file format the macro would open 
and which format it would convert to, as well as allowing the user to change the resolution of 
the image using the ‘series’ which are a feature of the .vsi file format. Coding language is 
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Dialog.addMessage("Hi there! Hopefully this will work!"); 
Dialog.show(); 
 
//ZChoice = "Yes" 
 
//Choose starting filetype 
Dialog.create("File Type"); 
Dialog.addString("What type of file are you processing?",".vsi",5); 
Dialog.show(); 
filetype = Dialog.getString(); 
 
//Choose export/save filetype 
Dialog.create("Convert to?"); 
Dialog.addString("What file type would you like to convert \n the files into (no dots 
please)?","tiff",5); 
Dialog.show(); 
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//Step completed visual confirmation  
print(filetype+" files will be converted to ."+convert+" files."); 
 





//Dialog.addNumber("Which Z-Plane would you like to use?", 1) 
//Dialog.show(); 
 
//z = Dialog.getNumber; 
 
//v = Array.concat(v, z); 
//Array.sort(v); 






NNS – non-smokers  LABA/LAMA – long-acting β-agonist/muscarinic antagonist 
NLFS – smokers with normal lung function  pHBECs – primary human bronchial epithelial cells 
COPD-CS – current smokers with airflow limitation  TGF-β – transforming growth factor-β1 
COPD-ES – ex-smokers with airflow limitation  CSE – cigarette smoke extract 
 
366 
//Dialog.addChoice("Would you like to add another Z-Plane?", newArray("No", "Yes")) 
//Dialog.show(); 
//ZChoice = Dialog.getChoice; 
 
//} while (ZChoice == "Yes"); 
 
//Choose 'series' (resolution) that bioformats exports 
Dialog.create("Series choice"); 
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//Defines if multiple series chosen 
seriesnum=series1+series2+series3+series4+series5+series6+series7 
 






print("Series to be exported: "+seriesstring); 
 
//Eventually to be functional if only want to select files not whole folder 
Dialog.create("Import select files or the whole folder?") 
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//Simple selection of folder with files and folder to save in 
if(Input=="Folder"){ 
 inDir= getDirectory("Choose the folder to open."); 
 outDir= getDirectory("Choose where to save the files."); 
}; 
 
//Placeholder while 'file' option is broken 
if(Input=="Files"){ 
 Dialog.create("File location information."); 
 Dialog.addMessage("Please note that the files you wish to convert must be in the 
same folder, and they must be in an unbroken sequence. Unfortunately, I can't figure out how 
to make this program select only specific files, so it relies on file location within the folder. 
Sorry about that. :)"); 
 Dialog.show(); 
 Dialog.create("Enter the file range you wish to convert.") 
 Dialog.addString("Please enter the number of the first file you wish to convert - count 
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 Dialog.create("Enter the file range you wish to convert.") 
 Dialog.addString("Please enter the number of the last file you wish to convert - count 
from the first file in the folder, ignoring any subfolders.","# here",5); 
 Dialog.show(); 
 finish=Dialog.getString(); 
 inDir= getDirectory("Choose the folder to open."); 
 outDir= getDirectory("Choose where to save the files."); 
 
function processFolderFiles(inDir){ 
 files = getFileList(inDir); 
 Array.print(files); 
 for (i=start; i<finish; i++){ 
  if(File.isDirectory(files[i])) 
  processFolder("" + inDir + files[i]); 
  if(endsWith(files[i], filetype)); 
  filename = File.getName(files[i]); 
  print(filename); 
  processFile(inDir, outDir, files[i]); 
  } 
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//For future feature - useful for immunofluorescence 
Dialog.create("Image type?"); 
Dialog.addChoice("Are you converting single channel or multi-channel images? (multi-




print("Images will be imported as "+channel+"-channel images."); 
 
//Allow specification of which channels to use 
if(channel=="Multi"){ 
 colour= newArray("Blue", "Cyan", "Green", "Grey", "Magenta", "Red", "Yellow"); 
 
Dialog.create("Visible Channels"); 
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 files = getFileList(inDir); 
 Array.print(files); 
 for (i=0; i<files.length; i+=iterator){ 
  if(File.isDirectory(files[i])) 
  processFolder("" + inDir + files[i]); 
  if(endsWith(files[i], filetype)) 
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  processFile(inDir, outDir, files[i])}; 
 
 setBatchMode(true); 
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//Define new function to iterate through files in folder and only for certain file types 
//Change i initial value to change start point for conversion 
function processFolder(inDir){ 
 files = getFileList(inDir); 
 Array.print(files); 
 for (i=0; i<files.length; i++){ 
  if(File.isDirectory(files[i])) 
  processFolder("" + inDir + files[i]); 
  if(endsWith(files[i], filetype)); 
  filename = File.getName(files[i]); 
  print(filename); 
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  processFile(inDir, outDir, files[i]); 
  } 
}   
 
//Define new function to open and name files 
function processFile(inDir, outDir, file){ 
 if(seriesnum>1){ 
  if(series1==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] 
autoscale color_mode=Default rois_import=[ROI manager] view=Hyperstack 
stack_order=XYCZT Series_1]"); 
  print("Processing:" +inDir+filename+" Series 1"); 
  saveAs(convert,outDir+filename+"Series_1"); 
  print("Saving "+file+"Series_1 to "+outDir); 
  close(); 
  run("Collect Garbage"); 
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 if(series2==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] autoscale 
color_mode=Default rois_import=[ROI manager] view=Hyperstack stack_order=XYCZT 
Series_2]"); 
  print("Processing:" +inDir+filename+" Series 2"); 
  saveAs(convert,outDir+filename+"Series_2"); 
  print("Saving "+file+"Series_2 to "+outDir); 
  close(); 
  run("Collect Garbage"); 
  wait(500); 
 }; 
 if(series3==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] autoscale 
color_mode=Default rois_import=[ROI manager] view=Hyperstack stack_order=XYCZT 
Series_3]"); 
  print("Processing:" +inDir+filename+" Series 3"); 
  saveAs(convert,outDir+filename+"Series_3"); 
  print("Saving "+file+"Series_3 to "+outDir); 
  close(); 
  run("Collect Garbage"); 
  wait(500); 
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 if(series4==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] autoscale 
color_mode=Default rois_import=[ROI manager] view=Hyperstack stack_order=XYCZT 
Series_4]"); 
  print("Processing:" +inDir+filename+" Series 4"); 
  saveAs(convert,outDir+filename+"Series_4"); 
  print("Saving "+file+"Series_4 to "+outDir); 
  close(); 
  run("Collect Garbage"); 
  wait(500); 
 } 
 if(series5==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] autoscale 
color_mode=Default rois_import=[ROI manager] view=Hyperstack stack_order=XYCZT 
Series_5]"); 
  print("Processing:" +inDir+filename+" Series 5"); 
  saveAs(convert,outDir+filename+"Series_5"); 
  print("Saving "+file+"Series_5 to "+outDir); 
  close(); 
  run("Collect Garbage"); 
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  wait(500); 
 }; 
 if(series6==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] autoscale 
color_mode=Default rois_import=[ROI manager] view=Hyperstack stack_order=XYCZT 
Series_6]"); 
  print("Processing:" +inDir+filename+" Series 6"); 
  saveAs(convert,outDir+filename+"Series_6"); 
  print("Saving "+file+"Series_6 to "+outDir); 
  close(); 
  run("Collect Garbage"); 
  wait(500); 
 }; 
 if(series7==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] autoscale 
color_mode=Default rois_import=[ROI manager] view=Hyperstack stack_order=XYCZT 
Series_7]"); 
  print("Processing:" +inDir+filename+" Series 7"); 
  saveAs(convert,outDir+filename+"Series_7"); 
  print("Saving "+file+"Series_7 to "+outDir); 
  close(); 
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  run("Collect Garbage"); 




 else if (seriesnum==1){run("Bio-Formats Importer", "open=["+inDir+filename+"] 




 print("Saving "+file+seriesstring+" to "+outDir); 
 close(); 
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 //run Bioformats 
 //else 








Dialog.create("Successfully finished macro run") 
Dialog.addMessage("YAY!") 
Dialog.show(); 
//run("Bio-Formats Importer",  
//"open=[S:\\Research\\Respiratory Research Group\\Jo-
Maree\\Tricia\\BIProjectTake2\\BI01108.vsi] autoscale color_mode=Default 
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Macro for automatically sampling selections 
This macro was designed to iterate through a specified folder and open every file within it, 
before isolating pre-specified selections and saving them as individual RGB images. The 
selections had to be mapped and saved as a selection by ImageJ/FIJI prior to use, and the 
filepath for the selection criteria had to be accurately mapped. New files would be 
sequentially numbered beginning with ‘0’ and increasing by 1 for each selection from the 
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//explanation dialog of macro 
Dialog.create("Hi there."); 
Dialog.addMessage("This is a macro for taking small images from a larger whole and saving 
them as RGB files. It can only handle three-channel images."); 
Dialog.show(); 
 
//reminder to save ROIs somewhere 
Dialog.create("Reminder."); 
Dialog.addMessage("Remember to save the ROIs you want to use as selections somewhere 
and get the file path onto the clipboard."); 
Dialog.show(); 
 
//enter file suffix to search for 
 
Dialog.create("Starting file types") 
Dialog.addString("What type of files are the original images?",".tif"); 
Dialog.show(); 
 
//stores file suffix 
filetype = Dialog.getString(); 
 
//allows change of filetype if needed 
Dialog.create("New images"); 
Dialog.addString("What filetype would you like to save the new images as? Please do not 
include the dot.","tiff"); 
Dialog.show(); 
 
//stores new file suffix 
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//choose folder to search for images to convert 
Dialog.create("Open which file?"); 
Dialog.addMessage("Please choose the folder which contains the images you would like to 
apply this macro to."); 
Dialog.show(); 
 
inDir= getDirectory("Choose the folder to open."); 
 
//choose save destination 
Dialog.create("Save new files where?"); 
Dialog.addMessage("Please choose the folder where you would like to save the new files.") 
Dialog.show(); 
 
outDir= getDirectory("Choose where to save the files."); 
 
//Bit clunky but choose file containing ROIs required 
Dialog.create("ROI files"); 




ROIpath = Dialog.getString(); 
 
//Enter max iteration value to limit iterations (backup programming only) 
Dialog.create("Number of selections"); 
Dialog.addNumber("How many selections are you saving per image?",16); 
Dialog.show(); 
 
ROITotal = Dialog.getNumber; 
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//In case of crashing due to memory, allows easy start at any file 
Dialog.create("Start point"); 
Dialog.addNumber("If this program was interrupted or ran out of memory, please enter the 
value shown after the last file was closed in order to restart in the same position.",0); 
Dialog.show();  
 
ires = Dialog.getNumber(); 
 




//set function to go through folder 
function processFolder(inDir){ 
 files = getFileList(inDir); 
 Array.print(files); 
 for (i=ires; i<files.length; i++){ 
  if(File.isDirectory(files[i])) 
  processFolder("" + inDir + files[i]); 
  if(endsWith(files[i], filetype)); 
  filename = File.getName(files[i]); 
  processFile(inDir, outDir, files[i]); 
  } 
} //processFolder iteration  
 
//poss obsolete, reset ROI start point 
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//set function to process files 
function processFile(inDir, outDir, file){ 
 roiManager("Open", ROIpath); 
 print("Opening: "+filename);  
 open(inDir+filename); 
  for(ROINum=0;ROINum<ROITotal;ROINum++) { 
   roiManager("Select", ROINum); 
   print("Duplicating selection "+ROINum+" now."); 
   run("Duplicate...", "title=["+filename+"-"+ROINum+"] duplicate 
channels=1-3"); 
   title = filename+"-"+ROINum; 
   print("Converting to RGB."); 
   run("RGB Color"); 
   print("Saving "+title+" now."); 
   saveAs(newtype,outDir+title); 
   print("Closing RGB image now."); 
   close(); 
   print("Closing duplicate "+ROINum); 
   close(); 
   print("Collecting garbage..."); 
   run("Collect Garbage"); 
   wait(500); 
  }; // end ROI number iteration 
  print("Closing "+filename); 
  close(); 
  print(i+1); 
  print("Collecting garbage..."); 
  run("Collect Garbage"); 
  wait(1000); 
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Macro for allowing rapid semi-automated analysis of 
immunocytochemistry images 
This macro was initially written/coded by Dr. Jo-Maree Courtney for use in this study, 
however some alterations were made by the study author, which are noted in the code 
annotations.  
This macro was designed to open five images at random from each field of view/region of 
interest within a specified folder. The macro allows the user to count the number of nuclei 
visible in the image manually, and then allows the user to utilise the ‘threshold’ function to 
denote areas of staining. The number of nuclei, image name and number, the number of the 
region of interest (in this case the well number on the slide, SEE METHODS) and both the 
total area stained and the area stained/nuclei were then output in simple layout for ease of 
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dir = getDirectory("Choose a Directory "); 
setBatchMode(false); 
dirStructure = split(dir, "\\/"); 
folder = dirStructure[lengthOf(dirStructure)-1]; 
list = getFileList(dir); 
 
//SET UP TABLE 
tableTitle=folder; 
tableTitle2="["+tableTitle+"]"; 
run("Table...", "name="+tableTitle2+" width=1000 height=250"); 
//tableTitle="["+folder+"}"; 
//run("Table...", "name="+tableTitle+" width=1000 height=250"); 
print(tableTitle2, "\\Headings:Slide\tWell\tImage\tCell Count\tArea\tArea per cell"); 
 
for (n=0; n<9; n++) { 
  
 //GENERATE RANDOM NUMBER ARRAYS 
 selection = newArray(16); 
 while (occurencesInArray(selection, 1)<5) { 
  pick = round(random*15); 
  selection[pick] = 1; 
 } 
  
 for (i=0; i<list.length; i++) { 
  file = list[i]; 
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  filepath = dir + list[i]; 
  slide = "unknown"; 
  well = "unknown"; 
   
     if (endsWith(file, ".tif")) {  // DO EVERYTHING WITHIN THIS SECTION 
          
         if (startsWith(file, "BIT")) {  // GETTING SLIDE AND WELL DETAILS 
FROM BI AND BIT FILES 
          //get slide number 
          slide = substring(file, 3, 6); 
    //get well number 
    subs = substring(file, 3, 7); 
          if (endsWith(subs, "_")) 
           well = substring(file, 7, 9); 
    else 
           well = substring(file, 6, 8); 
         } 
         else if (startsWith(file, "BI")) { 
          //get slide number 
          slide = substring(file, 2, 5); 
    //get well number 
    subs = substring(file, 2, 6); 
          if (endsWith(subs, "_")) 
           well = substring(file, 6, 8); 
    else 
           well = substring(file, 5, 7); 
         } 
         else { 
          print("Not a BI file"); 
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          exit("Not a BI or BIT file"); 
         } // END OF GETTING SLIDE AND WELL INFO 
          
      //get image number 
      endName = substring(file, lengthOf(file)-6); 
      if (startsWith(endName, "-")) 
       image = substring(endName, 1, 2); 
      else 
       image = substring(endName, 0, 2); 
  
   wellNum = parseInt(well); 
   imgNum = parseInt(image); 
  
   if (wellNum == n && selection[imgNum] == 1) { 
    print(file); 
     
    // DO ANALYSIS 
============================================================= 
       open(filepath); 
    name = File.nameWithoutExtension; 
    //dir = getInfo("image.directory"); 
    rename("image"); 
     
    // DECONVULUTE IMAGE FIRST TO GET UNIMPEDED 
BROWN STAIN THEN GO BACK TO ORIGINAL FOR NUCLEI COUNT 
    selectWindow("image"); 
    // SET SCALE EDIT - TRICIA 
    run("Set Scale...", "distance=2.9034 known=1 pixel=1.000 
unit=micron global"); 
    run("Colour Deconvolution", "vectors=[H DAB] hide"); 
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    selectWindow("image-(Colour_3)"); 
    run("Close"); 
    selectWindow("image-(Colour_1)"); 
    run("Close"); 
     
    // COUNT NUCLEI MANUALLY 
     
    selectWindow("image"); 
    setTool("multipoint"); 
    waitForUser("Select all the nuclei"); 
    run("Clear Results"); 
    run("Measure"); 
     
    nuclei = nResults; 
     
    selectWindow("Results"); 
    run("Close"); 
     
    //GET TOTAL AREA OF BROWN STAIN 
    selectWindow("image-(Colour_2)"); 
    setAutoThreshold("Minimum"); 
    run("Threshold..."); 
    waitForUser("Is this threshold ok? Adjust if need be."); 
     
    run("Create Selection"); //EDIT BY TRICIA 
    run("Set Measurements...", "area area_fraction display 
redirect=None decimal=3"); 
    run("Measure"); 
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    area = getResult("Area"); 
    selectWindow("Results"); 
    run("Close"); 
     
    areaPerCell = area/nuclei; 
 
    print(tableTitle2, 
slide+"\t"+well+"\t"+image+"\t"+nuclei+"\t"+area+"\t"+areaPerCell); 
   
    run("Close All"); 
     
    // END OF ANALYSIS 
========================================================= 
 
   } 
    
     } // END OF IF TIFF STATEMENT 
     
 }  // END OF FILE ITERATION LOOP 
  
} // END OF WELL ITERATION LOOP 
 
//Returns the number of times the value occurs within the array 
function occurencesInArray(array, value) { 
    count=0; 
    for (a=0; a<lengthOf(array); a++) { 
        if (array[a]==value) { 
            count++; 
        } 
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    } 
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Appendix 2: Dissociation curves and isotype controls 
This appendix demonstrates the appearance of a clean dissociation curve for qPCR and a non-
staining isotype control for immunocytochemical analysis. The dissociation curves (Figure 
8.1-1) demonstrated smooth dissociation and a single pronounced peak, indicating specific 
primer binding and target amplification. The isotype control staining, which used mouse 
IGg1 in place of primary antibody, showed that the secondary antibodies did not bind non-
specifically to the cells  
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Figure 8.1-1. Dissociation (melting) curves for qPCR and isotype control for immunocytochemistry. 
A and B show qPCR melting curves for a primer set with smooth dissociation and a single pronounced 
peak, indicating specific primer binding and target amplification. C demonstrates isotype control 
‘staining’, showing that the secondary antibodies did not bind non-specifically to the cells. 
